setName	@SYSTEMATIC_NAME	@HISTORICAL_NAMES	@PMID	@AUTHORS	@GEOID	@EXACT_SOURCE	@GENESET_LISTING_URL	@EXTERNAL_DETAILS_URL	@CHIP	@CONTRIBUTOR	@CONTRIBUTOR_ORG	@DESCRIPTION_BRIEF	@DESCRIPTION_FULL	@TAGS	@FOUNDER_NAMES	@REFINEMENT_DATASETS	@VALIDATION_DATASETS	genes
HALLMARK_TNFA_SIGNALING_VIA_NFKB	M5890								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes regulated by NF-kB in response to TNF [GeneID=7124].			BIOCARTA_FREE_PATHWAY|PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN|KOBAYASHI_EGFR_SIGNALING_6HR_DN|ZERBINI_RESPONSE_TO_SULINDAC_UP|ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP|CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP|NEWMAN_ERCC6_TARGETS_UP|OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP|GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_UP|GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_MAGENTA_UP|GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_UP|ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP|ZHOU_INFLAMMATORY_RESPONSE_LPS_UP|NAGASHIMA_NRG1_SIGNALING_UP|NAGASHIMA_EGF_SIGNALING_UP|KIM_WT1_TARGETS_UP|KIM_WT1_TARGETS_8HR_UP|KIM_WT1_TARGETS_12HR_UP|GRAHAM_CML_QUIESCENT_VS_CML_DIVIDING_UP|GRAHAM_CML_QUIESCENT_VS_NORMAL_DIVIDING_UP|HAHTOLA_MYCOSIS_FUNGOIDES_CD4_UP|GESERICK_TERT_TARGETS_DN|BERENJENO_TRANSFORMED_BY_RHOA_FOREVER_DN|CHASSOT_SKIN_WOUND|RASHI_RESPONSE_TO_IONIZING_RADIATION_1|RASHI_RESPONSE_TO_IONIZING_RADIATION_2|RASHI_NFKB1_TARGETS|MATTIOLI_MGUS_VS_MULTIPLE_MYELOMA|DIRMEIER_LMP1_RESPONSE_EARLY|DAUER_STAT3_TARGETS_UP|WANG_METHYLATED_IN_BREAST_CANCER|SIMBULAN_UV_RESPONSE_NORMAL_UP|WATTEL_AUTONOMOUS_THYROID_ADENOMA_DN|TSAI_RESPONSE_TO_IONIZING_RADIATION|REN_MIF_TARGETS_DN|GALIE_TUMOR_ANGIOGENESIS|SCIAN_INVERSED_TARGETS_OF_TP53_AND_TP73_DN|GOUYER_TATI_TARGETS_UP|AMIT_DELAYED_EARLY_GENES|AMIT_EGF_RESPONSE_40_HELA|AMIT_EGF_RESPONSE_60_HELA|AMIT_EGF_RESPONSE_120_HELA|AMIT_EGF_RESPONSE_480_HELA|AMIT_EGF_RESPONSE_40_MCF10A|AMIT_EGF_RESPONSE_60_MCF10A|AMIT_EGF_RESPONSE_120_MCF10A|AMIT_SERUM_RESPONSE_40_MCF10A|AMIT_SERUM_RESPONSE_60_MCF10A|AMIT_SERUM_RESPONSE_120_MCF10A|ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP|ZUCCHI_METASTASIS_DN|BROCKE_APOPTOSIS_REVERSED_BY_IL6|JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN|OSAWA_TNF_TARGETS|ADDYA_ERYTHROID_DIFFERENTIATION_BY_HEMIN|GALINDO_IMMUNE_RESPONSE_TO_ENTEROTOXIN|HEDVAT_ELF4_TARGETS_UP|NEMETH_INFLAMMATORY_RESPONSE_LPS_UP|THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_UP|NGUYEN_NOTCH1_TARGETS_DN|BASSO_CD40_SIGNALING_UP|ABE_VEGFA_TARGETS_2HR|SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1A|ZHOU_TNF_SIGNALING_4HR|MCDOWELL_ACUTE_LUNG_INJURY_UP|BURTON_ADIPOGENESIS_PEAK_AT_2HR|ZHOU_TNF_SIGNALING_30MIN|ABE_VEGFA_TARGETS|BURTON_ADIPOGENESIS_1|SARTIPY_BLUNTED_BY_INSULIN_RESISTANCE_UP|SESTO_RESPONSE_TO_UV_C3|ABE_VEGFA_TARGETS_30MIN|MAHAJAN_RESPONSE_TO_IL1A_UP|DAZARD_UV_RESPONSE_CLUSTER_G2|BILD_HRAS_ONCOGENIC_SIGNATURE|FOSTER_TOLERANT_MACROPHAGE_DN|MATZUK_OVULATION|CHEN_HOXA5_TARGETS_6HR_UP|FERRARI_RESPONSE_TO_FENRETINIDE_UP|VILIMAS_NOTCH1_TARGETS_UP|SOUCEK_MYC_TARGETS|SEKI_INFLAMMATORY_RESPONSE_LPS_UP|LINDSTEDT_DENDRITIC_CELL_MATURATION_A|LINDSTEDT_DENDRITIC_CELL_MATURATION_B|MARTINELLI_IMMATURE_NEUTROPHIL_DN|MIZUKAMI_HYPOXIA_DN|HINATA_NFKB_TARGETS_KERATINOCYTE_UP|HINATA_NFKB_TARGETS_FIBROBLAST_UP|SCHOEN_NFKB_SIGNALING|UZONYI_RESPONSE_TO_LEUKOTRIENE_AND_THROMBIN|DORN_ADENOVIRUS_INFECTION_12HR_UP|DORN_ADENOVIRUS_INFECTION_12HR_DN|DORN_ADENOVIRUS_INFECTION_24HR_UP|DORN_ADENOVIRUS_INFECTION_24HR_DN|DORN_ADENOVIRUS_INFECTION_32HR_UP|DORN_ADENOVIRUS_INFECTION_32HR_DN|DORN_ADENOVIRUS_INFECTION_48HR_UP|DORN_ADENOVIRUS_INFECTION_48HR_DN|TIAN_TNF_SIGNALING_VIA_NFKB|TIAN_TNF_SIGNALING_NOT_VIA_NFKB|YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_5|DAZARD_UV_RESPONSE_CLUSTER_G28|BROWNE_HCMV_INFECTION_2HR_UP|WANG_TNF_TARGETS|WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2|WINZEN_DEGRADED_VIA_KHSRP|PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_1|PLASARI_TGFB1_TARGETS_1HR_UP|PLASARI_TGFB1_TARGETS_10HR_UP|KRIEG_HYPOXIA_VIA_KDM3A|PHONG_TNF_TARGETS_UP|PHONG_TNF_RESPONSE_VIA_P38_PARTIAL|PHONG_TNF_RESPONSE_NOT_VIA_P38|ALTEMEIER_RESPONSE_TO_LPS_WITH_MECHANICAL_VENTILATION|GHANDHI_DIRECT_IRRADIATION_UP|GHANDHI_BYSTANDER_IRRADIATION_UP|ZWANG_CLASS_2_TRANSIENTLY_INDUCED_BY_EGF|ZWANG_CLASS_3_TRANSIENTLY_INDUCED_BY_EGF|MODULE_14|MODULE_178|MODULE_362|MODULE_444|MODULE_516|HINATA_NFKB_IMMU_INF|CSR_EARLY_UP.V1_UP|P53_DN.V2_UP|RELA_DN.V1_UP|ALK_DN.V1_UP|BMI1_DN_MEL18_DN.V1_UP|BMI1_DN.V1_UP|MEL18_DN.V1_UP|TGFB_UP.V1_UP	GSE2639,TNF vs control HUVEC|GSE11961,memory vs germinal center B lymphocytes|GSE11199,M. tuberculosis vs PBS at 4h monocyte derived macrophages|GSE16193,LPS vs untreated THP-1 (acute myeloid leukemia)	GSE32141,LPS vs control THP-1 (acute myeloid leukemia)|GSE40885,LPS vs Saline at 6h macrophages|GSE41295,LPS vs mock macrophages	3726	2920	467	4792	7128	5743	2919	8870	9308	6364	2921	23764	4791	7127	1839	1316	330	5329	7538	3383	3725	1960	3553	597	23645	80149	6648	4929	3552	5971	7185	7832	1843	1326	2114	2152	6385	1958	3569	7124	23135	4790	3976	5806	8061	3164	182	6351	2643	6347	1827	1844	10938	9592	5966	8837	8767	4794	8013	22822	51278	8744	2669	1647	3627	10769	8553	1959	9021	11182	5734	1847	5055	4783	5054	10221	25976	5970	329	6372	9516	7130	960	3624	5328	4609	3604	6446	10318	10135	2355	10957	3398	969	3575	1942	7262	5209	6352	79693	3460	8878	10950	4616	8942	50486	694	4170	7422	5606	1026	3491	10010	3433	3606	7280	3659	2353	4973	388	374	4814	65986	8613	9314	6373	6303	1435	1880	56937	5791	7097	57007	7071	4082	3914	1051	9322	2150	687	3949	7050	127544	55332	2683	11080	1437	5142	8303	5341	6776	23258	595	23586	8877	941	25816	57018	2526	9034	80176	8848	9334	150094	23529	4780	2354	5187	10725	490	3593	3572	9120	19	3280	604	8660	6515	1052	51561	4088	6890	9242	64135	3601	79155	602	24145	24147	1906	10209	650	1846	10611	23308	9945	10365	3371	5271	4084
HALLMARK_HYPOXIA	M5891								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated in response to low oxygen levels (hypoxia).			chr1p11|KEGG_GLYCOLYSIS_GLUCONEOGENESIS|KEGG_PENTOSE_PHOSPHATE_PATHWAY|KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM|KEGG_GALACTOSE_METABOLISM|KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM|KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDROITIN_SULFATE|KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE|KEGG_PYRUVATE_METABOLISM|KEGG_SULFUR_METABOLISM|BIOCARTA_FEEDER_PATHWAY|BIOCARTA_GLYCOLYSIS_PATHWAY|PID_HIF1_TFPATHWAY|REACTOME_GLYCOGEN_BREAKDOWN_GLYCOGENOLYSIS|REACTOME_HS_GAG_DEGRADATION|REACTOME_CHONDROITIN_SULFATE_BIOSYNTHESIS|REACTOME_CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM|REACTOME_HS_GAG_BIOSYNTHESIS|REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM|REACTOME_GLYCOSAMINOGLYCAN_METABOLISM|REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIRED_FOR_GAG_SYNTHESIS|REACTOME_GLYCOLYSIS|REACTOME_GLUCONEOGENESIS|REACTOME_METABOLISM_OF_CARBOHYDRATES|REACTOME_CYTOSOLIC_SULFONATION_OF_SMALL_MOLECULES|REACTOME_GLUCOSE_METABOLISM|WINTER_HYPOXIA_UP|PRAMOONJAGO_SOX4_TARGETS_UP|ELVIDGE_HYPOXIA_UP|ELVIDGE_HYPOXIA_BY_DMOG_UP|ELVIDGE_HIF1A_TARGETS_DN|ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN|GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN|GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN|MOTAMED_RESPONSE_TO_ANDROGEN_UP|MAINA_VHL_TARGETS_DN|GROSS_ELK3_TARGETS_DN|GROSS_HYPOXIA_VIA_ELK3_DN|GROSS_HIF1A_TARGETS_DN|GROSS_HYPOXIA_VIA_HIF1A_DN|GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP|MANALO_HYPOXIA_UP|MENSE_HYPOXIA_UP|KIM_HYPOXIA|BRACHAT_RESPONSE_TO_METHOTREXATE_DN|HARRIS_HYPOXIA|LEONARD_HYPOXIA|BRACHAT_RESPONSE_TO_CAMPTOTHECIN_DN|SEMENZA_HIF1_TARGETS|WINTER_HYPOXIA_METAGENE|NGO_MALIGNANT_GLIOMA_1P_LOH|MOOTHA_GLUCONEOGENESIS|MOOTHA_GLYCOGEN_METABOLISM|MOOTHA_GLYCOLYSIS|QI_HYPOXIA|WANG_ADIPOGENIC_GENES_REPRESSED_BY_SIRT1|VANDESLUIS_COMMD1_TARGETS_GROUP_2_UP|VANDESLUIS_COMMD1_TARGETS_GROUP_3_UP|FARDIN_HYPOXIA_9|FARDIN_HYPOXIA_11|WACKER_HYPOXIA_TARGETS_OF_VHL|SMIRNOV_RESPONSE_TO_IR_2HR_DN|SMIRNOV_RESPONSE_TO_IR_6HR_DN|AMINO_SUGAR_METABOLIC_PROCESS|GLUCAN_METABOLIC_PROCESS|GLUCOSE_METABOLIC_PROCESS|ENERGY_RESERVE_METABOLIC_PROCESS|SULFUR_METABOLIC_PROCESS|GLUCOSE_CATABOLIC_PROCESS|SULFUR_COMPOUND_BIOSYNTHETIC_PROCESS|PROTEOGLYCAN_BIOSYNTHETIC_PROCESS|N_ACETYLGLUCOSAMINE_METABOLIC_PROCESS|CELLULAR_CARBOHYDRATE_METABOLIC_PROCESS|PROTEOGLYCAN_METABOLIC_PROCESS|ALCOHOL_METABOLIC_PROCESS|BIOPOLYMER_BIOSYNTHETIC_PROCESS|NUCLEOTIDE_SUGAR_METABOLIC_PROCESS|CARBOHYDRATE_METABOLIC_PROCESS|POLYSACCHARIDE_METABOLIC_PROCESS|CELLULAR_CARBOHYDRATE_CATABOLIC_PROCESS|CARBOHYDRATE_CATABOLIC_PROCESS|CARBOHYDRATE_BIOSYNTHETIC_PROCESS|GLUCOSAMINE_METABOLIC_PROCESS|CELLULAR_POLYSACCHARIDE_METABOLIC_PROCESS|SULFOTRANSFERASE_ACTIVITY|CARBOHYDRATE_KINASE_ACTIVITY|TRANSFERASE_ACTIVITY_TRANSFERRING_SULFUR_CONTAINING_GROUPS	GSE9649,hypoxia vs normoxia HMEC cells|GSE18494,0.5% oxygen 12h vs 0h U87 (glioma) and MDA-MB-231 (breast carcinoma)|GSE30979,hypoxia vs normoxia non-small cell lung cancer (NSCLC)|GSE33607,hypoxia vs normoxia B16-F10 (melanoma)	GSE14762,renal cell carcinoma vs normal kidney	5230	5163	2632	5211	226	2026	5236	10397	3099	230	2821	4601	6513	5033	133	8974	2023	5214	205	26355	5209	7422	665	7167	30001	55818	901	3939	2997	2597	8553	51129	3725	5054	4015	2645	8497	23764	54541	6515	3486	4783	2353	3516	3098	10370	3669	2584	26118	5837	6781	23036	694	123	1466	7436	23210	2131	2152	5165	55139	7360	229	8614	54206	2027	10957	3162	5228	26330	9435	55076	63827	467	857	272	2719	3340	8660	8819	2548	6385	8987	8870	5313	3484	5329	112464	8839	9215	25819	6275	58528	7538	1956	1907	3423	1026	6095	1843	4282	5507	10570	11015	1837	136	9957	284119	2908	1316	2239	3491	7128	771	3073	633	23645	55276	5292	25824	55577	1027	680	8277	4493	538	4502	9672	25976	5317	302	5224	1649	5578	2542	7852	1944	1356	8609	1490	9469	7163	56925	124872	10891	596	2651	3036	54800	949	6576	6383	839	7428	2309	5155	126792	6518	8406	1942	2745	57007	5066	7045	1634	6478	51316	2203	8459	5260	4627	1028	9380	5105	3623	3309	8509	23327	7162	7511	3569	6533	4214	3948	9590	26136	3798	3906	1289	2817	3069	10994	1463	7052	2113	3219	8991	2355	6820	7043
HALLMARK_CHOLESTEROL_HOMEOSTASIS	M5892								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes involved in cholesterol homeostasis.			KEGG_STEROID_BIOSYNTHESIS|KEGG_TERPENOID_BACKBONE_BIOSYNTHESIS|REACTOME_CHOLESTEROL_BIOSYNTHESIS|GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN|LE_EGR2_TARGETS_DN|UEDA_CENTRAL_CLOCK|UEDA_PERIFERAL_CLOCK|GERY_CEBP_TARGETS|BURTON_ADIPOGENESIS_10|WENG_POR_TARGETS_GLOBAL_UP|WENG_POR_DOSAGE|WENG_POR_TARGETS_LIVER_UP|JI_RESPONSE_TO_FSH_UP|ZHANG_GATA6_TARGETS_DN|PODAR_RESPONSE_TO_ADAPHOSTIN_DN|CHANG_CORE_SERUM_RESPONSE_DN|COULOUARN_TEMPORAL_TGFB1_SIGNATURE_DN|SCHMIDT_POR_TARGETS_IN_LIMB_BUD_UP|GUO_TARGETS_OF_IRS1_AND_IRS2|ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_UP|ZWANG_EGF_PERSISTENTLY_UP|HORTON_SREBF_TARGETS|MODULE_432|CSR_LATE_UP.V1_DN|AKT_UP_MTOR_DN.V1_UP|AKT_UP.V1_UP|MTOR_UP.V1_UP|HOXA9_DN.V1_DN	GSE6721,DMSO vs high cholesterol diet liver|GSE29748,high fat diet vs control proximal part of small intestine|E-TABM-253,control vs high cholesterol diet ApoE3Leiden liver	GSE24187,statins vs untreated controls or rifampicin primary hepatocytes|E-MEXP-1235,D374Y PCSK9 vs WT PCSK9 HepG2 (hepatocellular carcinoma)	2224	1595	3422	2222	1717	6713	3157	50814	4047	4597	3949	7108	230	10682	6319	10654	4598	4023	6309	9415	3156	51478	312	6721	5833	55902	467	127	23474	1891	875	2990	2194	3958	22809	308	94241	1119	2946	39	552	5359	1191	54206	57761	58191	51330	71	182	5641	26270	493869	10957	118429	114569	928	5468	2731	6811	134429	1499	27346	116496	5165	5329	7869	2770	20	6311	4783	214	2171	6282	132864
HALLMARK_MITOTIC_SPINDLE	M5893								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes important for mitotic spindle assembly.			BIOCARTA_MYOSIN_PATHWAY|BIOCARTA_PAR1_PATHWAY|PID_RHOA_REG_PATHWAY|PID_CDC42_REG_PATHWAY|PID_RAC1_REG_PATHWAY|REACTOME_SIGNALING_BY_RHO_GTPASES|REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION|REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK|REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE|REACTOME_P75_NTR_RECEPTOR_MEDIATED_SIGNALLING|REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS_AND_COMPLEXES|REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES|REACTOME_RECRUITMENT_OF_NUMA_TO_MITOTIC_CENTROSOMES|REACTOME_G_ALPHA1213_SIGNALLING_EVENTS|REACTOME_MITOTIC_G2_G2_M_PHASES|REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS|REACTOME_KINESINS|STEINER_ERYTHROCYTE_MEMBRANE_GENES|MODULE_196|MODULE_253|MICROTUBULE_ASSOCIATED_COMPLEX|MICROTUBULE_CYTOSKELETON|SPINDLE_POLE|MICROTUBULE_ORGANIZING_CENTER_PART|KINESIN_COMPLEX|NON_MEMBRANE_BOUND_ORGANELLE|CYTOSKELETAL_PART|SPINDLE|CYTOSKELETON|LAMELLIPODIUM|CELL_CORTEX_PART|PERINUCLEAR_REGION_OF_CYTOPLASM|CELL_CORTEX|SPINDLE_MICROTUBULE|MICROTUBULE|CELL_PROJECTION|RUFFLE|MICROTUBULE_ORGANIZING_CENTER|ACTIN_CYTOSKELETON|INTRACELLULAR_NON_MEMBRANE_BOUND_ORGANELLE|CENTROSOME|CORTICAL_CYTOSKELETON|LEADING_EDGE|CORTICAL_ACTIN_CYTOSKELETON|REGULATION_OF_RHO_PROTEIN_SIGNAL_TRANSDUCTION|CYTOKINESIS|REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS|CENTROSOME_ORGANIZATION_AND_BIOGENESIS|MICROTUBULE_BASED_PROCESS|ORGANELLE_ORGANIZATION_AND_BIOGENESIS|REGULATION_OF_PROTEIN_POLYMERIZATION|MICROTUBULE_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS|ACTIN_FILAMENT_BASED_PROCESS|NEGATIVE_REGULATION_OF_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS|REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION_AND_BIOGENESIS|RAS_PROTEIN_SIGNAL_TRANSDUCTION|REGULATION_OF_RAS_PROTEIN_SIGNAL_TRANSDUCTION|REGULATION_OF_ACTIN_FILAMENT_LENGTH|PROTEIN_POLYMERIZATION|ACTIN_POLYMERIZATION_AND_OR_DEPOLYMERIZATION|REGULATION_OF_ORGANELLE_ORGANIZATION_AND_BIOGENESIS|NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION_AND_BIOGENESIS|ACTIN_FILAMENT_POLYMERIZATION|ACTIN_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS|REGULATION_OF_ACTIN_POLYMERIZATION_AND_OR_DEPOLYMERIZATION|CELL_DIVISION|MICROTUBULE_ORGANIZING_CENTER_ORGANIZATION_AND_BIOGENESIS|REGULATION_OF_RHO_GTPASE_ACTIVITY|REGULATION_OF_CELL_SHAPE|POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION_AND_BIOGENESIS|REGULATION_OF_CELL_MORPHOGENESIS|REGULATION_OF_CELLULAR_COMPONENT_SIZE|POSITIVE_REGULATION_OF_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS|REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION|MITOTIC_SPINDLE_ORGANIZATION_AND_BIOGENESIS|REGULATION_OF_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS|REGULATION_OF_GTPASE_ACTIVITY|CENTROSOME_CYCLE|CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS|CDC42_PROTEIN_SIGNAL_TRANSDUCTION|CELL_PROJECTION_BIOGENESIS|CYTOSKELETON_DEPENDENT_INTRACELLULAR_TRANSPORT|MICROTUBULE_BASED_MOVEMENT|SPINDLE_ORGANIZATION_AND_BIOGENESIS|SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION|REGULATION_OF_RAS_GTPASE_ACTIVITY|RHO_PROTEIN_SIGNAL_TRANSDUCTION|MICROTUBULE_POLYMERIZATION_OR_DEPOLYMERIZATION|RAS_GTPASE_ACTIVATOR_ACTIVITY|RAS_GUANYL_NUCLEOTIDE_EXCHANGE_FACTOR_ACTIVITY|RAS_GTPASE_BINDING|GTPASE_REGULATOR_ACTIVITY|ENZYME_ACTIVATOR_ACTIVITY|MICROTUBULE_BINDING|MICROTUBULE_MOTOR_ACTIVITY|BETA_TUBULIN_BINDING|SMALL_GTPASE_REGULATOR_ACTIVITY|ACTIN_BINDING|TUBULIN_BINDING|RHO_GUANYL_NUCLEOTIDE_EXCHANGE_FACTOR_ACTIVITY|SMALL_GTPASE_BINDING|ACTIN_FILAMENT_BINDING|CYTOSKELETAL_PROTEIN_BINDING|MOTOR_ACTIVITY|RHO_GTPASE_ACTIVATOR_ACTIVITY|GTPASE_ACTIVATOR_ACTIVITY|GTPASE_BINDING|GUANYL_NUCLEOTIDE_EXCHANGE_FACTOR_ACTIVITY	GSE26922,6-8h (M phase) vs 0-2h (S phase) HeLa (cervical carcinoma)|GSE39042,control vs epirubicin MDA-MB-231 (breast adenocarcinoma)|GSE41296,colecmid or vincristine 4h vs 24h TK6 (lymphoblasts)	GSE4142,resting vs cycling cells lymphocytes	9181	23332	3832	9493	57679	382	4650	4627	10426	9793	29127	57580	50650	4926	6711	11004	3799	7272	324	11190	5048	10435	9371	55704	56992	332	116840	4763	7248	996	11064	114791	24137	22919	55785	675	5347	5921	4751	8936	7153	7204	9826	10300	9055	54443	55755	9126	10844	9700	55201	201176	9732	29901	3619	394	2934	10276	10128	23637	2317	64411	121512	29	55835	4690	1063	9585	10163	4628	1062	9266	4281	3831	57787	127829	9702	8409	393	23580	163786	9113	4983	8976	4296	6654	25	7074	23095	6453	134549	8440	9787	613	10048	2037	10801	11104	51174	22974	3797	357	85378	6709	23022	23647	9735	84376	25777	58526	1739	2316	79658	8476	23365	4082	51199	5108	10928	7430	85464	983	22930	10160	11346	54509	1894	2035	51735	3835	84333	6780	396	6790	26271	51203	5829	9564	23607	11214	10013	22994	3996	23192	5116	7840	285464	11133	667	22920	151987	9411	9462	9133	80119	5922	4739	8243	81	5311	7461	998	10403	9874	9344	6904	832	1794	2017	10051	10565	7277	4001	10006	6093	55125	699	50628	64857	253260	10018	1778	6624	8874	140735	4643	274	4853	5981	10611	89941	8470	11135	7414	6249	23012	7531	9771	55722	1453
HALLMARK_WNT_BETA_CATENIN_SIGNALING	M5895								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated by activation of WNT signaling through accumulation of beta catenin CTNNB1 [GeneID=1499].			KEGG_WNT_SIGNALING_PATHWAY|KEGG_NOTCH_SIGNALING_PATHWAY|KEGG_HEDGEHOG_SIGNALING_PATHWAY|KEGG_MELANOGENESIS|KEGG_BASAL_CELL_CARCINOMA|BIOCARTA_GSK3_PATHWAY|BIOCARTA_PITX2_PATHWAY|BIOCARTA_PS1_PATHWAY|BIOCARTA_WNT_PATHWAY|WNT_SIGNALING|ST_WNT_BETA_CATENIN_PATHWAY|PID_SMAD2_3NUCLEAR_PATHWAY|PID_NOTCH_PATHWAY|PID_WNT_NONCANONICAL_PATHWAY|PID_BETA_CATENIN_DEG_PATHWAY|PID_PS1_PATHWAY|PID_WNT_SIGNALING_PATHWAY|PID_WNT_CANONICAL_PATHWAY|PID_TELOMERASE_PATHWAY|PID_HEDGEHOG_GLI_PATHWAY|PID_BETA_CATENIN_NUC_PATHWAY|PID_SYNDECAN_3_PATHWAY|PID_P53_REGULATION_PATHWAY|PID_HES_HEY_PATHWAY|REACTOME_PRE_NOTCH_TRANSCRIPTION_AND_TRANSLATION|REACTOME_ACTIVATED_NOTCH1_TRANSMITS_SIGNAL_TO_THE_NUCLEUS|REACTOME_SIGNALING_BY_NOTCH4|REACTOME_SIGNALING_BY_NOTCH2|REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING|REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION|REACTOME_PRE_NOTCH_PROCESSING_IN_GOLGI|REACTOME_SIGNALING_BY_NOTCH1|REACTOME_SIGNALING_BY_NOTCH3|REACTOME_REGULATED_PROTEOLYSIS_OF_P75NTR|REACTOME_NRIF_SIGNALS_CELL_DEATH_FROM_THE_NUCLEUS|REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY|REACTOME_RECEPTOR_LIGAND_BINDING_INITIATES_THE_SECOND_PROTEOLYTIC_CLEAVAGE_OF_NOTCH_RECEPTOR|REACTOME_SIGNALING_BY_NOTCH|LIU_CDX2_TARGETS_UP|SHIN_B_CELL_LYMPHOMA_CLUSTER_7|ROZANOV_MMP14_CORRELATED|HOEGERKORP_CD44_TARGETS_DIRECT_DN|FUKUSHIMA_TNFSF11_TARGETS|LIU_IL13_PRIMING_MODEL|TAXCREB_02|GLYCOPROTEIN_CATABOLIC_PROCESS|PROTEIN_MATURATION|NOTCH_SIGNALING_PATHWAY|AMYLOID_PRECURSOR_PROTEIN_METABOLIC_PROCESS	GSE7430,CTNNB1 WT vs KO embryonic days 14-16 pancreas|GSE15232,CTNNB1 stabilized mutant vs WT cadiac progenitor|GSE18560,CTNNB1 WT vs KD (shRNA) Ls174T colorectal cancer|GSE44097,CTNNB1 WT vs KD (siRNA) SW480 (colon cancer)	GSE8671,colorectal adenoma vs normal mucosa of the colon	4609	1499	3714	4851	28514	8313	5664	8321	4855	51176	8312	85407	81029	8454	182	9794	2648	2770	7475	5727	9612	27121	3066	22943	6932	7471	8650	6868	1856	5467	23385	10014	894	10023	1454	3516	8325	7157	6502	23493	23462	79885
HALLMARK_TGF_BETA_SIGNALING	M5896								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated in response to TGFB1 [GeneID=7040].			KEGG_TGF_BETA_SIGNALING_PATHWAY|BIOCARTA_ALK_PATHWAY|BIOCARTA_TGFB_PATHWAY|PID_BMP_PATHWAY|PID_ALK1_PATHWAY|PID_ALK2_PATHWAY|PID_SMAD2_3PATHWAY|PID_TGFBR_PATHWAY|REACTOME_SIGNALING_BY_BMP|REACTOME_TGF_BETA_RECEPTOR_SIGNALING_IN_EMT_EPITHELIAL_TO_MESENCHYMAL_TRANSITION|REACTOME_DOWNREGULATION_OF_TGF_BETA_RECEPTOR_SIGNALING|REACTOME_SMAD2_SMAD3_SMAD4_HETEROTRIMER_REGULATES_TRANSCRIPTION|REACTOME_TGF_BETA_RECEPTOR_SIGNALING_ACTIVATES_SMADS|REACTOME_TRANSCRIPTIONAL_ACTIVITY_OF_SMAD2_SMAD3_SMAD4_HETEROTRIMER|REACTOME_DOWNREGULATION_OF_SMAD2_3_SMAD4_TRANSCRIPTIONAL_ACTIVITY|REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX|BREUHAHN_GROWTH_FACTOR_SIGNALING_IN_LIVER_CANCER|LAMB_CCND1_TARGETS|IIZUKA_LIVER_CANCER_PROGRESSION_G2_G3_DN|GENTILE_UV_RESPONSE_CLUSTER_D6|NADELLA_PRKAR1A_TARGETS_UP|MIKKELSEN_DEDIFFERENTIATED_STATE_DN|HMX1_01|REGULATION_OF_TRANSFORMING_GROWTH_FACTOR_BETA_RECEPTOR_SIGNALING_PATHWAY|REGULATION_OF_GENE_SPECIFIC_TRANSCRIPTION|EPITHELIAL_TO_MESENCHYMAL_TRANSITION|TRANSFORMING_GROWTH_FACTOR_BETA_RECEPTOR_SIGNALING_PATHWAY|TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY|SMAD_BINDING	GSE7568,TGFB1 at 24h vs control BC284 (macrophages)|GSE17708,TGFB1 at 8-16h vs 0-0.5h A549 (non small cell carcinoma)|GSE45945,TGFB1 2-4h vs control and 20min HepG2 (hepatocellular carcinoma)|GSE46109,TGFB1 8h vs untreated common dendritic progenitors	GSE14491,TGFB1 vs control in MDA-MB-231 (breast carcinoma)|GSE40151,pulmonary fibrosis by bleomycin vs control days 7-14 lung	7046	4092	7040	64750	57154	659	6498	6497	90	56937	9612	5054	3726	4086	4091	23645	7050	5045	4088	2280	6885	657	1499	28996	7071	650	2022	324	5494	331	999	3397	7044	1028	51592	11031	7082	6574	1025	3399	9241	51742	3460	3398	5499	6711	25937	8412	7057	2339	3065	7323	4053	387
HALLMARK_IL6_JAK_STAT3_SIGNALING	M5897								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated by IL6 [GeneID=3569] via STAT3 [GeneID=6774], e.g., during acute phase response.			KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION|KEGG_JAK_STAT_SIGNALING_PATHWAY|KEGG_HEMATOPOIETIC_CELL_LINEAGE|BIOCARTA_IL10_PATHWAY|BIOCARTA_IL22BP_PATHWAY|ST_INTERFERON_GAMMA_PATHWAY|ST_IL_13_PATHWAY|ST_JAK_STAT_PATHWAY|ST_STAT3_PATHWAY|ST_TYPE_I_INTERFERON_PATHWAY|REACTOME_REGULATION_OF_IFNG_SIGNALING|REACTOME_IL_6_SIGNALING|ELVIDGE_HIF2A_TARGETS_UP|TENEDINI_MEGAKARYOCYTE_MARKERS|GAVIN_IL2_RESPONSIVE_FOXP3_TARGETS_UP|WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_DN|MODULE_73|MODULE_265|INTERLEUKIN_BINDING|HEMATOPOIETIN_INTERFERON_CLASSD200_DOMAIN_CYTOKINE_RECEPTOR_ACTIVITY|INTERLEUKIN_RECEPTOR_ACTIVITY|GROWTH_FACTOR_BINDING|CYTOKINE_BINDING	GSE11819,IL6 STAT3 activation by GOF gp130 in IHCA vs normal hepatocytes|GSE22009,acute phase response (CLP) vs normal liver|GSE32105,acute phase response (pneumonia) vs control liver|GSE35514,acute phase response (pneumonia) in STAT3 KO vs STAT3 WT liver|GSE37546,acute phase response (LPS) vs control liver WT only	GSE21060,IL6 vs saline liver|GSE26695,acute phase response (trauma and shock) vs control liver	3566	3572	6772	3554	1439	9021	6774	9180	3561	3459	7297	3597	7097	3460	3588	3569	7850	3563	3454	7132	4615	91	1441	3690	5967	2919	2	1438	3601	10379	56034	10456	578	10148	83729	64109	7133	929	5770	5771	3553	1435	8809	7124	5196	10563	4055	355	23765	3627	3581	10254	51330	6773	3162	3953	867	928	2921	7040	1326	3676	952	3725	8651	94	5292	27242	23533	2885	3659	1791	1437	3559	5781	3594	1230	1271	5320	4283	960	3574	6373	6354	4050	55540	948
HALLMARK_DNA_REPAIR	M5898								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes involved in DNA repair.			chr19q12|KEGG_PURINE_METABOLISM|KEGG_PYRIMIDINE_METABOLISM|KEGG_RNA_POLYMERASE|KEGG_NUCLEOTIDE_EXCISION_REPAIR|REACTOME_RNA_POL_III_TRANSCRIPTION_INITIATION_FROM_TYPE_2_PROMOTER|REACTOME_RNA_POL_I_TRANSCRIPTION_TERMINATION|REACTOME_MICRORNA_MIRNA_BIOGENESIS|REACTOME_REGULATORY_RNA_PATHWAYS|REACTOME_RNA_POL_II_TRANSCRIPTION|REACTOME_RNA_POL_III_TRANSCRIPTION|REACTOME_MRNA_CAPPING|REACTOME_TRANSCRIPTION_COUPLED_NER_TC_NER|REACTOME_RNA_POL_II_TRANSCRIPTION_PRE_INITIATION_AND_PROMOTER_OPENING|REACTOME_NUCLEOTIDE_EXCISION_REPAIR|REACTOME_FORMATION_OF_RNA_POL_II_ELONGATION_COMPLEX_|REACTOME_ELONGATION_ARREST_AND_RECOVERY|REACTOME_FORMATION_OF_TRANSCRIPTION_COUPLED_NER_TC_NER_REPAIR_COMPLEX|REACTOME_DNA_REPAIR|REACTOME_RNA_POL_II_PRE_TRANSCRIPTION_EVENTS|REACTOME_GLOBAL_GENOMIC_NER_GG_NER|REACTOME_FORMATION_OF_INCISION_COMPLEX_IN_GG_NER|REACTOME_RNA_POL_III_TRANSCRIPTION_INITIATION_FROM_TYPE_3_PROMOTER|REACTOME_HIV_LIFE_CYCLE|REACTOME_ABORTIVE_ELONGATION_OF_HIV1_TRANSCRIPT_IN_THE_ABSENCE_OF_TAT|REACTOME_RNA_POL_III_TRANSCRIPTION_TERMINATION|REACTOME_FORMATION_OF_THE_HIV1_EARLY_ELONGATION_COMPLEX|REACTOME_VIRAL_MESSENGER_RNA_SYNTHESIS|REACTOME_LATE_PHASE_OF_HIV_LIFE_CYCLE|REACTOME_RNA_POL_III_CHAIN_ELONGATION|REACTOME_RNA_POL_I_TRANSCRIPTION_INITIATION|POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_UP|MCGOWAN_RSP6_TARGETS_DN|YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_10|DNA_DIRECTED_RNA_POLYMERASE_COMPLEX|DNA_DIRECTED_RNA_POLYMERASEII_CORE_COMPLEX|RNA_POLYMERASE_COMPLEX|NUCLEAR_DNA_DIRECTED_RNA_POLYMERASE_COMPLEX|RNA_ELONGATION|NUCLEOTIDE_EXCISION_REPAIR|TRANSCRIPTION_FROM_RNA_POLYMERASE_III_PROMOTER|TRANSCRIPTION_ELONGATION_REGULATOR_ACTIVITY|PROTEIN_N_TERMINUS_BINDING|RNA_POLYMERASE_ACTIVITY	GSE19510,0.5 or 1 uM BPDE vs DMSO or 0.1 uM BPDE WI-38 (fibroblasts)|GSE30240,ionizing radiation vs untreated HepG2 (cervical carcinoma)|GSE30240,ionizing radiation vs untreated TK6 (lymphoblasts)|GSE31199,ERCC1 KO vs WT hippocampus|GSE38123,cisplatin vs PBS primary mouse hepatocytes	GSE1572,young (age =< 42) vs old (age >= 73) frontal cortex|GSE1676,DNA damage by NCS control	5437	5430	5436	5434	5439	5435	5432	5440	2967	5433	2071	1643	9533	7508	5111	5438	6827	10714	84265	10623	2959	51082	22916	7936	2962	2073	3978	2067	2072	57804	25920	5982	8178	6881	50484	6829	6119	10302	6749	5983	6118	6924	6883	51497	6884	6878	6880	2958	155382	4830	8731	2068	56655	79720	51251	6621	8086	30834	5984	3704	9883	55290	5985	29901	10978	4833	5557	51160	7251	8237	9013	6895	5429	1069	5424	124583	5142	54487	5888	6834	4860	100	4832	9328	30833	203	2965	3059	353	1161	3615	5423	6386	10946	1603	65109	2987	7157	11047	29927	23649	2237	286075	53343	5148	7298	10134	1642	4799	5893	112	23204	1716	27343	4090	4350	1854	5422	192670	5898	11130	4059	7084	1479	404672	3251	552900	2879	25874	978	10189	64976	4882	5980	8721	1687	10959	6809	8480	7372	10289	50808	11051	9978	6431	51292	51164	10063	129607	10309
HALLMARK_G2M_CHECKPOINT	M5901								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes involved in the G2/M checkpoint, as in progression through the cell division cycle.			KEGG_DNA_REPLICATION|KEGG_BASE_EXCISION_REPAIR|KEGG_MISMATCH_REPAIR|KEGG_HOMOLOGOUS_RECOMBINATION|KEGG_CELL_CYCLE|BIOCARTA_SRCRPTP_PATHWAY|BIOCARTA_ATM_PATHWAY|BIOCARTA_MCM_PATHWAY|BIOCARTA_G1_PATHWAY|BIOCARTA_G2_PATHWAY|BIOCARTA_CELLCYCLE_PATHWAY|BIOCARTA_SKP2E2F_PATHWAY|BIOCARTA_P53_PATHWAY|BIOCARTA_RB_PATHWAY|BIOCARTA_P27_PATHWAY|BIOCARTA_ATRBRCA_PATHWAY|BIOCARTA_PTC1_PATHWAY|SA_G1_AND_S_PHASES|SA_G2_AND_M_PHASES|SA_REG_CASCADE_OF_CYCLIN_EXPR|PID_FANCONI_PATHWAY|PID_AURORA_B_PATHWAY|PID_E2F_PATHWAY|PID_ATR_PATHWAY|PID_ATM_PATHWAY|PID_PLK1_PATHWAY|PID_FOXM1_PATHWAY|PID_AURORA_A_PATHWAY|PID_BARD1_PATHWAY|PID_RB_1PATHWAY|REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX|REACTOME_BASE_EXCISION_REPAIR|REACTOME_G0_AND_EARLY_G1|REACTOME_RESOLUTION_OF_AP_SITES_VIA_THE_MULTIPLE_NUCLEOTIDE_PATCH_REPLACEMENT_PATHWAY|REACTOME_ASSOCIATION_OF_LICENSING_FACTORS_WITH_THE_PRE_REPLICATIVE_COMPLEX|REACTOME_E2F_ENABLED_INHIBITION_OF_PRE_REPLICATION_COMPLEX_FORMATION|REACTOME_BASE_FREE_SUGAR_PHOSPHATE_REMOVAL_VIA_THE_SINGLE_NUCLEOTIDE_REPLACEMENT_PATHWAY|REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_LAGGING_STRAND|REACTOME_HOMOLOGOUS_RECOMBINATION_REPAIR_OF_REPLICATION_INDEPENDENT_DOUBLE_STRAND_BREAKS|REACTOME_G1_PHASE|REACTOME_CDC6_ASSOCIATION_WITH_THE_ORC_ORIGIN_COMPLEX|REACTOME_POL_SWITCHING|REACTOME_REGULATION_OF_THE_FANCONI_ANEMIA_PATHWAY|REACTOME_FANCONI_ANEMIA_PATHWAY|REACTOME_CYCLIN_A_B1_ASSOCIATED_EVENTS_DURING_G2_M_TRANSITION|REACTOME_REPAIR_SYNTHESIS_FOR_GAP_FILLING_BY_DNA_POL_IN_TC_NER|REACTOME_DOUBLE_STRAND_BREAK_REPAIR|REACTOME_LAGGING_STRAND_SYNTHESIS|REACTOME_INHIBITION_OF_REPLICATION_INITIATION_OF_DAMAGED_DNA_BY_RB1_E2F1|REACTOME_E2F_MEDIATED_REGULATION_OF_DNA_REPLICATION|REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS|REACTOME_UNWINDING_OF_DNA|REACTOME_G1_S_SPECIFIC_TRANSCRIPTION|REACTOME_REMOVAL_OF_THE_FLAP_INTERMEDIATE_FROM_THE_C_STRAND|REACTOME_EXTENSION_OF_TELOMERES|REACTOME_G2_M_CHECKPOINTS|REACTOME_G2_M_DNA_DAMAGE_CHECKPOINT|REACTOME_DNA_STRAND_ELONGATION|REACTOME_RESOLUTION_OF_AP_SITES_VIA_THE_SINGLE_NUCLEOTIDE_REPLACEMENT_PATHWAY|NAKAMURA_CANCER_MICROENVIRONMENT_DN|WEST_ADRENOCORTICAL_TUMOR_MARKERS_UP|PYEON_HPV_POSITIVE_TUMORS_UP|FOURNIER_ACINAR_DEVELOPMENT_LATE_DN|SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP|CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_UP|ZERBINI_RESPONSE_TO_SULINDAC_DN|WILCOX_RESPONSE_TO_PROGESTERONE_UP|HORIUCHI_WTAP_TARGETS_DN|BASAKI_YBX1_TARGETS_UP|VECCHI_GASTRIC_CANCER_EARLY_UP|SLEBOS_HEAD_AND_NECK_CANCER_WITH_HPV_UP|GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_DN|ODONNELL_TFRC_TARGETS_DN|ODONNELL_TARGETS_OF_MYC_AND_TFRC_DN|SCIBETTA_KDM5B_TARGETS_DN|GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_UP|GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_UP|GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN|BIDUS_METASTASIS_UP|LINDGREN_BLADDER_CANCER_CLUSTER_1_DN|LINDGREN_BLADDER_CANCER_CLUSTER_3_UP|NADERI_BREAST_CANCER_PROGNOSIS_UP|MARKEY_RB1_CHRONIC_LOF_UP|MARKEY_RB1_ACUTE_LOF_UP|CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN|BERENJENO_TRANSFORMED_BY_RHOA_UP|MISSIAGLIA_REGULATED_BY_METHYLATION_DN|TANG_SENESCENCE_TP53_TARGETS_DN|JOHANSSON_GLIOMAGENESIS_BY_PDGFB_UP|NUNODA_RESPONSE_TO_DASATINIB_IMATINIB_UP|OLSSON_E2F3_TARGETS_DN|MARKS_HDAC_TARGETS_DN|KONG_E2F3_TARGETS|EGUCHI_CELL_CYCLE_RB1_TARGETS|CROSBY_E2F4_TARGETS|RIZ_ERYTHROID_DIFFERENTIATION|RIZ_ERYTHROID_DIFFERENTIATION_CCNE1|WAKASUGI_HAVE_ZNF143_BINDING_SITES|BAKER_HEMATOPOIESIS_STAT3_TARGETS|BAKER_HEMATOPOESIS_STAT5_TARGETS|MATHEW_FANCONI_ANEMIA_GENES|IWANAGA_E2F1_TARGETS_NOT_INDUCED_BY_SERUM|FARMER_BREAST_CANCER_CLUSTER_2|ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER|OHASHI_AURKA_TARGETS|OHASHI_AURKB_TARGETS|HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2|HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_DN|XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_DN|XU_HGF_TARGETS_INDUCED_BY_AKT1_48HR_DN|KORKOLA_TERATOMA|AMUNDSON_GENOTOXIC_SIGNATURE|LI_WILMS_TUMOR_ANAPLASTIC_UP|MANN_RESPONSE_TO_AMIFOSTINE_DN|OXFORD_RALA_OR_RALB_TARGETS_UP|LI_WILMS_TUMOR_VS_FETAL_KIDNEY_2_UP|SEMBA_FHIT_TARGETS_DN|FURUKAWA_DUSP6_TARGETS_PCI35_DN|PUJANA_BREAST_CANCER_LIT_INT_NETWORK|PUJANA_XPRSS_INT_NETWORK|PUJANA_BRCA2_PCC_NETWORK|PUJANA_BRCA_CENTERED_NETWORK|KAUFFMANN_MELANOMA_RELAPSE_UP|GROSS_HYPOXIA_VIA_ELK3_UP|GROSS_HYPOXIA_VIA_HIF1A_UP|GROSS_HYPOXIA_VIA_ELK3_ONLY_DN|GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_DN|FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_UP|SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_DN|GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN|RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_DN|BENPORATH_CYCLING_GENES|BENPORATH_PROLIFERATION|BENPORATH_ES_CORE_NINE_CORRELATED|GEORGES_CELL_CYCLE_MIR192_TARGETS|JEON_SMAD6_TARGETS_DN|MORI_PRE_BI_LYMPHOCYTE_UP|MORI_LARGE_PRE_BII_LYMPHOCYTE_UP|MORI_IMMATURE_B_LYMPHOCYTE_DN|KAUFFMANN_DNA_REPAIR_GENES|KAUFFMANN_DNA_REPLICATION_GENES|SHEPARD_BMYB_MORPHOLINO_DN|SHEPARD_BMYB_TARGETS|SHEPARD_CRUSH_AND_BURN_MUTANT_DN|MANALO_HYPOXIA_DN|VANTVEER_BREAST_CANCER_METASTASIS_DN|LE_EGR2_TARGETS_UP|PENG_GLUCOSE_DEPRIVATION_DN|VANTVEER_BREAST_CANCER_METASTASIS_UP|REN_BOUND_BY_E2F|PEART_HDAC_PROLIFERATION_CLUSTER_DN|SASAKI_ADULT_T_CELL_LEUKEMIA|YU_MYC_TARGETS_UP|LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_DN|NEMETH_INFLAMMATORY_RESPONSE_LPS_DN|ZHAN_MULTIPLE_MYELOMA_PR_UP|PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP|AFFAR_YY1_TARGETS_DN|VERNELL_RETINOBLASTOMA_PATHWAY_UP|KAMMINGA_EZH2_TARGETS|GREENBAUM_E2A_TARGETS_UP|PETROVA_PROX1_TARGETS_UP|LY_AGING_PREMATURE_DN|ZAMORA_NOS2_TARGETS_UP|PAL_PRMT5_TARGETS_UP|CHUANG_OXIDATIVE_STRESS_RESPONSE_DN|KANG_DOXORUBICIN_RESISTANCE_UP|RHODES_UNDIFFERENTIATED_CANCER|BURTON_ADIPOGENESIS_3|BURTON_ADIPOGENESIS_PEAK_AT_24HR|SONG_TARGETS_OF_IE86_CMV_PROTEIN|MMS_MOUSE_LYMPH_HIGH_4HRS_UP|LIANG_SILENCED_BY_METHYLATION_DN|KALMA_E2F1_TARGETS|LY_AGING_OLD_DN|WANG_CISPLATIN_RESPONSE_AND_XPC_UP|SIMBULAN_PARP1_TARGETS_DN|LY_AGING_MIDDLE_DN|HU_GENOTOXIC_DAMAGE_4HR|BURTON_ADIPOGENESIS_PEAK_AT_16HR|GAVIN_FOXP3_TARGETS_CLUSTER_P6|MARSON_BOUND_BY_E2F4_UNSTIMULATED|STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_DN|AMUNDSON_GAMMA_RADIATION_RESPONSE|FINETTI_BREAST_CANCER_KINOME_RED|SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_UP|FUJII_YBX1_TARGETS_DN|MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN|MITSIADES_RESPONSE_TO_APLIDIN_DN|SMID_BREAST_CANCER_LUMINAL_A_DN|KUMAMOTO_RESPONSE_TO_NUTLIN_3A_DN|ZHENG_GLIOBLASTOMA_PLASTICITY_UP|MATZUK_MEIOTIC_AND_DNA_REPAIR|MATZUK_SPERMATOCYTE|WHITEFORD_PEDIATRIC_CANCER_MARKERS|WEST_ADRENOCORTICAL_TUMOR_UP|BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_UP|RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_UP|THUM_MIR21_TARGETS_HEART_DISEASE_DN|BLUM_RESPONSE_TO_SALIRASIB_DN|MUELLER_PLURINET|REICHERT_G1S_REGULATORS_AS_PI3K_TARGETS|BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_UP|PIONTEK_PKD1_TARGETS_DN|FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN|GOLDRATH_ANTIGEN_RESPONSE|RUIZ_TNC_TARGETS_DN|CHANG_CORE_SERUM_RESPONSE_UP|CHANG_CYCLING_GENES|HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_UP|LEE_EARLY_T_LYMPHOCYTE_UP|LI_WILMS_TUMOR|SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6|ZHANG_TLX_TARGETS_36HR_DN|ZHANG_TLX_TARGETS_60HR_DN|ZHANG_TLX_TARGETS_DN|CROONQUIST_IL6_DEPRIVATION_DN|CROONQUIST_NRAS_SIGNALING_DN|ISHIDA_E2F_TARGETS|BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP|BOYAULT_LIVER_CANCER_SUBCLASS_G23_UP|BOYAULT_LIVER_CANCER_SUBCLASS_G123_UP|CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP|MONTERO_THYROID_CANCER_POOR_SURVIVAL_UP|GLINSKY_CANCER_DEATH_UP|PUJANA_BREAST_CANCER_WITH_BRCA1_MUTATED_UP|STEIN_ESR1_TARGETS|KOBAYASHI_EGFR_SIGNALING_24HR_DN|FOURNIER_ACINAR_DEVELOPMENT_LATE_2|PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP|CAIRO_HEPATOBLASTOMA_CLASSES_UP|WINNEPENNINCKX_MELANOMA_METASTASIS_UP|VANTVEER_BREAST_CANCER_POOR_PROGNOSIS|CHIARETTI_T_ALL_RELAPSE_PROGNOSIS|WONG_EMBRYONIC_STEM_CELL_CORE|NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP|YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_15|WHITFIELD_CELL_CYCLE_LITERATURE|WU_APOPTOSIS_BY_CDKN1A_VIA_TP53|WU_APOPTOSIS_BY_CDKN1A_NOT_VIA_TP53|WHITFIELD_CELL_CYCLE_G1_S|WHITFIELD_CELL_CYCLE_S|WHITFIELD_CELL_CYCLE_G2|WHITFIELD_CELL_CYCLE_G2_M|WHITFIELD_CELL_CYCLE_M_G1|WANG_METASTASIS_OF_BREAST_CANCER_ESR1_UP|WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_DN|DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP|ZHU_SKIL_TARGETS_DN|DELPUECH_FOXO3_TARGETS_DN|DORMOY_ELAVL1_TARGETS|FEVR_CTNNB1_TARGETS_DN|GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP|WANG_THOC1_TARGETS_UP|JUBAN_TARGETS_OF_SPI1_AND_FLI1_DN|LE_NEURONAL_DIFFERENTIATION_DN|REICHERT_MITOSIS_LIN9_TARGETS|YU_BAP1_TARGETS|ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_2HR|ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR|ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR|E2F_01|E2F_02|E2F_Q3|E2F_Q4|E2F_Q6|E2F1_Q3|E2F1_Q4|E2F1_Q6|E2F_03|E2F1DP1_01|E2F1DP2_01|E2F4DP1_01|E2F4DP2_01|E2F1DP1RB_01|E2F_Q3_01|E2F_Q4_01|E2F_Q6_01|E2F1_Q3_01|E2F1_Q4_01|E2F1_Q6_01|KTGGYRSGAA_UNKNOWN|RRCCGTTA_UNKNOWN|SGCGSSAAA_E2F1DP2_01|GNF2_BUB1|GNF2_CDC20|GNF2_CDC2|GNF2_CENPE|GNF2_CENPF|GNF2_CCNA2|GNF2_CCNB2|GNF2_ESPL1|GNF2_FEN1|GNF2_H2AFX|GNF2_PCNA|GNF2_RFC3|GNF2_RFC4|GNF2_RRM1|GNF2_RRM2|GNF2_SMC2L1|GNF2_SMC4L1|GNF2_BUB1B|GNF2_CKS1B|GNF2_CKS2|GNF2_HMMR|GNF2_MCM4|GNF2_MKI67|GNF2_TTK|MODULE_54|MODULE_57|MODULE_98|MODULE_123|MODULE_124|MODULE_125|MODULE_158|MODULE_197|MODULE_198|MODULE_244|MODULE_252|MODULE_303|MODULE_308|MODULE_315|MODULE_320|MODULE_325|MODULE_337|MODULE_360|MODULE_372|MODULE_397|MODULE_403|MODULE_451|MODULE_485|CHROMATIN|NUCLEAR_REPLICATION_FORK|NUCLEAR_CHROMOSOME|CHROMOSOMEPERICENTRIC_REGION|CONDENSED_NUCLEAR_CHROMOSOME|REPLICATION_FORK|KINETOCHORE|NUCLEAR_CHROMATIN|NUCLEOLAR_PART|CHROMOSOMAL_PART|CONDENSED_CHROMOSOME|CHROMOSOME|NUCLEAR_CHROMOSOME_PART|DNA_METABOLIC_PROCESS|DNA_REPAIR|MITOTIC_CELL_CYCLE_CHECKPOINT|NEGATIVE_REGULATION_OF_DNA_METABOLIC_PROCESS|MEIOSIS_I|REGULATION_OF_DNA_REPLICATION|RESPONSE_TO_ENDOGENOUS_STIMULUS|M_PHASE|NEGATIVE_REGULATION_OF_CELL_CYCLE|DNA_INTEGRITY_CHECKPOINT|REGULATION_OF_MITOSIS|INTERPHASE|CELL_CYCLE_PROCESS|MITOTIC_SISTER_CHROMATID_SEGREGATION|REGULATION_OF_DNA_METABOLIC_PROCESS|MEIOTIC_CELL_CYCLE|MITOTIC_CELL_CYCLE|CELL_CYCLE_PHASE|S_PHASE|CELL_CYCLE_CHECKPOINT_GO_0000075|DNA_REPLICATION_INITIATION|CHROMOSOME_SEGREGATION|G1_PHASE_OF_MITOTIC_CELL_CYCLE|REGULATION_OF_MITOTIC_CELL_CYCLE|DNA_REPLICATION|DNA_DAMAGE_RESPONSESIGNAL_TRANSDUCTION|DNA_DAMAGE_RESPONSESIGNAL_TRANSDUCTION_RESULTING_IN_INDUCTION_OF_APOPTOSIS|DNA_DAMAGE_CHECKPOINT|DOUBLE_STRAND_BREAK_REPAIR|NEGATIVE_REGULATION_OF_DNA_REPLICATION|DNA_RECOMBINATION|G1_PHASE|S_PHASE_OF_MITOTIC_CELL_CYCLE|MEIOTIC_RECOMBINATION|CELL_CYCLE_ARREST_GO_0007050|MITOSIS|CELL_CYCLE_GO_0007049|SISTER_CHROMATID_SEGREGATION|POSITIVE_REGULATION_OF_CELL_CYCLE|DNA_DEPENDENT_DNA_REPLICATION|DNA_DAMAGE_RESPONSESIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR|INTERPHASE_OF_MITOTIC_CELL_CYCLE|BASE_EXCISION_REPAIR|RESPONSE_TO_DNA_DAMAGE_STIMULUS|REGULATION_OF_CELL_CYCLE|RNA_CATABOLIC_PROCESS|M_PHASE_OF_MITOTIC_CELL_CYCLE|CHROMOSOME_CONDENSATION|G1_S_TRANSITION_OF_MITOTIC_CELL_CYCLE|INDUCTION_OF_APOPTOSIS_BY_INTRACELLULAR_SIGNALS|ENDODEOXYRIBONUCLEASE_ACTIVITY|DAMAGED_DNA_BINDING|SINGLE_STRANDED_DNA_BINDING|HYDROLASE_ACTIVITY_HYDROLYZING_N_GLYCOSYL_COMPOUNDS|RIBONUCLEASE_ACTIVITY|NUCLEOTIDYLTRANSFERASE_ACTIVITY|DEOXYRIBONUCLEASE_ACTIVITY|ENDORIBONUCLEASE_ACTIVITY|DNA_POLYMERASE_ACTIVITY|3_5_EXONUCLEASE_ACTIVITY|DNA_DIRECTED_DNA_POLYMERASE_ACTIVITY|DOUBLE_STRANDED_DNA_BINDING|ENDONUCLEASE_ACTIVITY|EXONUCLEASE_ACTIVITY|STRUCTURE_SPECIFIC_DNA_BINDING|CHROMATIN_BINDING|NUCLEASE_ACTIVITY|ENDONUCLEASE_ACTIVITY_GO_0016893|E2F1_UP.V1_UP|GCNP_SHH_UP_EARLY.V1_UP|GCNP_SHH_UP_LATE.V1_UP|CSR_LATE_UP.V1_UP|RB_DN.V1_UP|RB_P107_DN.V1_UP|RB_P130_DN.V1_UP|RPS14_DN.V1_DN	GSE6410,untreated vs cisplatin A549 (non small cell carcinoma)|GSE19510,DMSO vs 1 uM BPDE WI-38 (fibroblasts)|GSE20928,calactin vs untreated K562 (chronic myelogenous leukemia)|GSE26922,6-8h (M phase) vs 0-2h (S phase) HeLa (cervical carcinoma)	GSE30240,untreated vs ionized radiation both at 3-6h HepG2 (hepatocellular carcinoma)	6790	890	7153	9133	1058	332	991	5347	7272	9055	10403	3832	51203	1164	11004	4288	9212	22974	10051	699	1063	29127	1062	9493	11065	4175	4172	9232	983	24137	9700	4085	4751	3835	3161	3838	1033	993	3014	994	10733	990	899	4174	4001	1871	56992	1111	27338	7468	3149	10926	10460	4171	1031	1027	2176	4678	10274	51659	26271	10721	2146	5885	3925	6839	5558	1869	10036	9221	2935	9184	8243	3609	8317	3619	1163	9156	3015	7027	595	3837	51155	3930	3364	9585	7150	23047	6426	6491	25	1841	996	580	22809	8318	4953	7514	6421	7112	5371	675	10664	57082	387893	81539	6434	4605	10024	11044	8452	1432	85236	4609	262	10951	5119	1736	91746	904	7040	546	3980	10762	8140	5933	4926	8438	1946	8899	7371	5926	8454	5976	1810	4331	10592	10432	6118	6713	23594	1019	5426	9462	3226	9252	8451	6541	1112	3159	6760	10293	10419	8065	10212	4082	55872	5001	8819	11104	3184	23649	7290	3091	10492	7090	4691	5887	1870	1950	3151	10772	6632	9994	6599	6558	4853	30000	4088	51776	3312	10146	26255	1756	4211	3192	6427	4502	4928	2130	3799	22823	1874	602	5813	4212	5048	7486	94239	4957
HALLMARK_APOPTOSIS	M5902								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes mediating programmed cell death (apoptosis) by activation of caspases.			chr4q34|KEGG_AMYOTROPHIC_LATERAL_SCLEROSIS_ALS|BIOCARTA_DNAFRAGMENT_PATHWAY|BIOCARTA_CHEMICAL_PATHWAY|BIOCARTA_CASPASE_PATHWAY|BIOCARTA_TID_PATHWAY|BIOCARTA_D4GDI_PATHWAY|BIOCARTA_FAS_PATHWAY|BIOCARTA_SET_PATHWAY|BIOCARTA_HIVNEF_PATHWAY|BIOCARTA_DEATH_PATHWAY|BIOCARTA_PML_PATHWAY|BIOCARTA_MITOCHONDRIA_PATHWAY|BIOCARTA_HSP27_PATHWAY|BIOCARTA_TNFR1_PATHWAY|SA_CASPASE_CASCADE|SA_FAS_SIGNALING|SA_MMP_CYTOKINE_CONNECTION|SA_PROGRAMMED_CELL_DEATH|PID_HIV_NEF_PATHWAY|PID_CASPASE_PATHWAY|REACTOME_APOPTOTIC_CLEAVAGE_OF_CELLULAR_PROTEINS|REACTOME_SIGNALING_BY_HIPPO|REACTOME_APOPTOSIS_INDUCED_DNA_FRAGMENTATION|REACTOME_CASPASE_MEDIATED_CLEAVAGE_OF_CYTOSKELETAL_PROTEINS|REACTOME_APOPTOTIC_CLEAVAGE_OF_CELL_ADHESION_PROTEINS|REACTOME_ROLE_OF_DCC_IN_REGULATING_APOPTOSIS|REACTOME_ACTIVATION_OF_BH3_ONLY_PROTEINS|REACTOME_INTRINSIC_PATHWAY_FOR_APOPTOSIS|REACTOME_APOPTOTIC_EXECUTION_PHASE|HUMMEL_BURKITTS_LYMPHOMA_DN|KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_UP|KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_DN|KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_UP|KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_DN|LAU_APOPTOSIS_CDKN2A_UP|NUNODA_RESPONSE_TO_DASATINIB_IMATINIB_DN|MARKS_HDAC_TARGETS_UP|GALLUZZI_PERMEABILIZE_MITOCHONDRIA|DUTTA_APOPTOSIS_VIA_NFKB|GALLUZZI_PREVENT_MITOCHONDIAL_PERMEABILIZATION|MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_18|DIRMEIER_LMP1_RESPONSE_LATE_UP|SHANK_TAL1_TARGETS_DN|SHIN_B_CELL_LYMPHOMA_CLUSTER_3|STANELLE_E2F1_TARGETS|HOFMANN_CELL_LYMPHOMA_DN|ABRAHAM_ALPC_VS_MULTIPLE_MYELOMA_UP|NATSUME_RESPONSE_TO_INTERFERON_BETA_UP|GEISS_RESPONSE_TO_DSRNA_UP|TESAR_JAK_TARGETS_MOUSE_ES_D3_UP|GALI_TP53_TARGETS_APOPTOTIC_UP|MODULE_254|MODULE_300|MODULE_312|MODULE_399|MODULE_439|MODULE_537|MITOCHONDRIAL_OUTER_MEMBRANE|OUTER_MEMBRANE|ORGANELLE_OUTER_MEMBRANE|REGULATION_OF_HYDROLASE_ACTIVITY|PROTEIN_TARGETING_TO_MITOCHONDRION|CELL_STRUCTURE_DISASSEMBLY_DURING_APOPTOSIS|APOPTOTIC_NUCLEAR_CHANGES|INDUCTION_OF_APOPTOSIS_BY_EXTRACELLULAR_SIGNALS|RESPONSE_TO_TOXIN|CELLULAR_COMPONENT_DISASSEMBLY|NUCLEAR_ORGANIZATION_AND_BIOGENESIS|POSITIVE_REGULATION_OF_HYDROLASE_ACTIVITY|MITOCHONDRIAL_MEMBRANE_ORGANIZATION_AND_BIOGENESIS|POSITIVE_REGULATION_OF_CASPASE_ACTIVITY|MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS|DNA_CATABOLIC_PROCESS|APOPTOTIC_MITOCHONDRIAL_CHANGES|APOPTOTIC_PROGRAM|DNA_FRAGMENTATION_DURING_APOPTOSIS|MITOCHONDRIAL_TRANSPORT|REGULATION_OF_MEMBRANE_POTENTIAL|CASPASE_ACTIVATION	GSE11618,XIAP KD (shRNA) vs control HCT116 (large intestine carcinoma)|GSE24224,decitabine vs control HL-60 (acute myeloid leukemia)|GSE36619,ET-770 vs control U373MG (glioblastoma)|E-MTAB-696,-NGF vs +NGF developing sympathetic neurons|GSE41827,Cas-II-gly vs control HeLa	GSE39042,paclitaxel vs control MDA-MB-231 (breast carcinoma)|GSE43714,MG132 vs untreated both ATF5 WT MEF	836	842	1676	840	8837	330	5366	841	3725	10018	4170	3553	6709	56616	581	638	3552	637	1026	1647	1649	1027	7124	2934	8743	839	8878	356	1960	960	355	3606	3489	5551	1611	595	10950	2149	6304	665	837	51330	1387	388	2878	5159	706	894	331	7076	1499	3659	3315	118	7077	7832	7078	51176	834	2876	8915	3482	994	150209	952	5534	3082	1191	467	3958	4060	4000	4616	1017	3456	54884	4092	6647	5747	2026	3162	8870	10017	914	2643	4313	7417	6890	5327	3459	351	672	6093	5663	1634	5664	6648	90427	2069	3875	7042	5970	7465	5914	929	969	8682	5611	835	1491	5330	650	3148	9890	3005	7049	10682	10628	56172	89941	1540	2944	2936	633	598	2769	4255	5538	2147	3569	6309	10410	6041	2012	857	10059	301	7153	3669	6574	8567	5526	10134	2065	4739	6303	27250	599	9638	2064	3301	7818	1806	4744	5058	2232	2879	2107	8900	3000	552
HALLMARK_NOTCH_SIGNALING	M5903								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated by activation of Notch signaling.			KEGG_WNT_SIGNALING_PATHWAY|KEGG_NOTCH_SIGNALING_PATHWAY|KEGG_HEDGEHOG_SIGNALING_PATHWAY|KEGG_MELANOGENESIS|KEGG_BASAL_CELL_CARCINOMA|BIOCARTA_GSK3_PATHWAY|BIOCARTA_PITX2_PATHWAY|BIOCARTA_PS1_PATHWAY|BIOCARTA_WNT_PATHWAY|WNT_SIGNALING|ST_WNT_BETA_CATENIN_PATHWAY|PID_SMAD2_3NUCLEAR_PATHWAY|PID_NOTCH_PATHWAY|PID_WNT_NONCANONICAL_PATHWAY|PID_BETA_CATENIN_DEG_PATHWAY|PID_PS1_PATHWAY|PID_WNT_SIGNALING_PATHWAY|PID_WNT_CANONICAL_PATHWAY|PID_TELOMERASE_PATHWAY|PID_HEDGEHOG_GLI_PATHWAY|PID_BETA_CATENIN_NUC_PATHWAY|PID_SYNDECAN_3_PATHWAY|PID_P53_REGULATION_PATHWAY|PID_HES_HEY_PATHWAY|REACTOME_PRE_NOTCH_TRANSCRIPTION_AND_TRANSLATION|REACTOME_ACTIVATED_NOTCH1_TRANSMITS_SIGNAL_TO_THE_NUCLEUS|REACTOME_SIGNALING_BY_NOTCH4|REACTOME_SIGNALING_BY_NOTCH2|REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING|REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION|REACTOME_PRE_NOTCH_PROCESSING_IN_GOLGI|REACTOME_SIGNALING_BY_NOTCH1|REACTOME_SIGNALING_BY_NOTCH3|REACTOME_REGULATED_PROTEOLYSIS_OF_P75NTR|REACTOME_NRIF_SIGNALS_CELL_DEATH_FROM_THE_NUCLEUS|REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY|REACTOME_RECEPTOR_LIGAND_BINDING_INITIATES_THE_SECOND_PROTEOLYTIC_CLEAVAGE_OF_NOTCH_RECEPTOR|REACTOME_SIGNALING_BY_NOTCH|LIU_CDX2_TARGETS_UP|SHIN_B_CELL_LYMPHOMA_CLUSTER_7|ROZANOV_MMP14_CORRELATED|HOEGERKORP_CD44_TARGETS_DIRECT_DN|FUKUSHIMA_TNFSF11_TARGETS|LIU_IL13_PRIMING_MODEL|TAXCREB_02|GLYCOPROTEIN_CATABOLIC_PROCESS|PROTEIN_MATURATION|NOTCH_SIGNALING_PATHWAY|AMYLOID_PRECURSOR_PROTEIN_METABOLIC_PROCESS	GSE6495,vehicle vs GSI MOLT4 cells (acute lymphoblastic T cell leukemia)|GSE14995,JAG1 OE vs control|GSE16906,JAG1 OE vs control|GSE42259,DLL4-Fc vs untreated THP-1 (acute myeloid leukemia)	GSE5716,vehicle vs GSI at 24h in GSI sensitive T-ALL cells	182	4854	4853	51107	3280	595	8321	5664	8324	1840	28514	7855	84441	4851	55851	7474	8454	7472	23220	8819	5467	2648	26508	6500	9978	6934	408	3955	5578	113878	10402	23291
HALLMARK_ADIPOGENESIS	M5905								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated during adipocyte differentiation (adipogenesis).			KEGG_BIOSYNTHESIS_OF_UNSATURATED_FATTY_ACIDS|KEGG_PPAR_SIGNALING_PATHWAY|KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY|REACTOME_TRIGLYCERIDE_BIOSYNTHESIS|REACTOME_FATTY_ACYL_COA_BIOSYNTHESIS|REACTOME_SYNTHESIS_OF_VERY_LONG_CHAIN_FATTY_ACYL_COAS|LANDIS_BREAST_CANCER_PROGRESSION_DN|LANDIS_ERBB2_BREAST_TUMORS_65_DN|LANDIS_ERBB2_BREAST_PRENEOPLASTIC_DN|LANDIS_ERBB2_BREAST_TUMORS_324_DN|BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_DN|NADLER_OBESITY_DN|URS_ADIPOCYTE_DIFFERENTIATION_UP|RUAN_RESPONSE_TO_TROGLITAZONE_UP|RUAN_RESPONSE_TO_TNF_TROGLITAZONE_DN|RUAN_RESPONSE_TO_TNF_DN|BURTON_ADIPOGENESIS_5|LI_ADIPOGENESIS_BY_ACTIVATED_PPARG|GERHOLD_ADIPOGENESIS_UP|BURTON_ADIPOGENESIS_6|SMID_BREAST_CANCER_RELAPSE_IN_LUNG_DN|SMID_BREAST_CANCER_RELAPSE_IN_LIVER_DN|SMID_BREAST_CANCER_LUMINAL_A_UP|BOQUEST_STEM_CELL_CULTURED_VS_FRESH_DN|RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_DN|CADWELL_ATG16L1_TARGETS_UP|ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_DN|ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_DN|NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN|RUAN_RESPONSE_TO_TROGLITAZONE_DN|WANG_CLASSIC_ADIPOGENIC_TARGETS_OF_PPARG|STEGER_ADIPOGENESIS_UP|WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_36HR|WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D|WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4K20ME1_MARK|VERNOCHET_ADIPOGENESIS	GSE2192,adipogenesis day 10 vs day 0 NIH-3T3L1 (fibroblasts)|GSE6795,adipogenesis day 3..28 vs earlier timepoints NIH-3T3L1 (fibroblasts)|GSE20697,adipogenesis days 5..14 vs days -2..3 adipose stem cells|GSE38321,FAT vs WT subcutaneous white adipose tissue	E-TABM-668,adipocyte differentiation day 11 vs day 6 MEF|GSE2926,SCD1 KO vs WT liver|GSE44626,hydrocortisone vs control adipose stem cells	2167	9370	5468	3991	8694	4023	1376	948	57678	79602	10449	2109	51	34	3033	3417	10580	35	83549	6342	1666	1031	6888	7263	56922	5236	7905	23786	1468	4199	5264	415116	7532	4706	2820	149685	1892	5860	1431	1891	6576	33	10140	80273	1384	2632	8436	949	10400	400916	204	348	29796	10010	51129	50	2184	47	3459	8884	84522	2053	3421	2878	84173	5004	54884	2101	26275	8802	6776	3679	56246	123	1537	217	26994	226	6817	1652	6390	977	376497	593	718	3952	112	79071	4056	8404	55177	23788	65124	6510	51727	92840	4698	8322	128338	4259	483	56729	2040	23344	27069	29103	1647	7423	5211	51805	64859	1580	5495	369	284119	1282	10989	51635	1306	4836	84274	3910	56894	11176	3419	3977	10113	5733	10243	5209	2879	8082	58472	54996	1738	80760	9936	64225	137964	10162	7086	7384	847	4958	1737	29088	8780	10313	1147	9908	6391	25813	10124	6623	27250	57017	334	6647	55037	23187	5168	26353	9131	901	84919	4191	19	1349	4638	1351	25979	84895	11343	6453	1717	6239	134147	7316	539	10935	1629	4722	28512	83871	1149	27089	5195	604	1337	4189	8491	284	29979	4713	6573	11194	130814	5447	7351	10975
HALLMARK_ESTROGEN_RESPONSE_EARLY	M5906								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes defining early response to estrogen.			SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN|SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN|CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_DN|CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP|CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP|CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP|DOANE_BREAST_CANCER_CLASSES_UP|DOANE_RESPONSE_TO_ANDROGEN_UP|DOANE_BREAST_CANCER_ESR1_UP|RODRIGUES_NTN1_TARGETS_DN|JAEGER_METASTASIS_DN|WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP|WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP|DODD_NASOPHARYNGEAL_CARCINOMA_UP|COLDREN_GEFITINIB_RESISTANCE_DN|AIGNER_ZEB1_TARGETS|FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL|FARMER_BREAST_CANCER_APOCRINE_VS_BASAL|FARMER_BREAST_CANCER_BASAL_VS_LULMINAL|LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN|YANG_BREAST_CANCER_ESR1_UP|WILLIAMS_ESR1_TARGETS_UP|WU_CELL_MIGRATION|ONDER_CDH1_TARGETS_2_DN|FRASOR_RESPONSE_TO_ESTRADIOL_UP|STOSSI_RESPONSE_TO_ESTRADIOL|XU_GH1_AUTOCRINE_TARGETS_DN|CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1|CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2|CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4|RIGGINS_TAMOXIFEN_RESISTANCE_DN|STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_UP|MASSARWEH_TAMOXIFEN_RESISTANCE_DN|MASSARWEH_RESPONSE_TO_ESTRADIOL|MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_UP|SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_DN|SMID_BREAST_CANCER_RELAPSE_IN_BONE_UP|SMID_BREAST_CANCER_LUMINAL_B_UP|SMID_BREAST_CANCER_ERBB2_UP|SMID_BREAST_CANCER_BASAL_DN|HUANG_DASATINIB_RESISTANCE_DN|VANTVEER_BREAST_CANCER_ESR1_UP|STEIN_ESTROGEN_RESPONSE_NOT_VIA_ESRRA|DUTERTRE_ESTRADIOL_RESPONSE_6HR_UP|BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP|BHAT_ESR1_TARGETS_VIA_AKT1_UP|LIM_MAMMARY_STEM_CELL_DN|LIM_MAMMARY_LUMINAL_MATURE_UP|ZWANG_EGF_INTERVAL_DN|MODULE_139|MODULE_180|MODULE_342|EGFR_UP.V1_DN|ERB2_UP.V1_DN|P53_DN.V1_UP|LTE2_UP.V1_DN|MEK_UP.V1_DN|RAF_UP.V1_DN|LEF1_UP.V1_DN	GSE5840,10 nM estradiol vs DMSO 4h MCF7 (breast carcinoma)|GSE9757,ESR1 vs empty vector both 1 nM estradiol 6h MDA-MB-231 (breast carcinoma)|GSE15717,10 nM estradiol vs ethanol 4h MCF7 (breast carcinoma)|GSE36683,10 nM estradiol vs ethanol 6h MCF7 (breast carcinoma)	GSE9936,6 nM estradiol vs ethanol 4h MCF7 (breast carcinoma)|GSE11791,100 nM estradiol vs ethanol 6h MCF7 (breast carcinoma)	9687	771	9368	4602	8416	3487	55638	4886	5174	8204	79083	26353	1960	3880	26018	23030	5241	22836	7164	54898	5979	7162	7031	4137	6337	18	2317	7494	1952	11031	4603	55686	399665	4477	8614	54463	6478	7739	10560	6509	2274	596	5366	374	58495	25987	115	10125	4582	23254	11001	2288	6387	64699	5914	55540	863	7033	7357	595	6584	7466	9536	23286	8839	4609	3705	84187	403	23389	7869	3875	6566	27134	1836	9214	6820	28966	7022	22996	2697	11098	10439	51195	79754	25976	21	2444	10202	360	60598	60436	2296	1999	65055	8800	5420	9314	573	9620	11145	8140	744	7074	1366	26509	5932	56944	2674	10160	6840	7052	64798	56603	9060	6505	10395	3717	4299	5655	5029	645	1154	2717	120	27295	55793	2353	3856	54020	2683	799	80004	3480	4681	2810	23596	11057	367	25800	91683	960	9862	64919	124583	3860	3866	10140	6542	3898	347733	23329	23541	23052	55806	949	9612	29984	22876	10105	9249	2222	9846	9094	7071	3280	2289	6513	267	55191	3625	8553	794	2194	56994	10514	60481	6990	3983	6658	57419	64284	375449	8645	1997	6196	81875	3572	9145	9467	221	79875	9022	29107	89797	23223	107	1717	4277	8165
HALLMARK_ESTROGEN_RESPONSE_LATE	M5907								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes defining late response to estrogen.			SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN|SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN|CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_DN|CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP|CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP|CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP|DOANE_BREAST_CANCER_CLASSES_UP|DOANE_RESPONSE_TO_ANDROGEN_UP|DOANE_BREAST_CANCER_ESR1_UP|RODRIGUES_NTN1_TARGETS_DN|JAEGER_METASTASIS_DN|WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP|WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP|DODD_NASOPHARYNGEAL_CARCINOMA_UP|COLDREN_GEFITINIB_RESISTANCE_DN|AIGNER_ZEB1_TARGETS|FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL|FARMER_BREAST_CANCER_APOCRINE_VS_BASAL|FARMER_BREAST_CANCER_BASAL_VS_LULMINAL|LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN|YANG_BREAST_CANCER_ESR1_UP|WILLIAMS_ESR1_TARGETS_UP|WU_CELL_MIGRATION|ONDER_CDH1_TARGETS_2_DN|FRASOR_RESPONSE_TO_ESTRADIOL_UP|STOSSI_RESPONSE_TO_ESTRADIOL|XU_GH1_AUTOCRINE_TARGETS_DN|CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1|CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2|CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4|RIGGINS_TAMOXIFEN_RESISTANCE_DN|STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_UP|MASSARWEH_TAMOXIFEN_RESISTANCE_DN|MASSARWEH_RESPONSE_TO_ESTRADIOL|MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_UP|SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_DN|SMID_BREAST_CANCER_RELAPSE_IN_BONE_UP|SMID_BREAST_CANCER_LUMINAL_B_UP|SMID_BREAST_CANCER_ERBB2_UP|SMID_BREAST_CANCER_BASAL_DN|HUANG_DASATINIB_RESISTANCE_DN|VANTVEER_BREAST_CANCER_ESR1_UP|STEIN_ESTROGEN_RESPONSE_NOT_VIA_ESRRA|DUTERTRE_ESTRADIOL_RESPONSE_6HR_UP|BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP|BHAT_ESR1_TARGETS_VIA_AKT1_UP|LIM_MAMMARY_STEM_CELL_DN|LIM_MAMMARY_LUMINAL_MATURE_UP|ZWANG_EGF_INTERVAL_DN|MODULE_139|MODULE_180|MODULE_342|EGFR_UP.V1_DN|ERB2_UP.V1_DN|P53_DN.V1_UP|LTE2_UP.V1_DN|MEK_UP.V1_DN|RAF_UP.V1_DN|LEF1_UP.V1_DN	GSE2251,ESR1 OE 100 nM estradiol vs ethanol 24h MDA-MB-231 (breast carcinoma)|GSE2292,estradiol vs control 24h U-2 OS (osteosarcoma)|GSE8597,25 nM estradiol vs ethanol 24h MCF7 (breast carcinoma)|GSE26834,10 nM estradiol vs control 24h MCF7 (breast carcinoma)	GSE9936,6 nM estradiol vs ethanol 24h MCF7 (breast carcinoma)|GSE11352,estradiol vs untreated >12h MCF7 (breast carcinoma)	7031	9368	7164	11098	771	5174	8416	1952	27134	5241	5979	4602	7162	1960	403	10439	4886	6337	7494	374	55540	8204	445	7033	2288	11001	7869	2852	3993	10551	3880	8839	645	2317	27250	799	3487	56521	7074	27075	6387	11031	11187	56603	2289	6478	3669	64699	12	7466	4137	27295	5932	2707	5618	6509	2353	11145	8140	5104	3613	1717	26509	999	2013	58495	9231	6658	56994	5655	60481	51195	3717	1836	6584	3705	5121	9060	4665	399665	596	51599	9254	760	429	8309	1154	2717	9536	64065	23596	3860	26353	7358	9022	11012	10761	11057	949	51181	595	2810	21	6820	8900	6491	4277	7538	857	4681	960	55806	9455	10950	51083	2109	573	2444	6566	4299	7022	3547	3251	990	10160	267	10202	29107	6280	2030	57419	2296	10112	10140	2222	64215	7177	7264	2261	6446	3398	2582	10538	5603	2171	4232	3716	57834	8645	1363	7517	9547	57758	991	3572	51659	23650	10497	3918	9215	29988	5364	5577	6196	22824	7980	5265	7134	3158	224	928	3418	6652	4192	221	5733	9135	9314	10105	29887	56339	10733	1345	6768	9612	4338	10874	7054	10535	64377	7263	7153	1152	4057	1844	5777	493	10610	120	6990
HALLMARK_ANDROGEN_RESPONSE	M5908								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes defining response to androgens.			PID_AR_PATHWAY|WANG_RESPONSE_TO_ANDROGEN_UP|WANG_RESPONSE_TO_FORSKOLIN_UP|WANG_RESPONSE_TO_FORSKOLIN_DN|BYSTRYKH_SCP2_QTL|NELSON_RESPONSE_TO_ANDROGEN_UP|ACGCACA_MIR210|GGCGGCA_MIR371	GSE4636,10 nM DHT vs ethanol 24h LNCaP (prostate adenocarcinoma)|GSE14988,100 nM DHT vs control 48h LNCaP (prostate adenocarcinoma)|GSE39354,10 nM DHT vs ethanol 16h VCaP (prostate adenocarcinoma)|GSE39354,10 nM DHT vs ethanol 16h LNCaP (prostate adenocarcinoma)	GSE44905,100 nM DHT vs vehicle 16h LNCaP (prostate adenocarcinoma)	354	3817	2181	8554	10645	4824	7113	10513	55839	658	4094	3992	65986	3156	60559	3638	55768	51465	2005	10257	60481	220	445347	563	11057	6303	1622	1718	6652	27347	7163	3422	567	9053	4189	2289	8916	5238	9455	22936	6675	9871	3998	56937	8821	23223	6414	10397	3880	3685	2683	4117	25803	2936	3856	3977	8611	79689	2982	6728	896	10788	5867	1836	6611	57178	6446	10461	3248	56172	2773	6722	54407	3157	84159	8555	25816	7520	23171	87	6197	8848	10611	23585	9510	8031	9590	6319	2185	1021	11047	3005	51171	9218	595	2547	10627	7329	11099	207	5036
HALLMARK_MYOGENESIS	M5909								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes involved in development of skeletal muscle (myogenesis).			chr10p11|REACTOME_STRIATED_MUSCLE_CONTRACTION|REACTOME_MUSCLE_CONTRACTION|REACTOME_SMOOTH_MUSCLE_CONTRACTION|PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_DN|BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN|HUMMERICH_BENIGN_SKIN_TUMOR_DN|HUMMERICH_MALIGNANT_SKIN_TUMOR_DN|EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_UP|HUMMERICH_SKIN_CANCER_PROGRESSION_DN|EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION|WEINMANN_ADAPTATION_TO_HYPOXIA_UP|WEINMANN_ADAPTATION_TO_HYPOXIA_DN|OXFORD_RALA_OR_RALB_TARGETS_DN|TOMLINS_PROSTATE_CANCER_DN|RICKMAN_HEAD_AND_NECK_CANCER_F|NIKOLSKY_BREAST_CANCER_19P13_AMPLICON|COLLER_MYC_TARGETS_DN|DELASERNA_MYOD_TARGETS_UP|APRELIKOVA_BRCA1_TARGETS|KUNINGER_IGF1_VS_PDGFB_TARGETS_UP|DELASERNA_TARGETS_OF_MYOD_AND_SMARCA4|NIELSEN_LEIOMYOSARCOMA_CNN1_UP|DASU_IL6_SIGNALING_SCAR_DN|MARCHINI_TRABECTEDIN_RESISTANCE_DN|DAIRKEE_CANCER_PRONE_RESPONSE_E2|YAUCH_HEDGEHOG_SIGNALING_PARACRINE_DN|FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_UP|DASU_IL6_SIGNALING_DN|WANG_NFKB_TARGETS|CHEMELLO_SOLEUS_VS_EDL_MYOFIBERS_UP|CHEMELLO_SOLEUS_VS_EDL_MYOFIBERS_DN|GNF2_MYL2|GNF2_MYL3|GNF2_TTN|MODULE_201|MODULE_202|MODULE_329|MODULE_330|MODULE_387|MODULE_419|MODULE_512|MODULE_524|SARCOMERE|CONTRACTILE_FIBER|MYOFIBRIL|MYOSIN_COMPLEX|CONTRACTILE_FIBER_PART|ACTIN_FILAMENT|MUSCLE_DEVELOPMENT|DEVELOPMENTAL_MATURATION|STRIATED_MUSCLE_DEVELOPMENT|MYOBLAST_DIFFERENTIATION|REGULATION_OF_MUSCLE_CONTRACTION|MUSCLE_CELL_DIFFERENTIATION|STRIATED_MUSCLE_CONTRACTION_GO_0006941|SMOOTH_MUSCLE_CONTRACTION_GO_0006939|SKELETAL_MUSCLE_DEVELOPMENT|ACTIN_FILAMENT_BASED_MOVEMENT|CELL_MATURATION|ADP_BINDING|STRUCTURAL_CONSTITUENT_OF_MUSCLE|CALMODULIN_BINDING	GSE989,differentiation timecourse days 8-10 vs before day 0 C2C12 (myoblasts)|GSE4131,myotube vs myoblast fetal skeletal myoblasts|GSE10435,myotube vs myoblast FM95-14 (embryonic myoblasts)|GSE16992,differentiation timecourse 96-144h vs (-24)-0.5h C2C12 (myoblasts)	GSE20059,myotube (48h) vs myoblast (95% confluence) C2C12 (myoblasts)|GSE24811,differentiation timecourse day 2 vs day 0 primary myoblasts|GSE24811,differentiation timecourse day 5 vs day 0 primary myoblasts	58	7136	4632	7134	7125	4621	29895	7140	7139	845	70	8736	4635	4608	4625	4626	88	7135	1410	6445	3270	7138	1674	58529	6261	8048	8038	487	1158	6840	9172	140465	7169	4633	1160	274	4619	2027	2314	5348	7170	1756	3486	1140	10290	2273	89	8557	4638	4634	5837	11155	1339	2170	58498	3693	1134	8082	1281	3756	2702	4618	4620	6300	5224	4656	4622	165	1839	4208	4842	1266	3490	8912	2934	786	8497	4151	8877	29970	4209	6525	1026	2548	7164	3316	6442	624	1346	1284	23654	1489	1306	3757	375790	4641	22933	6444	10580	7433	2247	2281	7004	844	688	9260	203	6876	6016	4205	26287	208	3908	6764	3475	4684	9144	9463	1293	1384	1760	4629	4627	3479	1152	10468	2878	5816	11156	3688	26353	43	1146	5569	89797	10014	537	1191	2180	1277	22808	9659	178	2065	11345	859	8553	5507	9215	23175	1012	1728	5621	5664	23604	4046	6535	65055	1974	25970	4607	3679	6709	10174	5091	6319	2775	8614	1675	5925	573	3983	5740	22924	79629	6450	4851	7249	7040	2224	816	2049	4616	351	187	3691	6649	4303	10278	5213	1292	1837	3801	6678	25803	6588	25937	948	115	347
HALLMARK_PROTEIN_SECRETION	M5910								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes involved in protein secretion pathway.			KEGG_ENDOCYTOSIS|BIOCARTA_ARAP_PATHWAY|PID_ARF_3PATHWAY|REACTOME_COPI_MEDIATED_TRANSPORT|REACTOME_NEF_MEDIATED_DOWNREGULATION_OF_MHC_CLASS_I_COMPLEX_CELL_SURFACE_EXPRESSION|REACTOME_MEMBRANE_TRAFFICKING|REACTOME_NEF_MEDIATES_DOWN_MODULATION_OF_CELL_SURFACE_RECEPTORS_BY_RECRUITING_THEM_TO_CLATHRIN_ADAPTERS|REACTOME_TRANS_GOLGI_NETWORK_VESICLE_BUDDING|REACTOME_RETROGRADE_NEUROTROPHIN_SIGNALLING|REACTOME_EGFR_DOWNREGULATION|REACTOME_TRAFFICKING_OF_AMPA_RECEPTORS|REACTOME_TRAFFICKING_OF_GLUR2_CONTAINING_AMPA_RECEPTORS|REACTOME_LYSOSOME_VESICLE_BIOGENESIS|REACTOME_GOLGI_ASSOCIATED_VESICLE_BIOGENESIS|REACTOME_L1CAM_INTERACTIONS|REACTOME_SIGNAL_TRANSDUCTION_BY_L1|REACTOME_RECYCLING_PATHWAY_OF_L1|REACTOME_THE_ROLE_OF_NEF_IN_HIV1_REPLICATION_AND_DISEASE_PATHOGENESIS|MODULE_39|MODULE_264|MODULE_395|MODULE_509|CYTOPLASMIC_VESICLE_MEMBRANE|GOLGI_MEMBRANE|COATED_VESICLE|MEMBRANE_BOUND_VESICLE|LATE_ENDOSOME|VESICLE_COAT|INTEGRAL_TO_GOLGI_MEMBRANE|GOLGI_APPARATUS|LYTIC_VACUOLE|VESICLE|GOLGI_APPARATUS_PART|VACUOLE|SYNAPTIC_VESICLE|CYTOPLASMIC_VESICLE|VACUOLAR_PART|EARLY_ENDOSOME|CYTOPLASMIC_VESICLE_PART|LYSOSOMAL_MEMBRANE|VACUOLAR_MEMBRANE|ENDOSOME|CLATHRIN_COATED_VESICLE|COATED_VESICLE_MEMBRANE|TRANSPORT_VESICLE|CYTOPLASMIC_MEMBRANE_BOUND_VESICLE|SECRETORY_GRANULE|MEMBRANE_COAT|TRANS_GOLGI_NETWORK|GOLGI_ASSOCIATED_VESICLE|LYSOSOME|INTRINSIC_TO_GOLGI_MEMBRANE|COATED_MEMBRANE|TRANS_GOLGI_NETWORK_TRANSPORT_VESICLE|VESICLE_MEMBRANE|REGULATION_OF_CELLULAR_PH|LYSOSOME_ORGANIZATION_AND_BIOGENESIS|SECRETORY_PATHWAY|SECRETION_BY_CELL|MONOVALENT_INORGANIC_CATION_HOMEOSTASIS|POST_GOLGI_VESICLE_MEDIATED_TRANSPORT|INTRA_GOLGI_VESICLE_MEDIATED_TRANSPORT|SPERM_MOTILITY|REGULATION_OF_PH|VACUOLE_ORGANIZATION_AND_BIOGENESIS|CELLULAR_MONOVALENT_INORGANIC_CATION_HOMEOSTASIS|MEMBRANE_ORGANIZATION_AND_BIOGENESIS|SECRETION|GOLGI_VESICLE_TRANSPORT|VESICLE_MEDIATED_TRANSPORT|EXOCYTOSIS|ER_TO_GOLGI_VESICLE_MEDIATED_TRANSPORT|RECEPTOR_MEDIATED_ENDOCYTOSIS|MEMBRANE_FUSION	GSE6475,normal vs acne skin|GSE10432,untreated vs 13-cis retionic acid (inhibits secretion) SEB-1|GSE25724,healthy vs type 2 DM (low insulin secretion) islets|GSE27864,normal vs lesional NOMID (high IL1 secretion) skin	GSE16390,H. pylori uninfected vs infected gastric epithelial cells	372	10972	9276	51552	538	1315	3920	1956	3482	11316	5538	1176	10282	1182	1175	1213	1173	11079	23095	375	4952	3382	23041	10564	10959	8774	81542	5066	9522	6456	5862	22796	9341	51614	23033	8674	9525	8775	2778	8417	9554	11311	8675	10652	6643	10565	1211	1203	4074	259230	8615	7251	10059	3998	286451	27236	81611	7103	667	9805	22872	6845	10067	163	57403	8546	7163	51606	8729	3875	858	476	664	9183	2581	102	5868	2803	9871	164	5594	9570	6197	8027	19	8773	6647	2717	525	23673	967	10040	8082	26286	9367	1075
HALLMARK_INTERFERON_ALPHA_RESPONSE	M5911								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated in response to alpha interferon proteins.			REACTOME_INTERFERON_GAMMA_SIGNALING|REACTOME_INTERFERON_SIGNALING|REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM|NOJIMA_SFRP2_TARGETS_DN|GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREY_DN|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_UP|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP|MAHADEVAN_RESPONSE_TO_MP470_UP|FARMER_BREAST_CANCER_CLUSTER_1|BOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIX|BOWIE_RESPONSE_TO_TAMOXIFEN|XU_HGF_TARGETS_INDUCED_BY_AKT1_6HR|XU_AKT1_TARGETS_6HR|EINAV_INTERFERON_SIGNATURE_IN_CANCER|DAUER_STAT3_TARGETS_DN|SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP|KANG_GIST_WITH_PDGFRA_UP|MEINHOLD_OVARIAN_CANCER_LOW_GRADE_DN|YAN_ESCAPE_FROM_ANOIKIS|GRANDVAUX_IFN_RESPONSE_NOT_VIA_IRF3|JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP|DER_IFN_ALPHA_RESPONSE_UP|BECKER_TAMOXIFEN_RESISTANCE_UP|RADAEVA_RESPONSE_TO_IFNA1_UP|DER_IFN_BETA_RESPONSE_UP|GRANDVAUX_IRF3_TARGETS_UP|SANA_RESPONSE_TO_IFNG_UP|SANA_TNF_SIGNALING_UP|DER_IFN_GAMMA_RESPONSE_UP|XU_RESPONSE_TO_TRETINOIN_AND_NSC682994_UP|TAVOR_CEBPA_TARGETS_DN|ROETH_TERT_TARGETS_UP|BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS|LIANG_SILENCED_BY_METHYLATION_2|CHANG_IMMORTALIZED_BY_HPV31_DN|BROWNE_INTERFERON_RESPONSIVE_GENES|KRASNOSELSKAYA_ILF3_TARGETS_UP|ZHU_CMV_ALL_UP|ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_UP|HAN_JNK_SINGALING_UP|JACKSON_DNMT1_TARGETS_UP|LIU_SMARCA4_TARGETS|ZHU_CMV_24_HR_UP|BROWNE_HCMV_INFECTION_6HR_UP|ZHU_CMV_8_HR_UP|KIM_LRRC3B_TARGETS|MOSERLE_IFNA_RESPONSE|HONMA_DOCETAXEL_RESISTANCE|ISHIKAWA_STING_SIGNALING|ZHANG_INTERFERON_RESPONSE|JISON_SICKLE_CELL_DISEASE_UP|CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_UP|TSAI_DNAJB4_TARGETS_UP|UROSEVIC_RESPONSE_TO_IMIQUIMOD|ZHAN_MULTIPLE_MYELOMA_LB_DN|YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_9|BAUS_TFF2_TARGETS_UP|STAMBOLSKY_TARGETS_OF_MUTATED_TP53_DN|GREGORY_SYNTHETIC_LETHAL_WITH_IMATINIB|JOHNSTONE_PARVB_TARGETS_2_UP|KRIEG_KDM3A_TARGETS_NOT_HYPOXIA|BOSCO_INTERFERON_INDUCED_ANTIVIRAL_MODULE|HECKER_IFNB1_TARGETS|MODULE_119|MODULE_145|MODULE_171|MODULE_188|MODULE_208|MODULE_238|MODULE_292|MODULE_301|MODULE_345|MODULE_361|MODULE_436|WNT_UP.V1_DN|ALK_DN.V1_DN|BMI1_DN_MEL18_DN.V1_DN|BMI1_DN.V1_DN|MEL18_DN.V1_DN	GSE31019,interferon alpha vs control SK-OV-3 (ovary adenocarcinoma) and HT-1080 (fibrosarcoma)|GSE31193,interferon alpha vs control primary hepatocytes|GSE43723,interferon alpha vs Control primary hepatocytes	GSE50635,lupus RBP+ vs contol whole blood	4599	9636	4938	3437	10561	3430	3665	91543	10964	8519	3429	10379	8638	5610	3433	3627	6890	3431	55601	9246	11274	5696	64135	684	3959	103	3669	2634	3659	5359	5698	55008	54809	129607	10410	64108	6773	219285	4061	10581	85441	6373	6737	54625	7726	64761	9111	55072	3107	834	9830	23424	79132	83666	87178	7706	5720	7453	94240	7318	5721	567	85363	716	51056	27074	115361	135112	55281	972	2766	5684	10544	3574	10437	3660	1435	3600	1267	55603	3566	23070	961	10161	4343	841	10628	81894	6402	10906	116071	8767	9034	51667	11054	93343	1997
HALLMARK_INTERFERON_GAMMA_RESPONSE	M5913								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated in response to IFNG [GeneID=3458].			REACTOME_INTERFERON_GAMMA_SIGNALING|REACTOME_INTERFERON_SIGNALING|REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM|NOJIMA_SFRP2_TARGETS_DN|GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREY_DN|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_UP|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP|MAHADEVAN_RESPONSE_TO_MP470_UP|FARMER_BREAST_CANCER_CLUSTER_1|BOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIX|BOWIE_RESPONSE_TO_TAMOXIFEN|XU_HGF_TARGETS_INDUCED_BY_AKT1_6HR|XU_AKT1_TARGETS_6HR|EINAV_INTERFERON_SIGNATURE_IN_CANCER|DAUER_STAT3_TARGETS_DN|SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP|KANG_GIST_WITH_PDGFRA_UP|MEINHOLD_OVARIAN_CANCER_LOW_GRADE_DN|YAN_ESCAPE_FROM_ANOIKIS|GRANDVAUX_IFN_RESPONSE_NOT_VIA_IRF3|JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP|DER_IFN_ALPHA_RESPONSE_UP|BECKER_TAMOXIFEN_RESISTANCE_UP|RADAEVA_RESPONSE_TO_IFNA1_UP|DER_IFN_BETA_RESPONSE_UP|GRANDVAUX_IRF3_TARGETS_UP|SANA_RESPONSE_TO_IFNG_UP|SANA_TNF_SIGNALING_UP|DER_IFN_GAMMA_RESPONSE_UP|XU_RESPONSE_TO_TRETINOIN_AND_NSC682994_UP|TAVOR_CEBPA_TARGETS_DN|ROETH_TERT_TARGETS_UP|BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS|LIANG_SILENCED_BY_METHYLATION_2|CHANG_IMMORTALIZED_BY_HPV31_DN|BROWNE_INTERFERON_RESPONSIVE_GENES|KRASNOSELSKAYA_ILF3_TARGETS_UP|ZHU_CMV_ALL_UP|ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_UP|HAN_JNK_SINGALING_UP|JACKSON_DNMT1_TARGETS_UP|LIU_SMARCA4_TARGETS|ZHU_CMV_24_HR_UP|BROWNE_HCMV_INFECTION_6HR_UP|ZHU_CMV_8_HR_UP|KIM_LRRC3B_TARGETS|MOSERLE_IFNA_RESPONSE|HONMA_DOCETAXEL_RESISTANCE|ISHIKAWA_STING_SIGNALING|ZHANG_INTERFERON_RESPONSE|JISON_SICKLE_CELL_DISEASE_UP|CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_UP|TSAI_DNAJB4_TARGETS_UP|UROSEVIC_RESPONSE_TO_IMIQUIMOD|ZHAN_MULTIPLE_MYELOMA_LB_DN|YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_9|BAUS_TFF2_TARGETS_UP|STAMBOLSKY_TARGETS_OF_MUTATED_TP53_DN|GREGORY_SYNTHETIC_LETHAL_WITH_IMATINIB|JOHNSTONE_PARVB_TARGETS_2_UP|KRIEG_KDM3A_TARGETS_NOT_HYPOXIA|BOSCO_INTERFERON_INDUCED_ANTIVIRAL_MODULE|HECKER_IFNB1_TARGETS|MODULE_119|MODULE_145|MODULE_171|MODULE_188|MODULE_208|MODULE_238|MODULE_292|MODULE_301|MODULE_345|MODULE_361|MODULE_436|WNT_UP.V1_DN|ALK_DN.V1_DN|BMI1_DN_MEL18_DN.V1_DN|BMI1_DN.V1_DN|MEL18_DN.V1_DN	GSE11886,interferon gamma vs control macrophages|GSE35825,interferon gamma vs control macrophages|GSE39349,interferon gamma vs control macrophages	GSE36287,interferon gamma vs untreated primary keratinocytes|GSE48970,interferon gamma vs untreated STAT1 WT macrophages	6772	9636	3434	4599	3437	3430	3665	3433	4939	6890	5610	91543	4600	3659	4940	8743	10379	3627	10561	684	54739	3431	8638	5696	10964	10410	55601	3959	115361	3394	5698	5371	64135	9246	3429	103	4061	6773	4283	3587	5321	6737	11274	5743	94240	716	23586	3600	84166	9111	3620	5699	6373	3695	25939	55008	129607	219285	64108	5771	54625	7127	10581	5359	8651	834	3383	7453	5720	3669	3660	9830	2209	55016	9021	3717	3108	64761	7130	7726	7412	29126	4261	10135	6403	2841	2357	85441	5721	710	6352	55072	6648	7706	51056	5684	57674	57162	629	942	10628	3117	2643	4860	6354	5777	84888	3566	87178	79132	694	841	10437	6347	10875	840	6398	3601	958	10906	3123	163351	3937	3135	4502	8737	22914	7378	5690	23424	3091	317649	8673	5214	952	81030	55024	27348	10616	5142	9961	3574	669	23070	26053	567	8767	969	4615	5683	5292	10392	3075	6892	81894	5770	7128	8082	9688	10797	1026	3662	4790	116071	3106	26524	3663	57823	51015	9934	6774	8202	3105	3569	3001	3455	972	51735	837	355	11054	10124	6717	256586	1439	8869	715	836	1240	4792	196410	7903	6375	3560	10791	10068	57169	84159	80830	6775
HALLMARK_APICAL_JUNCTION	M5915								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes encoding components of apical junction complex.			chr10q|KEGG_CELL_ADHESION_MOLECULES_CAMS|KEGG_TIGHT_JUNCTION|KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION|BIOCARTA_CELL2CELL_PATHWAY|REACTOME_CELL_CELL_COMMUNICATION|REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS|REACTOME_CELL_CELL_JUNCTION_ORGANIZATION|REACTOME_TIGHT_JUNCTION_INTERACTIONS|REACTOME_CELL_JUNCTION_ORGANIZATION|BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_24HR_DN|BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_48HR_DN|BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_48HR_DN|BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_24HR_DN|ADHERENS_JUNCTION|CELL_JUNCTION|TIGHT_JUNCTION|INTERCELLULAR_JUNCTION|APICAL_JUNCTION_COMPLEX|CELL_SUBSTRATE_ADHERENS_JUNCTION|CELL_MATRIX_JUNCTION|BASOLATERAL_PLASMA_MEMBRANE|FOCAL_ADHESION|APICOLATERAL_PLASMA_MEMBRANE|ACTIN_FILAMENT_ORGANIZATION|FOCAL_ADHESION_FORMATION|HETEROPHILIC_CELL_ADHESION|HOMOPHILIC_CELL_ADHESION|CELL_RECOGNITION|CELL_SUBSTRATE_ADHESION|CALCIUM_INDEPENDENT_CELL_CELL_ADHESION|CELL_CELL_ADHESION|ESTABLISHMENT_AND_OR_MAINTENANCE_OF_CELL_POLARITY|CELL_MATRIX_ADHESION|ACTIN_FILAMENT_BUNDLE_FORMATION|INTEGRIN_BINDING|PROTEIN_COMPLEX_BINDING	GSE5264,mucociliary differentiation time course days 0-4 vs days 14-28 bronchial epithelial cells|GSE19299,RB WT vs KO MC3T3 (osteoblasts)|GSE32217,EGF vs vehicle 100% confluence normal epidermal keratinocytes|GSE38628,CaCl2 12-48h vs 0-3h normal epidermal keratinocytes	GSE15768,GRHL3 WT vs KO E18.5 bladder|GSE20257,non-smokers vs smokers with COPD airway epithelium	87	1366	89	149461	1739	7082	1308	5818	9080	1001	1500	999	51474	7414	357	25945	5819	23562	5788	7070	7408	3688	7791	81	1364	57863	3675	4771	2683	91624	1004	8751	5747	3033	3914	5010	1002	3667	10174	9073	51466	24146	7059	81607	83700	1009	3691	5921	208	51754	3909	6251	3383	51208	2962	7248	3918	4892	1495	4267	6624	1307	2771	7045	64398	3728	88	3638	143903	5216	1265	9344	347902	4192	3636	9074	10109	6714	5089	1432	5871	5728	794	1272	7106	1462	1006	478	2037	10398	10290	147	6850	253559	247	6376	4628	1758	1041	5603	103910	5880	2200	1823	947	3386	4478	5600	70	7185	92359	3673	8515	10458	9459	71	4597	79849	8754	5097	9353	3881	8910	2770	5291	57555	7533	55742	1384	11096	268	1956	3384	29126	1013	6464	10205	65266	23114	8503	9672	140885	2886	2318	84552	1297	9379	51776	7781	54509	649	4313	7087	7450	4627	30835	7412	8449	72	257194	4763	8745	5335	3757	51148	4902	8517	1825	60	7283	5522	3265	4318	4982	5310	1024	2533	57463	80381	2593	54413	8935	6237	10487	60412	58	7073	26119	7410	10000	8189	6810	5175	8174	3680	942	7216	7122	9019	8976
HALLMARK_APICAL_SURFACE	M5916								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes encoding proteins over-represented on the apical surface of epithelial cells, e.g., important for cell polarity (apical area).			chr6q|CELL_PROJECTION_PART|BRUSH_BORDER|EXTERNAL_SIDE_OF_PLASMA_MEMBRANE|CELL_SURFACE|ANCHORED_TO_MEMBRANE|APICAL_PART_OF_CELL|APICAL_PLASMA_MEMBRANE|ANCHORED_TO_PLASMA_MEMBRANE|RESPONSE_TO_STEROID_HORMONE_STIMULUS|RESPONSE_TO_HORMONE_STIMULUS|KINASE_ACTIVATOR_ACTIVITY	GSE5264,mucociliary differentiation time course days 0-4 vs days 14-28 bronchial epithelial cells|GSE19299,RB WT vs KO MC3T3 (osteoblasts)|GSE32217,EGF vs vehicle 100% confluence normal epidermal keratinocytes|GSE38628,CaCl2 12-48h vs 0-3h normal epidermal keratinocytes	GSE15768,GRHL3 WT vs KO E18.5 bladder|GSE20257,non-smokers vs smokers with COPD airway epithelium	2683	51458	4118	27076	5314	50617	202	357	8406	266727	51754	7070	255738	2050	131566	51738	4067	2619	2319	5329	9465	5205	1946	142680	351	2947	3315	6517	3560	146760	23054	55959	102	672	2625	84632	3561	11126	79602	116085	22854	80274	6376	9696
HALLMARK_HEDGEHOG_SIGNALING	M5919								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated by activation of hedgehog signaling.			BIOCARTA_P35ALZHEIMERS_PATHWAY|PID_REELIN_PATHWAY|PID_LIS1_PATHWAY|PID_HEDGEHOG_2PATHWAY|SEMBA_FHIT_TARGETS_UP|COURTOIS_SENESCENCE_TRIGGERS|PALOMERO_GSI_SENSITIVITY_UP|KIM_PTEN_TARGETS_DN|MODULE_220|MODULE_234|MODULE_400|MODULE_497|AXON|CELL_SOMA|DENDRITE|SITE_OF_POLARIZED_GROWTH|GROWTH_CONE|NEURON_PROJECTION|AXON_GUIDANCE|SYSTEM_DEVELOPMENT|TISSUE_MORPHOGENESIS|SYNAPTOGENESIS|NERVOUS_SYSTEM_DEVELOPMENT|NEURITE_DEVELOPMENT|TUBE_MORPHOGENESIS|PATTERN_SPECIFICATION_PROCESS|REGULATION_OF_SYNAPSE_STRUCTURE_AND_ACTIVITY|REGULATION_OF_CELL_MIGRATION|REGULATION_OF_AXONOGENESIS|REGIONALIZATION|SKELETAL_DEVELOPMENT|ANATOMICAL_STRUCTURE_MORPHOGENESIS|AXONOGENESIS|NEGATIVE_REGULATION_OF_ANGIOGENESIS|EPITHELIAL_CELL_DIFFERENTIATION|CALCIUM_MEDIATED_SIGNALING|TUBE_DEVELOPMENT|REGULATION_OF_CELL_ADHESION|CELLULAR_MORPHOGENESIS_DURING_DIFFERENTIATION|GENERATION_OF_NEURONS|MESODERM_DEVELOPMENT|MULTICELLULAR_ORGANISMAL_DEVELOPMENT|BRAIN_DEVELOPMENT|ANATOMICAL_STRUCTURE_FORMATION|ORGAN_MORPHOGENESIS|ENDOTHELIAL_CELL_PROLIFERATION|EXTRACELLULAR_STRUCTURE_ORGANIZATION_AND_BIOGENESIS|MORPHOGENESIS_OF_AN_EPITHELIUM|ANGIOGENESIS|NEGATIVE_REGULATION_OF_CELL_ADHESION|REGULATION_OF_ANGIOGENESIS|SYNAPSE_ORGANIZATION_AND_BIOGENESIS|VASCULATURE_DEVELOPMENT|EMBRYONIC_MORPHOGENESIS|BONE_REMODELING|EMBRYONIC_DEVELOPMENT|ANATOMICAL_STRUCTURE_DEVELOPMENT|REGULATION_OF_NEUROGENESIS|NEUROGENESIS|REGULATION_OF_CELL_CELL_ADHESION|POSITIVE_REGULATION_OF_CELL_MIGRATION|GLAND_DEVELOPMENT|HEART_DEVELOPMENT|DEVELOPMENTAL_GROWTH|POSITIVE_REGULATION_OF_CELL_ADHESION|POSITIVE_REGULATION_OF_ANGIOGENESIS|NEURON_DIFFERENTIATION|ENDOTHELIAL_CELL_MIGRATION|NEURON_DEVELOPMENT|REGULATION_OF_NEURON_APOPTOSIS|TISSUE_REMODELING|NEURON_APOPTOSIS|CELL_MIGRATION|ORGAN_DEVELOPMENT|NEGATIVE_REGULATION_OF_CELL_MIGRATION|CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT|CELL_FATE_COMMITMENT|REGULATION_OF_ENDOTHELIAL_CELL_PROLIFERATION|COLLAGEN_BINDING	GSE4936,RAHh (SHH agonist) vs RA (control) embryoid bodies|GSE7598,ZPA positive vs negative limb bud at E10.5|GSE11063,SHH high (POST SmoM2) vs SHH low (ANT Shh Mut) E11.5 forelimb|GSE36855,control vs dominant negative GLI Panc-1 (pacreas epithelioid carcinoma)|GSE42565,activated SHH pathway vs control neural progenitors	E-MEXP-3142,SHH WT vs mutant forelimb bud|GSE18393,IHH WT vs KO colon tissue|GSE29316,SHH vs untreated colon fibroblasts|GSE40612,SmoM2 (7 weeks TAM) vs control (no TAM) interfollicular epidermis	6469	5727	4897	8829	7857	154796	8633	9289	23462	2735	7070	6585	1021	23493	8828	7090	7088	3897	5340	4825	4763	5921	2114	6252	1400	4627	7422	9620	1271	43	5371	8851	7436	4983	8861	1808
HALLMARK_COMPLEMENT	M5921								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes encoding components of the complement system, which is part of the innate immune system.			chr13q34|chr11q21|KEGG_COMPLEMENT_AND_COAGULATION_CASCADES|KEGG_PRION_DISEASES|BIOCARTA_AMI_PATHWAY|BIOCARTA_CLASSIC_PATHWAY|BIOCARTA_COMP_PATHWAY|BIOCARTA_EXTRINSIC_PATHWAY|BIOCARTA_FIBRINOLYSIS_PATHWAY|BIOCARTA_INTRINSIC_PATHWAY|BIOCARTA_LECTIN_PATHWAY|REACTOME_GAMMA_CARBOXYLATION_TRANSPORT_AND_AMINO_TERMINAL_CLEAVAGE_OF_PROTEINS|REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX|REACTOME_REGULATION_OF_COMPLEMENT_CASCADE|REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2_|REACTOME_COMMON_PATHWAY|REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE|REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION|REACTOME_INTRINSIC_PATHWAY|REACTOME_HEMOSTASIS|REACTOME_COMPLEMENT_CASCADE|REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION|REACTOME_CREATION_OF_C4_AND_C2_ACTIVATORS|REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT|VETTER_TARGETS_OF_PRKCA_AND_ETS1_DN|OZANNE_AP1_TARGETS_UP|MAHADEVAN_GIST_MORPHOLOGICAL_SWITCH|BAKER_HEMATOPOESIS_STAT1_TARGETS|OXFORD_RALA_TARGETS_UP|OXFORD_RALB_TARGETS_DN|OXFORD_RALA_AND_RALB_TARGETS_UP|GROSS_HYPOXIA_VIA_HIF1A_ONLY|MAGRANGEAS_MULTIPLE_MYELOMA_IGG_VS_IGA_DN|SMID_BREAST_CANCER_RELAPSE_IN_LIVER_UP|WILSON_PROTEASES_AT_TUMOR_BONE_INTERFACE_UP|JU_AGING_TERC_TARGETS_UP|MODULE_58|MODULE_107|MODULE_109|MODULE_130|MODULE_131|MODULE_172|MODULE_209|MODULE_210|MODULE_211|MODULE_226|MODULE_280|MODULE_281|MODULE_324|MODULE_371|MODULE_562|HEMOSTASIS|REGULATION_OF_BODY_FLUID_LEVELS|BLOOD_COAGULATION|WOUND_HEALING|COAGULATION|ACUTE_INFLAMMATORY_RESPONSE|CATION_BINDING|SERINE_TYPE_PEPTIDASE_ACTIVITY|ZINC_ION_BINDING|CALCIUM_ION_BINDING|METALLOPEPTIDASE_ACTIVITY|CYSTEINE_TYPE_PEPTIDASE_ACTIVITY|ION_BINDING|ENDOPEPTIDASE_ACTIVITY|SERINE_HYDROLASE_ACTIVITY|PEPTIDASE_ACTIVITY|CYSTEINE_TYPE_ENDOPEPTIDASE_ACTIVITY|TRANSITION_METAL_ION_BINDING|SERINE_TYPE_ENDOPEPTIDASE_ACTIVITY|METALLOENDOPEPTIDASE_ACTIVITY	GSE13917,CD21+ vs CD21 low/- B lymphocytes|GSE17938,complement induced by co-culture of retinal pigment epithelial cells with activated T lymphocytes|GSE23203,peripheral EPC/CAC cells vs bone marrow EPC	GSE40586,bacterial meningitis vs control PBMC	717	716	629	715	5054	4323	710	1514	2153	4322	2155	1520	5641	5340	712	834	3001	8754	808	714	7076	1803	3816	3818	966	1380	4324	51056	9806	2159	1508	5265	1519	959	868	54704	725	5341	2815	5329	718	2147	837	6810	1075	9958	1378	1848	5055	2820	3075	2335	948	760	5698	60489	2219	3003	5155	1191	843	4035	1509	6280	7454	27154	5327	978	4504	840	146547	5216	3002	6047	6935	838	3659	10404	8851	475	5290	164656	1368	9986	801	23348	8942	10125	9097	3937	2811	3796	59345	3932	4973	5550	51734	4048	23414	4067	88	51548	341	5580	3684	160851	4057	23764	30819	27445	55619	10019	5877	6714	51440	4179	11108	2773	735	5516	3660	2534	3717	5321	5547	9101	391	91133	3920	5292	2919	2152	2771	842	7511	5359	3665	1604	3309	2783	8445	7941	6283	2885	5251	2793	9732	4321	30818	2230	7077	4317	2207	64145	308	1515	25801	10938	5646	1284	1465	23533	462	283	200316	2625	1847	836	10600	1356	5663	3988	255738	1608	54331	4199	2764	29106	5531	6352	1512	2157	337	3569	11216	64167	80124	3303	5894	4855	151	1051	3172	3958	7128	1012	3697	7980	5294	6284
HALLMARK_UNFOLDED_PROTEIN_RESPONSE	M5922								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated during unfolded protein response, a cellular stress response related to the endoplasmic reticulum.			chr13q21|KEGG_RNA_DEGRADATION|REACTOME_DIABETES_PATHWAYS|REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_XBP1S|REACTOME_PERK_REGULATED_GENE_EXPRESSION|REACTOME_ACTIVATION_OF_CHAPERONES_BY_ATF6_ALPHA|REACTOME_ACTIVATION_OF_GENES_BY_ATF4|REACTOME_UNFOLDED_PROTEIN_RESPONSE|REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_ATF6_ALPHA|REACTOME_DEADENYLATION_OF_MRNA|REACTOME_MRNA_DECAY_BY_5_TO_3_EXORIBONUCLEASE|REACTOME_MRNA_DECAY_BY_3_TO_5_EXORIBONUCLEASE|REACTOME_DEADENYLATION_DEPENDENT_MRNA_DECAY|REACTOME_DESTABILIZATION_OF_MRNA_BY_BRF1|REACTOME_DESTABILIZATION_OF_MRNA_BY_KSRP|REACTOME_DESTABILIZATION_OF_MRNA_BY_TRISTETRAPROLIN_TTP|GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_RED_UP|HU_GENOTOXIC_DAMAGE_24HR|MARIADASON_RESPONSE_TO_CURCUMIN_SULINDAC_5|RRNA_PROCESSING|RIBOSOME_BIOGENESIS_AND_ASSEMBLY|RRNA_METABOLIC_PROCESS	GSE2980,SFTPC MUT (misfolded) vs control HEK293 (embryonic kidney epithelium)|GSE27038,tunicamycin vs control both WT ERN1 liver|GSE29929,tunicamycin vs DMSO both WT EIF2AK3 liver|GSE43714,MG132 vs untreated both WT ATF5 MEF	GSE8322,ATF6 OE vs control left ventricle|GSE54255,diclofenac vs DMSO liver	468	9709	5073	54512	7184	7494	5393	3309	467	51013	56915	440	55738	7466	58477	4189	64061	4800	811	8570	5611	23404	8602	22926	10525	9136	10528	30827	3484	4850	167227	10130	9114	10113	22872	9570	27230	4801	55651	1639	8140	6745	9695	23644	9451	10797	6734	9221	2081	55033	7709	55062	10897	6347	1736	1978	1973	1965	9797	11260	25804	79094	8614	10954	64859	27257	55153	1974	1977	3376	1662	50628	6897	5832	54541	3313	23478	9775	10775	30001	1054	9531	11015	1051	4848	6464	60559	3014	6509	6208	4869	57472	1163	29968	1981	7534	64924	23517	3799	55802	3434	55272	28972	55466	7422	9652	7280	2521	5394	1938	55770	10605	8815
HALLMARK_PI3K_AKT_MTOR_SIGNALING	M5923								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated by activation of the PI3K/AKT/mTOR pathway.			chr11q|chr9p22|KEGG_INOSITOL_PHOSPHATE_METABOLISM|KEGG_FOLATE_BIOSYNTHESIS|KEGG_MAPK_SIGNALING_PATHWAY|KEGG_ERBB_SIGNALING_PATHWAY|KEGG_CALCIUM_SIGNALING_PATHWAY|KEGG_PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM|KEGG_OOCYTE_MEIOSIS|KEGG_REGULATION_OF_AUTOPHAGY|KEGG_MTOR_SIGNALING_PATHWAY|KEGG_APOPTOSIS|KEGG_VASCULAR_SMOOTH_MUSCLE_CONTRACTION|KEGG_DORSO_VENTRAL_AXIS_FORMATION|KEGG_AXON_GUIDANCE|KEGG_VEGF_SIGNALING_PATHWAY|KEGG_FOCAL_ADHESION|KEGG_ADHERENS_JUNCTION|KEGG_GAP_JUNCTION|KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY|KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY|KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY|KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY|KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY|KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY|KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY|KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY|KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS|KEGG_LONG_TERM_POTENTIATION|KEGG_NEUROTROPHIN_SIGNALING_PATHWAY|KEGG_LONG_TERM_DEPRESSION|KEGG_REGULATION_OF_ACTIN_CYTOSKELETON|KEGG_INSULIN_SIGNALING_PATHWAY|KEGG_GNRH_SIGNALING_PATHWAY|KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATION|KEGG_TYPE_II_DIABETES_MELLITUS|KEGG_ALDOSTERONE_REGULATED_SODIUM_REABSORPTION|KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION|KEGG_PATHWAYS_IN_CANCER|KEGG_COLORECTAL_CANCER|KEGG_RENAL_CELL_CARCINOMA|KEGG_PANCREATIC_CANCER|KEGG_ENDOMETRIAL_CANCER|KEGG_GLIOMA|KEGG_PROSTATE_CANCER|KEGG_THYROID_CANCER|KEGG_MELANOMA|KEGG_BLADDER_CANCER|KEGG_CHRONIC_MYELOID_LEUKEMIA|KEGG_ACUTE_MYELOID_LEUKEMIA|KEGG_SMALL_CELL_LUNG_CANCER|KEGG_NON_SMALL_CELL_LUNG_CANCER|BIOCARTA_RELA_PATHWAY|BIOCARTA_NO1_PATHWAY|BIOCARTA_AGR_PATHWAY|BIOCARTA_AKAP95_PATHWAY|BIOCARTA_AKT_PATHWAY|BIOCARTA_AT1R_PATHWAY|BIOCARTA_SPPA_PATHWAY|BIOCARTA_AGPCR_PATHWAY|BIOCARTA_BCELLSURVIVAL_PATHWAY|BIOCARTA_BCR_PATHWAY|BIOCARTA_BIOPEPTIDES_PATHWAY|BIOCARTA_RANKL_PATHWAY|BIOCARTA_CACAM_PATHWAY|BIOCARTA_CDMAC_PATHWAY|BIOCARTA_CBL_PATHWAY|BIOCARTA_CCR3_PATHWAY|BIOCARTA_CD40_PATHWAY|BIOCARTA_CERAMIDE_PATHWAY|BIOCARTA_HDAC_PATHWAY|BIOCARTA_GCR_PATHWAY|BIOCARTA_CTCF_PATHWAY|BIOCARTA_CXCR4_PATHWAY|BIOCARTA_CFTR_PATHWAY|BIOCARTA_RNA_PATHWAY|BIOCARTA_CALCINEURIN_PATHWAY|BIOCARTA_EGF_PATHWAY|BIOCARTA_NDKDYNAMIN_PATHWAY|BIOCARTA_EPHA4_PATHWAY|BIOCARTA_EPO_PATHWAY|BIOCARTA_ECM_PATHWAY|BIOCARTA_ERK_PATHWAY|BIOCARTA_EPONFKB_PATHWAY|BIOCARTA_FCER1_PATHWAY|BIOCARTA_FMLP_PATHWAY|BIOCARTA_GATA3_PATHWAY|BIOCARTA_GH_PATHWAY|BIOCARTA_SALMONELLA_PATHWAY|BIOCARTA_MPR_PATHWAY|BIOCARTA_HCMV_PATHWAY|BIOCARTA_IGF1_PATHWAY|BIOCARTA_IL2_PATHWAY|BIOCARTA_IL3_PATHWAY|BIOCARTA_IL4_PATHWAY|BIOCARTA_IL6_PATHWAY|BIOCARTA_IL2RB_PATHWAY|BIOCARTA_IL7_PATHWAY|BIOCARTA_RACCYCD_PATHWAY|BIOCARTA_GLEEVEC_PATHWAY|BIOCARTA_INSULIN_PATHWAY|BIOCARTA_INTEGRIN_PATHWAY|BIOCARTA_KERATINOCYTE_PATHWAY|BIOCARTA_PYK2_PATHWAY|BIOCARTA_MAPK_PATHWAY|BIOCARTA_MCALPAIN_PATHWAY|BIOCARTA_PPARA_PATHWAY|BIOCARTA_ETS_PATHWAY|BIOCARTA_MTOR_PATHWAY|BIOCARTA_IGF1R_PATHWAY|BIOCARTA_NGF_PATHWAY|BIOCARTA_VIP_PATHWAY|BIOCARTA_NFAT_PATHWAY|BIOCARTA_NTHI_PATHWAY|BIOCARTA_NFKB_PATHWAY|BIOCARTA_NOS1_PATHWAY|BIOCARTA_ARENRF2_PATHWAY|BIOCARTA_P38MAPK_PATHWAY|BIOCARTA_PDGF_PATHWAY|BIOCARTA_CCR5_PATHWAY|BIOCARTA_PTDINS_PATHWAY|BIOCARTA_PLCE_PATHWAY|BIOCARTA_EDG1_PATHWAY|BIOCARTA_CDK5_PATHWAY|BIOCARTA_AKAPCENTROSOME_PATHWAY|BIOCARTA_PTEN_PATHWAY|BIOCARTA_RAC1_PATHWAY|BIOCARTA_RAS_PATHWAY|BIOCARTA_NKCELLS_PATHWAY|BIOCARTA_BAD_PATHWAY|BIOCARTA_CK1_PATHWAY|BIOCARTA_EIF4_PATHWAY|BIOCARTA_PGC1A_PATHWAY|BIOCARTA_DREAM_PATHWAY|BIOCARTA_LEPTIN_PATHWAY|BIOCARTA_RHO_PATHWAY|BIOCARTA_AKAP13_PATHWAY|BIOCARTA_CARDIACEGF_PATHWAY|BIOCARTA_HER2_PATHWAY|BIOCARTA_ERK5_PATHWAY|BIOCARTA_MAL_PATHWAY|BIOCARTA_MEF2D_PATHWAY|BIOCARTA_ACH_PATHWAY|BIOCARTA_CDC42RAC_PATHWAY|BIOCARTA_BARR_MAPK_PATHWAY|BIOCARTA_BARRESTIN_SRC_PATHWAY|BIOCARTA_IL1R_PATHWAY|BIOCARTA_MET_PATHWAY|BIOCARTA_GPCR_PATHWAY|BIOCARTA_IGF1MTOR_PATHWAY|BIOCARTA_SODD_PATHWAY|BIOCARTA_SHH_PATHWAY|BIOCARTA_SPRY_PATHWAY|BIOCARTA_BARRESTIN_PATHWAY|BIOCARTA_STATHMIN_PATHWAY|BIOCARTA_TCR_PATHWAY|BIOCARTA_TALL1_PATHWAY|BIOCARTA_41BB_PATHWAY|BIOCARTA_LONGEVITY_PATHWAY|BIOCARTA_STRESS_PATHWAY|BIOCARTA_TNFR2_PATHWAY|BIOCARTA_TOLL_PATHWAY|BIOCARTA_TPO_PATHWAY|BIOCARTA_CREB_PATHWAY|BIOCARTA_CARM1_PATHWAY|BIOCARTA_TFF_PATHWAY|BIOCARTA_TRKA_PATHWAY|BIOCARTA_ARF_PATHWAY|BIOCARTA_UCALPAIN_PATHWAY|BIOCARTA_VEGF_PATHWAY|BIOCARTA_ACTINY_PATHWAY|ST_WNT_CA2_CYCLIC_GMP_PATHWAY|ST_DIFFERENTIATION_PATHWAY_IN_PC12_CELLS|ST_TUMOR_NECROSIS_FACTOR_PATHWAY|SA_B_CELL_RECEPTOR_COMPLEXES|ST_ERK1_ERK2_MAPK_PATHWAY|SIG_CD40PATHWAYMAP|SIG_PIP3_SIGNALING_IN_CARDIAC_MYOCTES|ST_GA12_PATHWAY|ST_G_ALPHA_S_PATHWAY|ST_G_ALPHA_I_PATHWAY|SIG_CHEMOTAXIS|ST_P38_MAPK_PATHWAY|SIG_IL4RECEPTOR_IN_B_LYPHOCYTES|SIG_REGULATION_OF_THE_ACTIN_CYTOSKELETON_BY_RHO_GTPASES|ST_GRANULE_CELL_SURVIVAL_PATHWAY|ST_ADRENERGIC|ST_INTEGRIN_SIGNALING_PATHWAY|ST_GAQ_PATHWAY|ST_GA13_PATHWAY|SIG_INSULIN_RECEPTOR_PATHWAY_IN_CARDIAC_MYOCYTES|ST_T_CELL_SIGNAL_TRANSDUCTION|ST_PAC1_RECEPTOR_PATHWAY|SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES|SIG_BCR_SIGNALING_PATHWAY|ST_B_CELL_ANTIGEN_RECEPTOR|ST_INTERLEUKIN_4_PATHWAY|ST_JNK_MAPK_PATHWAY|ST_FAS_SIGNALING_PATHWAY|ST_MYOCYTE_AD_PATHWAY|SA_PTEN_PATHWAY|SA_TRKA_RECEPTOR|ST_PHOSPHOINOSITIDE_3_KINASE_PATHWAY|PID_FCER1_PATHWAY|PID_ENDOTHELIN_PATHWAY|PID_BCR_5PATHWAY|PID_PRL_SIGNALING_EVENTS_PATHWAY|PID_RHOA_PATHWAY|PID_ERBB4_PATHWAY|PID_LYSOPHOSPHOLIPID_PATHWAY|PID_INSULIN_PATHWAY|PID_P38_MKK3_6PATHWAY|PID_GMCSF_PATHWAY|PID_NFKAPPAB_ATYPICAL_PATHWAY|PID_IL4_2PATHWAY|PID_GLYPICAN_1PATHWAY|PID_NFKAPPAB_CANONICAL_PATHWAY|PID_ER_NONGENOMIC_PATHWAY|PID_CD40_PATHWAY|PID_MET_PATHWAY|PID_PTP1B_PATHWAY|PID_S1P_S1P3_PATHWAY|PID_LPA4_PATHWAY|PID_NFAT_TFPATHWAY|PID_EPHB_FWD_PATHWAY|PID_AVB3_OPN_PATHWAY|PID_S1P_S1P4_PATHWAY|PID_FRA_PATHWAY|PID_NECTIN_PATHWAY|PID_P38_ALPHA_BETA_PATHWAY|PID_TRAIL_PATHWAY|PID_CDC42_PATHWAY|PID_RET_PATHWAY|PID_ARF6_PATHWAY|PID_LKB1_PATHWAY|PID_TCPTP_PATHWAY|PID_ANGIOPOIETIN_RECEPTOR_PATHWAY|PID_FAS_PATHWAY|PID_TXA2PATHWAY|PID_SHP2_PATHWAY|PID_S1P_S1P1_PATHWAY|PID_NETRIN_PATHWAY|PID_IL1_PATHWAY|PID_NFAT_3PATHWAY|PID_REG_GR_PATHWAY|PID_INTEGRIN_A9B1_PATHWAY|PID_ARF6_DOWNSTREAM_PATHWAY|PID_MTOR_4PATHWAY|PID_IL2_1PATHWAY|PID_CXCR4_PATHWAY|PID_IGF1_PATHWAY|PID_ERBB1_RECEPTOR_PROXIMAL_PATHWAY|PID_TNF_PATHWAY|PID_TCR_RAS_PATHWAY|PID_IL5_PATHWAY|PID_FOXO_PATHWAY|PID_THROMBIN_PAR4_PATHWAY|PID_PI3KCI_PATHWAY|PID_AJDISS_2PATHWAY|PID_IL2_PI3K_PATHWAY|PID_CERAMIDE_PATHWAY|PID_P75_NTR_PATHWAY|PID_S1P_META_PATHWAY|PID_ECADHERIN_NASCENT_AJ_PATHWAY|PID_AMB2_NEUTROPHILS_PATHWAY|PID_IFNG_PATHWAY|PID_ERBB1_DOWNSTREAM_PATHWAY|PID_SYNDECAN_4_PATHWAY|PID_ATF2_PATHWAY|PID_AP1_PATHWAY|PID_UPA_UPAR_PATHWAY|PID_ERBB2_ERBB3_PATHWAY|PID_EPHA_FWDPATHWAY|PID_IL3_PATHWAY|PID_IL6_7_PATHWAY|PID_ECADHERIN_KERATINOCYTE_PATHWAY|PID_PDGFRB_PATHWAY|PID_TRKR_PATHWAY|PID_TCR_JNK_PATHWAY|PID_NEPHRIN_NEPH1_PATHWAY|PID_P38_MK2_PATHWAY|PID_ERBB_NETWORK_PATHWAY|PID_PDGFRA_PATHWAY|PID_P38_GAMMA_DELTA_PATHWAY|PID_IL8_CXCR2_PATHWAY|PID_AR_NONGENOMIC_PATHWAY|PID_ERBB1_INTERNALIZATION_PATHWAY|PID_CXCR3_PATHWAY|PID_VEGFR1_PATHWAY|PID_P38_ALPHA_BETA_DOWNSTREAM_PATHWAY|PID_KIT_PATHWAY|PID_ECADHERIN_STABILIZATION_PATHWAY|PID_EPO_PATHWAY|PID_IL2_STAT5_PATHWAY|PID_TCR_CALCIUM_PATHWAY|PID_VEGFR1_2_PATHWAY|PID_THROMBIN_PAR1_PATHWAY|PID_SYNDECAN_2_PATHWAY|PID_INSULIN_GLUCOSE_PATHWAY|PID_PI3KCI_AKT_PATHWAY|PID_IL8_CXCR1_PATHWAY|PID_EPHRINB_REV_PATHWAY|PID_TOLL_ENDOGENOUS_PATHWAY|PID_NCADHERIN_PATHWAY|PID_ANTHRAX_PATHWAY|PID_S1P_S1P2_PATHWAY|PID_RAS_PATHWAY|PID_MAPK_TRK_PATHWAY|PID_PI3K_PLC_TRK_PATHWAY|PID_CD8_TCR_DOWNSTREAM_PATHWAY|PID_EPHA2_FWD_PATHWAY|PID_LYMPH_ANGIOGENESIS_PATHWAY|PID_ALPHA_SYNUCLEIN_PATHWAY|PID_FGF_PATHWAY|PID_INTEGRIN_A4B1_PATHWAY|PID_RAC1_PATHWAY|PID_FAK_PATHWAY|REACTOME_EXTRINSIC_PATHWAY_FOR_APOPTOSIS|REACTOME_SIGNALLING_BY_NGF|REACTOME_SIGNALING_BY_SCF_KIT|REACTOME_DEVELOPMENTAL_BIOLOGY|REACTOME_DAG_AND_IP3_SIGNALING|REACTOME_SPRY_REGULATION_OF_FGF_SIGNALING|REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALING|REACTOME_TRIF_MEDIATED_TLR3_SIGNALING|REACTOME_TETRAHYDROBIOPTERIN_BH4_SYNTHESIS_RECYCLING_SALVAGE_AND_REGULATION|REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING|REACTOME_REGULATION_OF_KIT_SIGNALING|REACTOME_ACTIVATED_AMPK_STIMULATES_FATTY_ACID_OXIDATION_IN_MUSCLE|REACTOME_IL_7_SIGNALING|REACTOME_SIGNALING_BY_ERBB4|REACTOME_DOWNREGULATION_OF_ERBB2_ERBB3_SIGNALING|REACTOME_PROLACTIN_RECEPTOR_SIGNALING|REACTOME_SIGNALING_BY_ERBB2|REACTOME_SIGNALING_BY_CONSTITUTIVELY_ACTIVE_EGFR|REACTOME_GRB2_EVENTS_IN_ERBB2_SIGNALING|REACTOME_SIGNALING_BY_EGFR_IN_CANCER|REACTOME_MEMBRANE_BINDING_AND_TARGETTING_OF_GAG_PROTEINS|REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING|REACTOME_SHC1_EVENTS_IN_ERBB4_SIGNALING|REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING|REACTOME_NUCLEAR_SIGNALING_BY_ERBB4|REACTOME_RIP_MEDIATED_NFKB_ACTIVATION_VIA_DAI|REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS|REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCADE|REACTOME_ARMS_MEDIATED_ACTIVATION|REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS|REACTOME_SIGNALLING_TO_RAS|REACTOME_NGF_SIGNALLING_VIA_TRKA_FROM_THE_PLASMA_MEMBRANE|REACTOME_SIGNALLING_TO_ERKS|REACTOME_P38MAPK_EVENTS|REACTOME_SIGNALING_BY_FGFR_IN_DISEASE|REACTOME_SYNTHESIS_OF_PIPS_AT_THE_EARLY_ENDOSOME_MEMBRANE|REACTOME_SIGNALLING_TO_P38_VIA_RIT_AND_RIN|REACTOME_SYNTHESIS_OF_PIPS_AT_THE_GOLGI_MEMBRANE|REACTOME_ACTIVATED_POINT_MUTANTS_OF_FGFR2|REACTOME_SYNTHESIS_OF_PIPS_AT_THE_LATE_ENDOSOME_MEMBRANE|REACTOME_SIGNALING_BY_FGFR1_MUTANTS|REACTOME_SYNTHESIS_OF_PIPS_AT_THE_PLASMA_MEMBRANE|REACTOME_SIGNALING_BY_FGFR1_FUSION_MUTANTS|REACTOME_SIGNALING_BY_ACTIVATED_POINT_MUTANTS_OF_FGFR1|REACTOME_PI_METABOLISM|REACTOME_SIGNALING_BY_FGFR3_MUTANTS|REACTOME_SIGNALING_BY_FGFR_MUTANTS|REACTOME_PLATELET_ADHESION_TO_EXPOSED_COLLAGEN|REACTOME_ENOS_ACTIVATION_AND_REGULATION|REACTOME_NUCLEAR_EVENTS_KINASE_AND_TRANSCRIPTION_FACTOR_ACTIVATION|REACTOME_ERKS_ARE_INACTIVATED|REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK|REACTOME_PI3K_AKT_ACTIVATION|REACTOME_PECAM1_INTERACTIONS|REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL|REACTOME_GAB1_SIGNALOSOME|REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING|REACTOME_ERK_MAPK_TARGETS|REACTOME_TIE2_SIGNALING|REACTOME_P75NTR_RECRUITS_SIGNALLING_COMPLEXES|REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES|REACTOME_P75NTR_SIGNALS_VIA_NFKB|REACTOME_NEURONAL_SYSTEM|REACTOME_NFKB_IS_ACTIVATED_AND_SIGNALS_SURVIVAL|REACTOME_INTEGRATION_OF_ENERGY_METABOLISM|REACTOME_OPIOID_SIGNALLING|REACTOME_CA_DEPENDENT_EVENTS|REACTOME_ADENYLATE_CYCLASE_ACTIVATING_PATHWAY|REACTOME_ADENYLATE_CYCLASE_INHIBITORY_PATHWAY|REACTOME_DARPP_32_EVENTS|REACTOME_NEUROTRANSMITTER_RECEPTOR_BINDING_AND_DOWNSTREAM_TRANSMISSION_IN_THE_POSTSYNAPTIC_CELL|REACTOME_P130CAS_LINKAGE_TO_MAPK_SIGNALING_FOR_INTEGRINS|REACTOME_PLC_BETA_MEDIATED_EVENTS|REACTOME_GRB2_SOS_PROVIDES_LINKAGE_TO_MAPK_SIGNALING_FOR_INTERGRINS_|REACTOME_G_PROTEIN_ACTIVATION|REACTOME_PKA_MEDIATED_PHOSPHORYLATION_OF_CREB|REACTOME_INTEGRIN_ALPHAIIB_BETA3_SIGNALING|REACTOME_GLUCAGON_SIGNALING_IN_METABOLIC_REGULATION|REACTOME_SIGNALING_BY_PDGF|REACTOME_GPVI_MEDIATED_ACTIVATION_CASCADE|REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION|REACTOME_AXON_GUIDANCE|REACTOME_REGULATION_OF_INSULIN_SECRETION_BY_GLUCAGON_LIKE_PEPTIDE1|REACTOME_CLASS_C_3_METABOTROPIC_GLUTAMATE_PHEROMONE_RECEPTORS|REACTOME_REGULATION_OF_INSULIN_SECRETION|REACTOME_INHIBITION_OF_INSULIN_SECRETION_BY_ADRENALINE_NORADRENALINE|REACTOME_CLASS_B_2_SECRETIN_FAMILY_RECEPTORS|REACTOME_GLUCAGON_TYPE_LIGAND_RECEPTORS|REACTOME_REGULATION_OF_INSULIN_SECRETION_BY_ACETYLCHOLINE|REACTOME_ADP_SIGNALLING_THROUGH_P2RY1|REACTOME_G_BETA_GAMMA_SIGNALLING_THROUGH_PLC_BETA|REACTOME_CD28_CO_STIMULATION|REACTOME_CRMPS_IN_SEMA3A_SIGNALING|REACTOME_OTHER_SEMAPHORIN_INTERACTIONS|REACTOME_ACTIVATION_OF_RAC|REACTOME_SEMA3A_PAK_DEPENDENT_AXON_REPULSION|REACTOME_CD28_DEPENDENT_VAV1_PATHWAY|REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING|REACTOME_SEMAPHORIN_INTERACTIONS|REACTOME_SEMA4D_INDUCED_CELL_MIGRATION_AND_GROWTH_CONE_COLLAPSE|REACTOME_SEMA3A_PLEXIN_REPULSION_SIGNALING_BY_INHIBITING_INTEGRIN_ADHESION|REACTOME_G_BETA_GAMMA_SIGNALLING_THROUGH_PI3KGAMMA|REACTOME_G_ALPHA_S_SIGNALLING_EVENTS|REACTOME_G_ALPHA_Z_SIGNALLING_EVENTS|REACTOME_COSTIMULATION_BY_THE_CD28_FAMILY|REACTOME_SIGNALING_BY_ROBO_RECEPTOR|REACTOME_CD28_DEPENDENT_PI3K_AKT_SIGNALING|REACTOME_G_PROTEIN_BETA_GAMMA_SIGNALLING|REACTOME_SIGNAL_AMPLIFICATION|REACTOME_RAS_ACTIVATION_UOPN_CA2_INFUX_THROUGH_NMDA_RECEPTOR|REACTOME_ACTIVATION_OF_NMDA_RECEPTOR_UPON_GLUTAMATE_BINDING_AND_POSTSYNAPTIC_EVENTS|REACTOME_CREB_PHOSPHORYLATION_THROUGH_THE_ACTIVATION_OF_RAS|REACTOME_POST_NMDA_RECEPTOR_ACTIVATION_EVENTS|REACTOME_UNBLOCKING_OF_NMDA_RECEPTOR_GLUTAMATE_BINDING_AND_ACTIVATION|REACTOME_CREB_PHOSPHORYLATION_THROUGH_THE_ACTIVATION_OF_CAMKII|REACTOME_THROMBOXANE_SIGNALLING_THROUGH_TP_RECEPTOR|REACTOME_ADP_SIGNALLING_THROUGH_P2RY12|REACTOME_FRS2_MEDIATED_CASCADE|REACTOME_PI_3K_CASCADE|REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR|REACTOME_TAK1_ACTIVATES_NFKB_BY_PHOSPHORYLATION_AND_ACTIVATION_OF_IKKS_COMPLEX|REACTOME_REGULATION_OF_AMPK_ACTIVITY_VIA_LKB1|REACTOME_MYOGENESIS|REACTOME_MAP_KINASE_ACTIVATION_IN_TLR_CASCADE|REACTOME_PHOSPHOLIPASE_C_MEDIATED_CASCADE|REACTOME_ACTIVATION_OF_KAINATE_RECEPTORS_UPON_GLUTAMATE_BINDING|REACTOME_IONOTROPIC_ACTIVITY_OF_KAINATE_RECEPTORS|REACTOME_ACTIVATION_OF_THE_AP1_FAMILY_OF_TRANSCRIPTION_FACTORS|REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES|REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1|REACTOME_SHC_MEDIATED_CASCADE|REACTOME_THROMBIN_SIGNALLING_THROUGH_PROTEINASE_ACTIVATED_RECEPTORS_PARS|REACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK|REACTOME_REGULATION_OF_RHEB_GTPASE_ACTIVITY_BY_AMPK|REACTOME_ACTIVATED_TAK1_MEDIATES_P38_MAPK_ACTIVATION|REACTOME_SIGNALING_BY_ILS|REACTOME_NETRIN1_SIGNALING|REACTOME_DCC_MEDIATED_ATTRACTIVE_SIGNALING|REACTOME_IL1_SIGNALING|REACTOME_REGULATION_OF_SIGNALING_BY_CBL|REACTOME_NEPHRIN_INTERACTIONS|REACTOME_IL_3_5_AND_GM_CSF_SIGNALING|REACTOME_AQUAPORIN_MEDIATED_TRANSPORT|REACTOME_IL_RECEPTOR_SHC_SIGNALING|REACTOME_RAP1_SIGNALLING|REACTOME_SIGNAL_REGULATORY_PROTEIN_SIRP_FAMILY_INTERACTIONS|REACTOME_PROSTACYCLIN_SIGNALLING_THROUGH_PROSTACYCLIN_RECEPTOR|REACTOME_REGULATION_OF_WATER_BALANCE_BY_RENAL_AQUAPORINS|REACTOME_IRAK1_RECRUITS_IKK_COMPLEX|REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION|REACTOME_TRAF6_MEDIATED_NFKB_ACTIVATION|REACTOME_INHIBITION_OF_VOLTAGE_GATED_CA2_CHANNELS_VIA_GBETA_GAMMA_SUBUNITS|REACTOME_IRAK2_MEDIATED_ACTIVATION_OF_TAK1_COMPLEX_UPON_TLR7_8_OR_9_STIMULATION|REACTOME_TRAF6_MEDIATED_INDUCTION_OF_NFKB_AND_MAP_KINASES_UPON_TLR7_8_OR_9_ACTIVATION|REACTOME_TRAF3_DEPENDENT_IRF_ACTIVATION_PATHWAY|REACTOME_GABA_B_RECEPTOR_ACTIVATION|REACTOME_NFKB_ACTIVATION_THROUGH_FADD_RIP1_PATHWAY_MEDIATED_BY_CASPASE_8_AND10|REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION_IN_TLR7_8_OR_9_SIGNALING|REACTOME_ACTIVATION_OF_IRF3_IRF7_MEDIATED_BY_TBK1_IKK_EPSILON|REACTOME_INTERFERON_ALPHA_BETA_SIGNALING|REACTOME_ADVANCED_GLYCOSYLATION_ENDPRODUCT_RECEPTOR_SIGNALING|REACTOME_GABA_RECEPTOR_ACTIVATION|REACTOME_REGULATION_OF_IFNA_SIGNALING|REACTOME_NEGATIVE_REGULATORS_OF_RIG_I_MDA5_SIGNALING|REACTOME_NFKB_AND_MAP_KINASES_ACTIVATION_MEDIATED_BY_TLR4_SIGNALING_REPERTOIRE|REACTOME_DSCAM_INTERACTIONS|REACTOME_TRAF6_MEDIATED_INDUCTION_OF_TAK1_COMPLEX|REACTOME_RIG_I_MDA5_MEDIATED_INDUCTION_OF_IFN_ALPHA_BETA_PATHWAYS|REACTOME_IKK_COMPLEX_RECRUITMENT_MEDIATED_BY_RIP1|REACTOME_ENDOSOMAL_SORTING_COMPLEX_REQUIRED_FOR_TRANSPORT_ESCRT|REACTOME_IL_2_SIGNALING|REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION|REACTOME_PKB_MEDIATED_EVENTS|REACTOME_HORMONE_SENSITIVE_LIPASE_HSL_MEDIATED_TRIACYLGLYCEROL_HYDROLYSIS|REACTOME_SIGNALING_BY_INSULIN_RECEPTOR|REACTOME_SIGNAL_ATTENUATION|REACTOME_SOS_MEDIATED_SIGNALLING|REACTOME_RAF_MAP_KINASE_CASCADE|REACTOME_SHC_MEDIATED_SIGNALLING|REACTOME_MYD88_MAL_CASCADE_INITIATED_ON_PLASMA_MEMBRANE|REACTOME_INNATE_IMMUNE_SYSTEM|REACTOME_ACTIVATED_TLR4_SIGNALLING|REACTOME_MTORC1_MEDIATED_SIGNALLING|REACTOME_TOLL_RECEPTOR_CASCADES|REACTOME_NOD1_2_SIGNALING_PATHWAY|REACTOME_PIP3_ACTIVATES_AKT_SIGNALING|REACTOME_NUCLEOTIDE_BINDING_DOMAIN_LEUCINE_RICH_REPEAT_CONTAINING_RECEPTOR_NLR_SIGNALING_PATHWAYS|REACTOME_INWARDLY_RECTIFYING_K_CHANNELS|REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION|REACTOME_FGFR2C_LIGAND_BINDING_AND_ACTIVATION|REACTOME_FGFR4_LIGAND_BINDING_AND_ACTIVATION|REACTOME_SIGNALING_BY_FGFR|REACTOME_FGFR1_LIGAND_BINDING_AND_ACTIVATION|REACTOME_PI3K_CASCADE|REACTOME_SHC_RELATED_EVENTS|BERENJENO_TRANSFORMED_BY_RHOA_REVERSIBLY_UP|CORRADETTI_MTOR_PATHWAY_REGULATORS_DN|TURJANSKI_MAPK1_AND_MAPK2_TARGETS|TURJANSKI_MAPK8_AND_MAPK9_TARGETS|TURJANSKI_MAPK7_TARGETS|TURJANSKI_MAPK11_TARGETS|TURJANSKI_MAPK14_TARGETS|GILMORE_CORE_NFKB_PATHWAY|SCHEIDEREIT_IKK_TARGETS|MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_12|MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_5|FARMER_BREAST_CANCER_CLUSTER_8|SCHEIDEREIT_IKK_INTERACTING_PROTEINS|JOHANSSON_BRAIN_CANCER_EARLY_VS_LATE_UP|STANHILL_HRAS_TRANSFROMATION_UP|THEODOROU_MAMMARY_TUMORIGENESIS|SCHLESINGER_H3K27ME3_IN_NORMAL_AND_METHYLATED_IN_CANCER|BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_UP|DEN_INTERACT_WITH_LCA5|AMIT_EGF_RESPONSE_20_HELA|ROZANOV_MMP14_TARGETS_DN|CHESLER_BRAIN_D6MIT150_QTL_TRANS|WEIGEL_OXIDATIVE_STRESS_BY_HNE_AND_H2O2|MEDINA_SMARCA4_TARGETS|MA_PITUITARY_FETAL_VS_ADULT_UP|YIH_RESPONSE_TO_ARSENITE_C4|FINETTI_BREAST_CANCER_KINOME_GREEN|OUYANG_PROSTATE_CANCER_PROGRESSION_UP|LIN_NPAS4_TARGETS_DN|KRISHNAN_FURIN_TARGETS_UP|VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_UP|VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_DN|ZAIDI_OSTEOBLAST_TRANSCRIPTION_FACTORS|HUNSBERGER_EXERCISE_REGULATED_GENES|KAPOSI_LIVER_CANCER_MET_DN|ONO_AML1_TARGETS_UP|ONO_AML1_TARGETS_DN|ONO_FOXP3_TARGETS_UP|ONO_FOXP3_TARGETS_DN|ABDELMOHSEN_ELAVL4_TARGETS|ZHANG_ADIPOGENESIS_BY_BMP7|MIZUSHIMA_AUTOPHAGOSOME_FORMATION|MODULE_51|MODULE_80|MODULE_85|MODULE_199|MODULE_200|MODULE_259|LIPID_RAFT|ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY|INSULIN_RECEPTOR_SIGNALING_PATHWAY|GLUTAMATE_SIGNALING_PATHWAY|EPIDERMAL_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY|POSITIVE_REGULATION_OF_EPITHELIAL_CELL_PROLIFERATION|TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY|MAP_KINASE_ACTIVITY|GLUTAMATE_RECEPTOR_ACTIVITY|PROTEIN_DOMAIN_SPECIFIC_BINDING|TRANSMEMBRANE_RECEPTOR_PROTEIN_KINASE_ACTIVITY|HEMATOPOIETIN_INTERFERON_CLASSD200_DOMAIN_CYTOKINE_RECEPTOR_BINDING|METABOTROPIC_GLUTAMATEGABA_B_LIKE_RECEPTOR_ACTIVITY|SH2_DOMAIN_BINDING|RECEPTOR_SIGNALING_PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY|SH3_DOMAIN_BINDING|HORMONE_BINDING|MOLECULAR_ADAPTOR_ACTIVITY|INSULIN_LIKE_GROWTH_FACTOR_RECEPTOR_BINDING|PROTEIN_TYROSINE_KINASE_ACTIVITY|INOSITOL_OR_PHOSPHATIDYLINOSITOL_PHOSPHATASE_ACTIVITY|LIPID_KINASE_ACTIVITY|IONOTROPIC_GLUTAMATE_RECEPTOR_ACTIVITY|NF_KAPPAB_BINDING|RECEPTOR_SIGNALING_PROTEIN_ACTIVITY|PROTEIN_BINDING_BRIDGING|PDZ_DOMAIN_BINDING|PROTEIN_SERINE_THREONINE_TYROSINE_KINASE_ACTIVITY|TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_ACTIVITY|SH3_SH2_ADAPTOR_ACTIVITY|INOSITOL_OR_PHOSPHATIDYLINOSITOL_KINASE_ACTIVITY	GSE17661,vehicle vs rapamycin both|GSE21755,mTOR high vs mTOR low MEF|GSE26599,vehicle vs rapamycin|GSE46693,RPTOR WT vs KO T lymphocytes|GSE47108,mTOR high (TIBC) vs mTOR low (SDBC) breast tumors	GSE55050,untreated vs BEZ235 Me13 (melanoma)	5599	8503	2885	4793	5608	5601	207	5594	5335	57761	2932	5606	1026	5879	8737	84335	10097	5576	7529	3265	5163	200576	29110	10096	1869	4615	3709	8878	6195	5781	79109	23236	5894	814	57521	1072	1019	7186	2792	7334	108	1027	10451	2251	51295	5899	375	8569	983	5728	396	156	8822	1649	51135	7074	1017	2810	5579	9630	1977	1213	7249	27006	5499	1845	7184	3565	6773	6503	1956	81579	5602	811	117145	6016	2872	5519	81617	10094	5308	4690	3561	5216	356	10392	27071	7323	51719	1173	6885	5571	1460	5563	466	6513	5300	7132	3932	6197	4803	7852	31	4087	10298
HALLMARK_MTORC1_SIGNALING	M5924								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated through activation of mTORC1 complex.			PARENT_MTOR_SIGNALING_UP|NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN|PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP|HOLLMANN_APOPTOSIS_VIA_CD40_DN|LIU_PROSTATE_CANCER_DN|LIU_SOX4_TARGETS_DN|ONKEN_UVEAL_MELANOMA_UP|ONKEN_UVEAL_MELANOMA_DN|BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN|SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP|KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP|SENGUPTA_NASOPHARYNGEAL_CARCINOMA_UP|GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_DN|ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_UP|DAVICIONI_MOLECULAR_ARMS_VS_ERMS_DN|SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP|FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_UP|FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_DN|GARY_CD5_TARGETS_UP|GARY_CD5_TARGETS_DN|HOOI_ST7_TARGETS_DN|PUIFFE_INVASION_INHIBITED_BY_ASCITES_DN|THUM_SYSTOLIC_HEART_FAILURE_UP|CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN|HUTTMANN_B_CLL_POOR_SURVIVAL_UP|DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_UP|DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_DN|DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN|CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN|CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN|DOANE_RESPONSE_TO_ANDROGEN_DN|HORIUCHI_WTAP_TARGETS_UP|GAL_LEUKEMIC_STEM_CELL_DN|BASAKI_YBX1_TARGETS_DN|RODRIGUES_DCC_TARGETS_DN|WANG_LMO4_TARGETS_UP|WANG_CLIM2_TARGETS_UP|VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_UP|VECCHI_GASTRIC_CANCER_EARLY_DN|SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCER_UP|OSMAN_BLADDER_CANCER_UP|OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_DN|GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_DN|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_DN|TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN|RHEIN_ALL_GLUCOCORTICOID_THERAPY_DN|TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_DN|UDAYAKUMAR_MED1_TARGETS_DN|SENESE_HDAC1_TARGETS_UP|SENESE_HDAC1_TARGETS_DN|SENESE_HDAC1_AND_HDAC2_TARGETS_UP|SENESE_HDAC1_AND_HDAC2_TARGETS_DN|SENESE_HDAC2_TARGETS_UP|SENESE_HDAC2_TARGETS_DN|SENESE_HDAC3_TARGETS_UP|SENESE_HDAC3_TARGETS_DN|LEE_NEURAL_CREST_STEM_CELL_UP|TIEN_INTESTINE_PROBIOTICS_2HR_DN|TIEN_INTESTINE_PROBIOTICS_6HR_DN|TIEN_INTESTINE_PROBIOTICS_24HR_UP|KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP|KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN|SABATES_COLORECTAL_ADENOMA_DN|KIM_WT1_TARGETS_DN|KIM_WT1_TARGETS_8HR_DN|KIM_WT1_TARGETS_12HR_DN|JAATINEN_HEMATOPOIETIC_STEM_CELL_DN|DODD_NASOPHARYNGEAL_CARCINOMA_DN|RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP|RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN|RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP|RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_DN|GOZGIT_ESR1_TARGETS_DN|HAHTOLA_MYCOSIS_FUNGOIDES_SKIN_UP|PROVENZANI_METASTASIS_DN|ENK_UV_RESPONSE_EPIDERMIS_UP|ENK_UV_RESPONSE_EPIDERMIS_DN|ENK_UV_RESPONSE_KERATINOCYTE_DN|DELYS_THYROID_CANCER_UP|DELYS_THYROID_CANCER_DN|CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN|CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_DN|MARKEY_RB1_CHRONIC_LOF_DN|MARKEY_RB1_ACUTE_LOF_DN|GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP|CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP|GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP|GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP|GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN|GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP|GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN|GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_UP|GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_UP|BERENJENO_TRANSFORMED_BY_RHOA_DN|MISSIAGLIA_REGULATED_BY_METHYLATION_UP|MCBRYAN_PUBERTAL_BREAST_3_4WK_UP|MCBRYAN_PUBERTAL_BREAST_4_5WK_UP|MCBRYAN_PUBERTAL_BREAST_4_5WK_DN|MCBRYAN_PUBERTAL_BREAST_5_6WK_UP|MCBRYAN_PUBERTAL_BREAST_5_6WK_DN|MCBRYAN_PUBERTAL_BREAST_6_7WK_UP|MCBRYAN_PUBERTAL_BREAST_6_7WK_DN|HAMAI_APOPTOSIS_VIA_TRAIL_UP|HAMAI_APOPTOSIS_VIA_TRAIL_DN|MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP|MCBRYAN_PUBERTAL_TGFB1_TARGETS_DN|KAN_RESPONSE_TO_ARSENIC_TRIOXIDE|MCBRYAN_TERMINAL_END_BUD_UP|MUELLER_METHYLATED_IN_GLIOBLASTOMA|RASHI_RESPONSE_TO_IONIZING_RADIATION_6|LINDGREN_BLADDER_CANCER_CLUSTER_2B|SCHLOSSER_SERUM_RESPONSE_DN|PATIL_LIVER_CANCER|DACOSTA_UV_RESPONSE_VIA_ERCC3_DN|DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN|AMUNDSON_RESPONSE_TO_ARSENITE|MARTORIATI_MDM4_TARGETS_FETAL_LIVER_DN|LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP|MOHANKUMAR_TLX1_TARGETS_UP|DAIRKEE_TERT_TARGETS_UP|GRUETZMANN_PANCREATIC_CANCER_UP|GRUETZMANN_PANCREATIC_CANCER_DN|FURUKAWA_DUSP6_TARGETS_PCI35_UP|SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1|SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP|SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_DN|PUJANA_BRCA1_PCC_NETWORK|PUJANA_ATM_PCC_NETWORK|PUJANA_CHEK2_PCC_NETWORK|NUYTTEN_NIPP1_TARGETS_UP|NUYTTEN_NIPP1_TARGETS_DN|NUYTTEN_EZH2_TARGETS_UP|NUYTTEN_EZH2_TARGETS_DN|BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP|BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN|LOPEZ_MBD_TARGETS|WEI_MYCN_TARGETS_WITH_E_BOX|RICKMAN_METASTASIS_DN|SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN|SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP|SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP|SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN|KOYAMA_SEMA3B_TARGETS_UP|KOYAMA_SEMA3B_TARGETS_DN|PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_UP|BENPORATH_ES_1|BENPORATH_NANOG_TARGETS|BENPORATH_OCT4_TARGETS|BENPORATH_SOX2_TARGETS|BENPORATH_NOS_TARGETS|BENPORATH_MYC_TARGETS_WITH_EBOX|BENPORATH_MYC_MAX_TARGETS|STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN|GEORGES_TARGETS_OF_MIR192_AND_MIR215|SHEN_SMARCA2_TARGETS_UP|ONDER_CDH1_TARGETS_2_UP|ONDER_CDH1_SIGNALING_VIA_CTNNB1|SMITH_TERT_TARGETS_UP|FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP|WIELAND_UP_BY_HBV_INFECTION|FRASOR_RESPONSE_TO_ESTRADIOL_DN|FERNANDEZ_BOUND_BY_MYC|OKUMURA_INFLAMMATORY_RESPONSE_LPS|BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS|FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN|FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP|BHATTACHARYA_EMBRYONIC_STEM_CELL|BROWN_MYELOID_CELL_DEVELOPMENT_UP|NADLER_OBESITY_UP|SANSOM_APC_TARGETS_DN|FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_UP|MATSUDA_NATURAL_KILLER_DIFFERENTIATION|LEI_MYB_TARGETS|HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN|LENAOUR_DENDRITIC_CELL_MATURATION_DN|HADDAD_B_LYMPHOCYTE_PROGENITOR|LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP|HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_DN|IGLESIAS_E2F_TARGETS_UP|KUMAR_TARGETS_OF_MLL_AF9_FUSION|IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR|REN_ALVEOLAR_RHABDOMYOSARCOMA_DN|BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_UP|DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP|IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR|IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM|BLALOCK_ALZHEIMERS_DISEASE_DN|RAMALHO_STEMNESS_DN|GENTILE_UV_RESPONSE_CLUSTER_D4|LIAN_LIPA_TARGETS_6M|RAMALHO_STEMNESS_UP|WANG_SMARCE1_TARGETS_DN|KAAB_HEART_ATRIUM_VS_VENTRICLE_UP|CUI_TCF21_TARGETS_2_DN|SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_2|BAELDE_DIABETIC_NEPHROPATHY_UP|WANG_CISPLATIN_RESPONSE_AND_XPC_DN|BLALOCK_ALZHEIMERS_DISEASE_UP|DAZARD_RESPONSE_TO_UV_SCC_DN|YAMAZAKI_TCEB3_TARGETS_DN|GAJATE_RESPONSE_TO_TRABECTEDIN_UP|LU_AGING_BRAIN_UP|LIAN_LIPA_TARGETS_3M|BURTON_ADIPOGENESIS_8|SATO_SILENCED_EPIGENETICALLY_IN_PANCREATIC_CANCER|LEE_AGING_NEOCORTEX_UP|GENTILE_UV_HIGH_DOSE_DN|MCLACHLAN_DENTAL_CARIES_DN|LEE_AGING_CEREBELLUM_UP|RODWELL_AGING_KIDNEY_NO_BLOOD_UP|RODWELL_AGING_KIDNEY_UP|BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_DN|KEEN_RESPONSE_TO_ROSIGLITAZONE_DN|DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_DN|BURTON_ADIPOGENESIS_PEAK_AT_0HR|DAZARD_RESPONSE_TO_UV_NHEK_DN|IVANOVA_HEMATOPOIESIS_STEM_CELL_AND_PROGENITOR|JIANG_HYPOXIA_NORMAL|BAELDE_DIABETIC_NEPHROPATHY_DN|SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC_CANCER|DAZARD_UV_RESPONSE_CLUSTER_G6|SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_1|WANG_SMARCE1_TARGETS_UP|GENTILE_RESPONSE_CLUSTER_D3|MARTINEZ_RESPONSE_TO_TRABECTEDIN_DN|BURTON_ADIPOGENESIS_9|MCLACHLAN_DENTAL_CARIES_UP|DOUGLAS_BMI1_TARGETS_UP|KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_UP|KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN|KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP|KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_DN|DURCHDEWALD_SKIN_CARCINOGENESIS_DN|MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP|MONNIER_POSTRADIATION_TUMOR_ESCAPE_DN|CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_3|CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5|ZHENG_BOUND_BY_FOXP3|MARSON_BOUND_BY_FOXP3_STIMULATED|MARSON_BOUND_BY_FOXP3_UNSTIMULATED|ZHENG_FOXP3_TARGETS_IN_THYMUS_UP|FOSTER_TOLERANT_MACROPHAGE_UP|KONDO_EZH2_TARGETS|STEARMAN_TUMOR_FIELD_EFFECT_UP|STEARMAN_LUNG_CANCER_EARLY_VS_LATE_DN|HELLER_SILENCED_BY_METHYLATION_UP|HELLER_SILENCED_BY_METHYLATION_DN|HELLER_HDAC_TARGETS_UP|HELLER_HDAC_TARGETS_DN|HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP|HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_DN|MARTINEZ_RB1_TARGETS_UP|MARTINEZ_RB1_TARGETS_DN|MARTINEZ_TP53_TARGETS_UP|MARTINEZ_TP53_TARGETS_DN|MARTINEZ_RB1_AND_TP53_TARGETS_UP|MARTINEZ_RB1_AND_TP53_TARGETS_DN|MASSARWEH_TAMOXIFEN_RESISTANCE_UP|WALLACE_PROSTATE_CANCER_RACE_UP|SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_DN|IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_DN|RIGGI_EWING_SARCOMA_PROGENITOR_DN|ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_UP|ACEVEDO_LIVER_CANCER_UP|ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_UP|MITSIADES_RESPONSE_TO_APLIDIN_UP|BONOME_OVARIAN_CANCER_SURVIVAL_SUBOPTIMAL_DEBULKING|TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C|IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_DN|ZHANG_BREAST_CANCER_PROGENITORS_UP|WILENSKY_RESPONSE_TO_DARAPLADIB|GRADE_COLON_CANCER_UP|GRADE_COLON_AND_RECTAL_CANCER_UP|BOQUEST_STEM_CELL_UP|BOQUEST_STEM_CELL_DN|BOQUEST_STEM_CELL_CULTURED_VS_FRESH_UP|WEST_ADRENOCORTICAL_TUMOR_DN|PODAR_RESPONSE_TO_ADAPHOSTIN_UP|CHEN_HOXA5_TARGETS_9HR_UP|HUANG_DASATINIB_RESISTANCE_UP|QI_PLASMACYTOMA_UP|BLUM_RESPONSE_TO_SALIRASIB_UP|BOYLAN_MULTIPLE_MYELOMA_C_D_DN|TOOKER_GEMCITABINE_RESISTANCE_DN|ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_UP|ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_UP|YOSHIMURA_MAPK8_TARGETS_DN|WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_UP|RUIZ_TNC_TARGETS_UP|RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP|RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_DN|RUTELLA_RESPONSE_TO_HGF_UP|RUTELLA_RESPONSE_TO_HGF_DN|RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_UP|RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN|SWEET_LUNG_CANCER_KRAS_UP|SWEET_LUNG_CANCER_KRAS_DN|SWEET_KRAS_ONCOGENIC_SIGNATURE|LEE_RECENT_THYMIC_EMIGRANT|HAN_SATB1_TARGETS_UP|HAN_SATB1_TARGETS_DN|COLINA_TARGETS_OF_4EBP1_AND_4EBP2|CHEN_METABOLIC_SYNDROM_NETWORK|MILI_PSEUDOPODIA_CHEMOTAXIS_DN|MILI_PSEUDOPODIA_HAPTOTAXIS_UP|MILI_PSEUDOPODIA_HAPTOTAXIS_DN|LIU_VAV3_PROSTATE_CARCINOGENESIS_UP|ROME_INSULIN_TARGETS_IN_MUSCLE_UP|VALK_AML_CLUSTER_5|POOLA_INVASIVE_BREAST_CANCER_UP|CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_DN|YAGI_AML_WITH_INV_16_TRANSLOCATION|KOBAYASHI_EGFR_SIGNALING_24HR_UP|BOYLAN_MULTIPLE_MYELOMA_PCA1_UP|HOSHIDA_LIVER_CANCER_SUBCLASS_S1|CAIRO_LIVER_DEVELOPMENT_UP|DANG_BOUND_BY_MYC|WONG_ADULT_TISSUE_STEM_MODULE|NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_UP|NIELSEN_SYNOVIAL_SARCOMA_DN|KARLSSON_TGFB1_TARGETS_DN|LI_INDUCED_T_TO_NATURAL_KILLER_UP|MARTENS_BOUND_BY_PML_RARA_FUSION|MARTENS_TRETINOIN_RESPONSE_DN|KIM_ALL_DISORDERS_OLIGODENDROCYTE_NUMBER_CORR_UP|KIM_BIPOLAR_DISORDER_OLIGODENDROCYTE_DENSITY_CORR_UP|KIM_ALL_DISORDERS_CALB1_CORR_UP|KIM_ALL_DISORDERS_DURATION_CORR_DN|HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_UP|CHICAS_RB1_TARGETS_SENESCENT|CHICAS_RB1_TARGETS_GROWING|CHICAS_RB1_TARGETS_CONFLUENT|LU_EZH2_TARGETS_DN|DEMAGALHAES_AGING_UP|DUTERTRE_ESTRADIOL_RESPONSE_6HR_DN|DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN|CHYLA_CBFA2T3_TARGETS_UP|ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_UP|PILON_KLF1_TARGETS_UP|PILON_KLF1_TARGETS_DN|BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN|BHAT_ESR1_TARGETS_VIA_AKT1_DN|JOHNSTONE_PARVB_TARGETS_2_DN|JOHNSTONE_PARVB_TARGETS_3_UP|JOHNSTONE_PARVB_TARGETS_3_DN|BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B|BRUINS_UVC_RESPONSE_LATE|BRUINS_UVC_RESPONSE_EARLY_LATE|MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN|KIM_GLIS2_TARGETS_UP|PASINI_SUZ12_TARGETS_UP|PASINI_SUZ12_TARGETS_DN|DELPUECH_FOXO3_TARGETS_UP|LEE_BMP2_TARGETS_UP|LEE_BMP2_TARGETS_DN|DALESSIO_TSA_RESPONSE|FEVR_CTNNB1_TARGETS_UP|TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_DN|KOINUMA_TARGETS_OF_SMAD2_OR_SMAD3|PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_DN|GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN|KATSANOU_ELAVL1_TARGETS_UP|SERVITJA_ISLET_HNF1A_TARGETS_UP|PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7|PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2|WAKABAYASHI_ADIPOGENESIS_PPARG_BOUND_8D|YANG_BCL3_TARGETS_UP|HUANG_GATA2_TARGETS_UP|PLASARI_TGFB1_TARGETS_10HR_DN|WANG_MLL_TARGETS|DELACROIX_RARG_BOUND_MEF|DELACROIX_RAR_TARGETS_UP|DELACROIX_RAR_BOUND_ES|KRIEG_HYPOXIA_NOT_VIA_KDM3A|ALFANO_MYC_TARGETS|FORTSCHEGGER_PHF8_TARGETS_DN|PEDRIOLI_MIR31_TARGETS_DN|PHONG_TNF_RESPONSE_VIA_P38_COMPLETE|RAO_BOUND_BY_SALL4_ISOFORM_B|RAO_BOUND_BY_SALL4|PECE_MAMMARY_STEM_CELL_DN|ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_DN|LIM_MAMMARY_STEM_CELL_UP|DURAND_STROMA_NS_UP|ZWANG_CLASS_1_TRANSIENTLY_INDUCED_BY_EGF|ZWANG_TRANSIENTLY_UP_BY_1ST_EGF_PULSE_ONLY|GNF2_CARD15|GNF2_CASP1|GNF2_CD14|GNF2_CD1D|GNF2_CD33|GNF2_FGR|GNF2_FOS|GNF2_HCK|GNF2_ITGB2|GNF2_MCL1|GNF2_PECAM1|GNF2_S100A4|GNF2_SPI1|GNF2_TNFRSF1B|GNF2_TNFSF10|MODULE_1|MODULE_2|MODULE_3|MODULE_5|MODULE_6|MODULE_7|MODULE_8|MODULE_11|MODULE_12|MODULE_13|MODULE_15|MODULE_16|MODULE_17|MODULE_18|MODULE_19|MODULE_23|MODULE_24|MODULE_33|MODULE_38|MODULE_41|MODULE_44|MODULE_45|MODULE_47|MODULE_52|MODULE_53|MODULE_55|MODULE_60|MODULE_66|MODULE_72|MODULE_79|MODULE_84|MODULE_88|MODULE_94|MODULE_99|MODULE_100|MODULE_104|MODULE_112|MODULE_117|MODULE_118|MODULE_128|MODULE_129|MODULE_137|MODULE_165|MODULE_170|MODULE_176|MODULE_181|MODULE_204|MODULE_213|MODULE_242|MODULE_321|MODULE_379|E2F1_UP.V1_DN|EGFR_UP.V1_UP|ERB2_UP.V1_UP|CYCLIN_D1_KE_.V1_DN|CYCLIN_D1_UP.V1_DN|AKT_UP_MTOR_DN.V1_DN|AKT_UP.V1_DN|MTOR_UP.V1_DN|PIGF_UP.V1_UP|VEGF_A_UP.V1_DN|ATF2_S_UP.V1_DN|ATF2_UP.V1_DN|P53_DN.V1_DN|SNF5_DN.V1_DN|SNF5_DN.V1_UP|LTE2_UP.V1_UP|MEK_UP.V1_UP|RAF_UP.V1_UP|MTOR_UP.N4.V1_UP|ESC_J1_UP_EARLY.V1_DN|ESC_J1_UP_LATE.V1_DN|ESC_V6.5_UP_EARLY.V1_DN|ESC_V6.5_UP_LATE.V1_DN|RPS14_DN.V1_UP|HOXA9_DN.V1_UP|STK33_NOMO_UP|STK33_SKM_UP|STK33_UP|KRAS.DF.V1_UP|TBK1.DF_DN|TBK1.DF_UP|LEF1_UP.V1_UP	GSE17661,vehicle vs rapamycin both|GSE21755,mTOR high vs mTOR low MEF|GSE26599,vehicle vs rapamycin|GSE46693,RPTOR WT vs KO T lymphocytes|GSE47108,mTOR high (TIBC) vs mTOR low (SDBC) breast tumors	GSE55050,untreated vs BEZ235 Me13 (melanoma)	3992	54541	811	3099	5230	8140	1075	2181	6510	4074	7037	1649	27346	3475	5352	7277	29968	11151	3939	10797	9415	7436	7453	6319	5033	10097	3417	6513	2632	871	26471	8624	5723	10135	1026	8553	3313	3309	112399	5641	4860	7494	6503	10212	3336	47	23657	6745	2717	8878	5163	5701	5052	27230	57761	4783	3157	2805	7167	79071	440	10213	5685	5464	3251	6790	3156	2597	1719	1717	10989	51377	10652	3638	6713	3488	10437	1595	10875	2023	3422	80777	6472	7296	2539	9368	5861	10682	56902	8503	10096	3949	6515	7323	60481	27101	9695	51382	26136	7108	5684	3689	205	6509	10452	6533	5478	120	4199	899	2542	226	7832	51569	900	6781	4836	5706	2232	6241	1718	5704	1491	10197	5199	10622	31	5860	4171	5718	6309	821	6184	3308	116496	29110	23478	586	5693	5719	5236	5347	2745	10987	2107	2932	23165	6652	26227	8833	9136	9521	4048	23753	2286	51109	7852	10962	2729	6917	5606	3329	54843	4173	23645	8615	4793	7374	2965	6117	7184	30001	2936	23760	2058	6715	7283	441024	79602	26747	993	11333	134429	699	81873	2821	8894	928	488	23062	3145	6016	8935	10963	27071	10061	4802	516	5211	908
HALLMARK_E2F_TARGETS	M5925								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes encoding cell cycle related targets of E2F transcription factors.			KEGG_DNA_REPLICATION|KEGG_BASE_EXCISION_REPAIR|KEGG_MISMATCH_REPAIR|KEGG_HOMOLOGOUS_RECOMBINATION|KEGG_CELL_CYCLE|BIOCARTA_SRCRPTP_PATHWAY|BIOCARTA_ATM_PATHWAY|BIOCARTA_MCM_PATHWAY|BIOCARTA_G1_PATHWAY|BIOCARTA_G2_PATHWAY|BIOCARTA_CELLCYCLE_PATHWAY|BIOCARTA_SKP2E2F_PATHWAY|BIOCARTA_P53_PATHWAY|BIOCARTA_RB_PATHWAY|BIOCARTA_P27_PATHWAY|BIOCARTA_ATRBRCA_PATHWAY|BIOCARTA_PTC1_PATHWAY|SA_G1_AND_S_PHASES|SA_G2_AND_M_PHASES|SA_REG_CASCADE_OF_CYCLIN_EXPR|PID_FANCONI_PATHWAY|PID_AURORA_B_PATHWAY|PID_E2F_PATHWAY|PID_ATR_PATHWAY|PID_ATM_PATHWAY|PID_PLK1_PATHWAY|PID_FOXM1_PATHWAY|PID_AURORA_A_PATHWAY|PID_BARD1_PATHWAY|PID_RB_1PATHWAY|REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX|REACTOME_BASE_EXCISION_REPAIR|REACTOME_G0_AND_EARLY_G1|REACTOME_RESOLUTION_OF_AP_SITES_VIA_THE_MULTIPLE_NUCLEOTIDE_PATCH_REPLACEMENT_PATHWAY|REACTOME_ASSOCIATION_OF_LICENSING_FACTORS_WITH_THE_PRE_REPLICATIVE_COMPLEX|REACTOME_E2F_ENABLED_INHIBITION_OF_PRE_REPLICATION_COMPLEX_FORMATION|REACTOME_BASE_FREE_SUGAR_PHOSPHATE_REMOVAL_VIA_THE_SINGLE_NUCLEOTIDE_REPLACEMENT_PATHWAY|REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_LAGGING_STRAND|REACTOME_HOMOLOGOUS_RECOMBINATION_REPAIR_OF_REPLICATION_INDEPENDENT_DOUBLE_STRAND_BREAKS|REACTOME_G1_PHASE|REACTOME_CDC6_ASSOCIATION_WITH_THE_ORC_ORIGIN_COMPLEX|REACTOME_POL_SWITCHING|REACTOME_REGULATION_OF_THE_FANCONI_ANEMIA_PATHWAY|REACTOME_FANCONI_ANEMIA_PATHWAY|REACTOME_CYCLIN_A_B1_ASSOCIATED_EVENTS_DURING_G2_M_TRANSITION|REACTOME_REPAIR_SYNTHESIS_FOR_GAP_FILLING_BY_DNA_POL_IN_TC_NER|REACTOME_DOUBLE_STRAND_BREAK_REPAIR|REACTOME_LAGGING_STRAND_SYNTHESIS|REACTOME_INHIBITION_OF_REPLICATION_INITIATION_OF_DAMAGED_DNA_BY_RB1_E2F1|REACTOME_E2F_MEDIATED_REGULATION_OF_DNA_REPLICATION|REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS|REACTOME_UNWINDING_OF_DNA|REACTOME_G1_S_SPECIFIC_TRANSCRIPTION|REACTOME_REMOVAL_OF_THE_FLAP_INTERMEDIATE_FROM_THE_C_STRAND|REACTOME_EXTENSION_OF_TELOMERES|REACTOME_G2_M_CHECKPOINTS|REACTOME_G2_M_DNA_DAMAGE_CHECKPOINT|REACTOME_DNA_STRAND_ELONGATION|REACTOME_RESOLUTION_OF_AP_SITES_VIA_THE_SINGLE_NUCLEOTIDE_REPLACEMENT_PATHWAY|NAKAMURA_CANCER_MICROENVIRONMENT_DN|WEST_ADRENOCORTICAL_TUMOR_MARKERS_UP|PYEON_HPV_POSITIVE_TUMORS_UP|FOURNIER_ACINAR_DEVELOPMENT_LATE_DN|SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP|CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_UP|ZERBINI_RESPONSE_TO_SULINDAC_DN|WILCOX_RESPONSE_TO_PROGESTERONE_UP|HORIUCHI_WTAP_TARGETS_DN|BASAKI_YBX1_TARGETS_UP|VECCHI_GASTRIC_CANCER_EARLY_UP|SLEBOS_HEAD_AND_NECK_CANCER_WITH_HPV_UP|GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_DN|ODONNELL_TFRC_TARGETS_DN|ODONNELL_TARGETS_OF_MYC_AND_TFRC_DN|SCIBETTA_KDM5B_TARGETS_DN|GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_UP|GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_UP|GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN|BIDUS_METASTASIS_UP|LINDGREN_BLADDER_CANCER_CLUSTER_1_DN|LINDGREN_BLADDER_CANCER_CLUSTER_3_UP|NADERI_BREAST_CANCER_PROGNOSIS_UP|MARKEY_RB1_CHRONIC_LOF_UP|MARKEY_RB1_ACUTE_LOF_UP|CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN|BERENJENO_TRANSFORMED_BY_RHOA_UP|MISSIAGLIA_REGULATED_BY_METHYLATION_DN|TANG_SENESCENCE_TP53_TARGETS_DN|JOHANSSON_GLIOMAGENESIS_BY_PDGFB_UP|NUNODA_RESPONSE_TO_DASATINIB_IMATINIB_UP|OLSSON_E2F3_TARGETS_DN|MARKS_HDAC_TARGETS_DN|KONG_E2F3_TARGETS|EGUCHI_CELL_CYCLE_RB1_TARGETS|CROSBY_E2F4_TARGETS|RIZ_ERYTHROID_DIFFERENTIATION|RIZ_ERYTHROID_DIFFERENTIATION_CCNE1|WAKASUGI_HAVE_ZNF143_BINDING_SITES|BAKER_HEMATOPOIESIS_STAT3_TARGETS|BAKER_HEMATOPOESIS_STAT5_TARGETS|MATHEW_FANCONI_ANEMIA_GENES|IWANAGA_E2F1_TARGETS_NOT_INDUCED_BY_SERUM|FARMER_BREAST_CANCER_CLUSTER_2|ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER|OHASHI_AURKA_TARGETS|OHASHI_AURKB_TARGETS|HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2|HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_DN|XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_DN|XU_HGF_TARGETS_INDUCED_BY_AKT1_48HR_DN|KORKOLA_TERATOMA|AMUNDSON_GENOTOXIC_SIGNATURE|LI_WILMS_TUMOR_ANAPLASTIC_UP|MANN_RESPONSE_TO_AMIFOSTINE_DN|OXFORD_RALA_OR_RALB_TARGETS_UP|LI_WILMS_TUMOR_VS_FETAL_KIDNEY_2_UP|SEMBA_FHIT_TARGETS_DN|FURUKAWA_DUSP6_TARGETS_PCI35_DN|PUJANA_BREAST_CANCER_LIT_INT_NETWORK|PUJANA_XPRSS_INT_NETWORK|PUJANA_BRCA2_PCC_NETWORK|PUJANA_BRCA_CENTERED_NETWORK|KAUFFMANN_MELANOMA_RELAPSE_UP|GROSS_HYPOXIA_VIA_ELK3_UP|GROSS_HYPOXIA_VIA_HIF1A_UP|GROSS_HYPOXIA_VIA_ELK3_ONLY_DN|GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_DN|FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_UP|SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_DN|GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN|RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_DN|BENPORATH_CYCLING_GENES|BENPORATH_PROLIFERATION|BENPORATH_ES_CORE_NINE_CORRELATED|GEORGES_CELL_CYCLE_MIR192_TARGETS|JEON_SMAD6_TARGETS_DN|MORI_PRE_BI_LYMPHOCYTE_UP|MORI_LARGE_PRE_BII_LYMPHOCYTE_UP|MORI_IMMATURE_B_LYMPHOCYTE_DN|KAUFFMANN_DNA_REPAIR_GENES|KAUFFMANN_DNA_REPLICATION_GENES|SHEPARD_BMYB_MORPHOLINO_DN|SHEPARD_BMYB_TARGETS|SHEPARD_CRUSH_AND_BURN_MUTANT_DN|MANALO_HYPOXIA_DN|VANTVEER_BREAST_CANCER_METASTASIS_DN|LE_EGR2_TARGETS_UP|PENG_GLUCOSE_DEPRIVATION_DN|VANTVEER_BREAST_CANCER_METASTASIS_UP|REN_BOUND_BY_E2F|PEART_HDAC_PROLIFERATION_CLUSTER_DN|SASAKI_ADULT_T_CELL_LEUKEMIA|YU_MYC_TARGETS_UP|LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_DN|NEMETH_INFLAMMATORY_RESPONSE_LPS_DN|ZHAN_MULTIPLE_MYELOMA_PR_UP|PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP|AFFAR_YY1_TARGETS_DN|VERNELL_RETINOBLASTOMA_PATHWAY_UP|KAMMINGA_EZH2_TARGETS|GREENBAUM_E2A_TARGETS_UP|PETROVA_PROX1_TARGETS_UP|LY_AGING_PREMATURE_DN|ZAMORA_NOS2_TARGETS_UP|PAL_PRMT5_TARGETS_UP|CHUANG_OXIDATIVE_STRESS_RESPONSE_DN|KANG_DOXORUBICIN_RESISTANCE_UP|RHODES_UNDIFFERENTIATED_CANCER|BURTON_ADIPOGENESIS_3|BURTON_ADIPOGENESIS_PEAK_AT_24HR|SONG_TARGETS_OF_IE86_CMV_PROTEIN|MMS_MOUSE_LYMPH_HIGH_4HRS_UP|LIANG_SILENCED_BY_METHYLATION_DN|KALMA_E2F1_TARGETS|LY_AGING_OLD_DN|WANG_CISPLATIN_RESPONSE_AND_XPC_UP|SIMBULAN_PARP1_TARGETS_DN|LY_AGING_MIDDLE_DN|HU_GENOTOXIC_DAMAGE_4HR|BURTON_ADIPOGENESIS_PEAK_AT_16HR|GAVIN_FOXP3_TARGETS_CLUSTER_P6|MARSON_BOUND_BY_E2F4_UNSTIMULATED|STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_DN|AMUNDSON_GAMMA_RADIATION_RESPONSE|FINETTI_BREAST_CANCER_KINOME_RED|SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_UP|FUJII_YBX1_TARGETS_DN|MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN|MITSIADES_RESPONSE_TO_APLIDIN_DN|SMID_BREAST_CANCER_LUMINAL_A_DN|KUMAMOTO_RESPONSE_TO_NUTLIN_3A_DN|ZHENG_GLIOBLASTOMA_PLASTICITY_UP|MATZUK_MEIOTIC_AND_DNA_REPAIR|MATZUK_SPERMATOCYTE|WHITEFORD_PEDIATRIC_CANCER_MARKERS|WEST_ADRENOCORTICAL_TUMOR_UP|BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_UP|RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_UP|THUM_MIR21_TARGETS_HEART_DISEASE_DN|BLUM_RESPONSE_TO_SALIRASIB_DN|MUELLER_PLURINET|REICHERT_G1S_REGULATORS_AS_PI3K_TARGETS|BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_UP|PIONTEK_PKD1_TARGETS_DN|FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN|GOLDRATH_ANTIGEN_RESPONSE|RUIZ_TNC_TARGETS_DN|CHANG_CORE_SERUM_RESPONSE_UP|CHANG_CYCLING_GENES|HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_UP|LEE_EARLY_T_LYMPHOCYTE_UP|LI_WILMS_TUMOR|SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6|ZHANG_TLX_TARGETS_36HR_DN|ZHANG_TLX_TARGETS_60HR_DN|ZHANG_TLX_TARGETS_DN|CROONQUIST_IL6_DEPRIVATION_DN|CROONQUIST_NRAS_SIGNALING_DN|ISHIDA_E2F_TARGETS|BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP|BOYAULT_LIVER_CANCER_SUBCLASS_G23_UP|BOYAULT_LIVER_CANCER_SUBCLASS_G123_UP|CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP|MONTERO_THYROID_CANCER_POOR_SURVIVAL_UP|GLINSKY_CANCER_DEATH_UP|PUJANA_BREAST_CANCER_WITH_BRCA1_MUTATED_UP|STEIN_ESR1_TARGETS|KOBAYASHI_EGFR_SIGNALING_24HR_DN|FOURNIER_ACINAR_DEVELOPMENT_LATE_2|PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP|CAIRO_HEPATOBLASTOMA_CLASSES_UP|WINNEPENNINCKX_MELANOMA_METASTASIS_UP|VANTVEER_BREAST_CANCER_POOR_PROGNOSIS|CHIARETTI_T_ALL_RELAPSE_PROGNOSIS|WONG_EMBRYONIC_STEM_CELL_CORE|NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP|YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_15|WHITFIELD_CELL_CYCLE_LITERATURE|WU_APOPTOSIS_BY_CDKN1A_VIA_TP53|WU_APOPTOSIS_BY_CDKN1A_NOT_VIA_TP53|WHITFIELD_CELL_CYCLE_G1_S|WHITFIELD_CELL_CYCLE_S|WHITFIELD_CELL_CYCLE_G2|WHITFIELD_CELL_CYCLE_G2_M|WHITFIELD_CELL_CYCLE_M_G1|WANG_METASTASIS_OF_BREAST_CANCER_ESR1_UP|WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_DN|DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP|ZHU_SKIL_TARGETS_DN|DELPUECH_FOXO3_TARGETS_DN|DORMOY_ELAVL1_TARGETS|FEVR_CTNNB1_TARGETS_DN|GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP|WANG_THOC1_TARGETS_UP|JUBAN_TARGETS_OF_SPI1_AND_FLI1_DN|LE_NEURONAL_DIFFERENTIATION_DN|REICHERT_MITOSIS_LIN9_TARGETS|YU_BAP1_TARGETS|ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_2HR|ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR|ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR|E2F_01|E2F_02|E2F_Q3|E2F_Q4|E2F_Q6|E2F1_Q3|E2F1_Q4|E2F1_Q6|E2F_03|E2F1DP1_01|E2F1DP2_01|E2F4DP1_01|E2F4DP2_01|E2F1DP1RB_01|E2F_Q3_01|E2F_Q4_01|E2F_Q6_01|E2F1_Q3_01|E2F1_Q4_01|E2F1_Q6_01|KTGGYRSGAA_UNKNOWN|RRCCGTTA_UNKNOWN|SGCGSSAAA_E2F1DP2_01|GNF2_BUB1|GNF2_CDC20|GNF2_CDC2|GNF2_CENPE|GNF2_CENPF|GNF2_CCNA2|GNF2_CCNB2|GNF2_ESPL1|GNF2_FEN1|GNF2_H2AFX|GNF2_PCNA|GNF2_RFC3|GNF2_RFC4|GNF2_RRM1|GNF2_RRM2|GNF2_SMC2L1|GNF2_SMC4L1|GNF2_BUB1B|GNF2_CKS1B|GNF2_CKS2|GNF2_HMMR|GNF2_MCM4|GNF2_MKI67|GNF2_TTK|MODULE_54|MODULE_57|MODULE_98|MODULE_123|MODULE_124|MODULE_125|MODULE_158|MODULE_197|MODULE_198|MODULE_244|MODULE_252|MODULE_303|MODULE_308|MODULE_315|MODULE_320|MODULE_325|MODULE_337|MODULE_360|MODULE_372|MODULE_397|MODULE_403|MODULE_451|MODULE_485|CHROMATIN|NUCLEAR_REPLICATION_FORK|NUCLEAR_CHROMOSOME|CHROMOSOMEPERICENTRIC_REGION|CONDENSED_NUCLEAR_CHROMOSOME|REPLICATION_FORK|KINETOCHORE|NUCLEAR_CHROMATIN|NUCLEOLAR_PART|CHROMOSOMAL_PART|CONDENSED_CHROMOSOME|CHROMOSOME|NUCLEAR_CHROMOSOME_PART|DNA_METABOLIC_PROCESS|DNA_REPAIR|MITOTIC_CELL_CYCLE_CHECKPOINT|NEGATIVE_REGULATION_OF_DNA_METABOLIC_PROCESS|MEIOSIS_I|REGULATION_OF_DNA_REPLICATION|RESPONSE_TO_ENDOGENOUS_STIMULUS|M_PHASE|NEGATIVE_REGULATION_OF_CELL_CYCLE|DNA_INTEGRITY_CHECKPOINT|REGULATION_OF_MITOSIS|INTERPHASE|CELL_CYCLE_PROCESS|MITOTIC_SISTER_CHROMATID_SEGREGATION|REGULATION_OF_DNA_METABOLIC_PROCESS|MEIOTIC_CELL_CYCLE|MITOTIC_CELL_CYCLE|CELL_CYCLE_PHASE|S_PHASE|CELL_CYCLE_CHECKPOINT_GO_0000075|DNA_REPLICATION_INITIATION|CHROMOSOME_SEGREGATION|G1_PHASE_OF_MITOTIC_CELL_CYCLE|REGULATION_OF_MITOTIC_CELL_CYCLE|DNA_REPLICATION|DNA_DAMAGE_RESPONSESIGNAL_TRANSDUCTION|DNA_DAMAGE_RESPONSESIGNAL_TRANSDUCTION_RESULTING_IN_INDUCTION_OF_APOPTOSIS|DNA_DAMAGE_CHECKPOINT|DOUBLE_STRAND_BREAK_REPAIR|NEGATIVE_REGULATION_OF_DNA_REPLICATION|DNA_RECOMBINATION|G1_PHASE|S_PHASE_OF_MITOTIC_CELL_CYCLE|MEIOTIC_RECOMBINATION|CELL_CYCLE_ARREST_GO_0007050|MITOSIS|CELL_CYCLE_GO_0007049|SISTER_CHROMATID_SEGREGATION|POSITIVE_REGULATION_OF_CELL_CYCLE|DNA_DEPENDENT_DNA_REPLICATION|DNA_DAMAGE_RESPONSESIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR|INTERPHASE_OF_MITOTIC_CELL_CYCLE|BASE_EXCISION_REPAIR|RESPONSE_TO_DNA_DAMAGE_STIMULUS|REGULATION_OF_CELL_CYCLE|RNA_CATABOLIC_PROCESS|M_PHASE_OF_MITOTIC_CELL_CYCLE|CHROMOSOME_CONDENSATION|G1_S_TRANSITION_OF_MITOTIC_CELL_CYCLE|INDUCTION_OF_APOPTOSIS_BY_INTRACELLULAR_SIGNALS|ENDODEOXYRIBONUCLEASE_ACTIVITY|DAMAGED_DNA_BINDING|SINGLE_STRANDED_DNA_BINDING|HYDROLASE_ACTIVITY_HYDROLYZING_N_GLYCOSYL_COMPOUNDS|RIBONUCLEASE_ACTIVITY|NUCLEOTIDYLTRANSFERASE_ACTIVITY|DEOXYRIBONUCLEASE_ACTIVITY|ENDORIBONUCLEASE_ACTIVITY|DNA_POLYMERASE_ACTIVITY|3_5_EXONUCLEASE_ACTIVITY|DNA_DIRECTED_DNA_POLYMERASE_ACTIVITY|DOUBLE_STRANDED_DNA_BINDING|ENDONUCLEASE_ACTIVITY|EXONUCLEASE_ACTIVITY|STRUCTURE_SPECIFIC_DNA_BINDING|CHROMATIN_BINDING|NUCLEASE_ACTIVITY|ENDONUCLEASE_ACTIVITY_GO_0016893|E2F1_UP.V1_UP|GCNP_SHH_UP_EARLY.V1_UP|GCNP_SHH_UP_LATE.V1_UP|CSR_LATE_UP.V1_UP|RB_DN.V1_UP|RB_P107_DN.V1_UP|RB_P130_DN.V1_UP|RPS14_DN.V1_DN	GSE9496,E2F1 OE vs control REF52 (fibroblasts)|GSE16454,Rb-/- vs Rb WT villi|GSE16533,E2F1 WT vs E2F1 MUT E17.5 embryo|GSE30488,E2f3a+/+E2f7-/-E2f8-/- vs E2f3a-/-E2f7+/+E2f8+/+ placenta|GSE38048,skin carcinoma (E2F MUT and RB MUT) vs normal skin|GSE54924,Rb-/- vs Rb WT MEF	GSE38264,GSM1414864-GSM1414876 tumor vs normal|GSE38264,GSM937678-GSM1414789 tumor vs normal|GSE50051,GSM1213161-GSM1213180 E2F1 OE vs GFP HMEC	6790	675	9738	1062	1164	64858	1786	29980	8726	9837	84296	3015	3978	4085	4171	4173	4174	4176	9833	253714	51691	4678	11051	23165	23594	5111	10733	5426	5558	10635	5982	6118	6119	6839	7112	29089	197335	983	4172	7153	4175	332	9133	6241	3148	701	5983	2146	1111	10051	4288	991	5347	11004	9787	9212	993	9319	3014	3161	79733	672	4605	5424	29127	1163	3838	4436	1033	29028	6117	3925	54962	7083	55143	9700	9918	5902	4361	24137	4001	3835	7374	8243	898	83461	55723	23649	8914	3070	27338	5591	5901	7398	10615	10714	1854	10460	146909	994	6426	64785	9221	7884	11200	57405	580	79077	9126	10535	7913	79019	5889	23468	5981	5425	79075	3609	55635	1633	1031	4609	6941	5810	3930	4683	9232	55148	56655	7283	10664	9125	203068	79677	9183	5036	6749	4673	81611	3149	10527	5885	1019	1026	84312	1503	10111	6434	1434	10606	10274	51747	8493	4830	6427	7514	3184	5395	25842	11340	4292	57122	4999	7157	7037	3159	11168	10212	6628	1027	10797	7465	10549	84844	9238	6470	5631	81624	9972	29893	2547	5411	3364	5931	23047	10528	83463	5511	2935	1029	204	11113	54556	51155	10248	10492	1965	55646	9924	147841
HALLMARK_MYC_TARGETS_V1	M5926								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	A subgroup of genes regulated by MYC - version 1 (v1).			KEGG_RIBOSOME|KEGG_SPLICEOSOME|KEGG_PROTEASOME|KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS|BIOCARTA_EIF_PATHWAY|BIOCARTA_HIF_PATHWAY|BIOCARTA_PROTEASOME_PATHWAY|BIOCARTA_RAB_PATHWAY|BIOCARTA_EIF2_PATHWAY|BIOCARTA_PARKIN_PATHWAY|PID_HIF2PATHWAY|PID_MYC_ACTIV_PATHWAY|PID_HIF1A_PATHWAY|REACTOME_TRANSLATION|REACTOME_INHIBITION_OF_THE_PROTEOLYTIC_ACTIVITY_OF_APC_C_REQUIRED_FOR_THE_ONSET_OF_ANAPHASE_BY_MITOTIC_SPINDLE_CHECKPOINT_COMPONENTS|REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_THE_43S_COMPLEX|REACTOME_PROCESSING_OF_INTRONLESS_PRE_MRNAS|REACTOME_SIGNALING_BY_WNT|REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES|REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION|REACTOME_ER_PHAGOSOME_PATHWAY|REACTOME_CELL_CYCLE|REACTOME_ORC1_REMOVAL_FROM_CHROMATIN|REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE|REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR|REACTOME_ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS|REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR|REACTOME_P53_INDEPENDENT_G1_S_DNA_DAMAGE_CHECKPOINT|REACTOME_REGULATION_OF_HYPOXIA_INDUCIBLE_FACTOR_HIF_BY_OXYGEN|REACTOME_OXYGEN_DEPENDENT_PROLINE_HYDROXYLATION_OF_HYPOXIA_INDUCIBLE_FACTOR_ALPHA|REACTOME_CDK_MEDIATED_PHOSPHORYLATION_AND_REMOVAL_OF_CDC6|REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA|REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S|REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES|REACTOME_REGULATION_OF_ORNITHINE_DECARBOXYLASE_ODC|REACTOME_SLBP_DEPENDENT_PROCESSING_OF_REPLICATION_DEPENDENT_HISTONE_PRE_MRNAS|REACTOME_REGULATION_OF_APOPTOSIS|REACTOME_PEPTIDE_CHAIN_ELONGATION|REACTOME_CELL_CYCLE_MITOTIC|REACTOME_CELL_CYCLE_CHECKPOINTS|REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRANSITION_|REACTOME_P53_DEPENDENT_G1_DNA_DAMAGE_RESPONSE|REACTOME_MRNA_PROCESSING|REACTOME_M_G1_TRANSITION|REACTOME_MRNA_SPLICING|REACTOME_MRNA_SPLICING_MINOR_PATHWAY|REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_REGULATION|REACTOME_PROCESSING_OF_CAPPED_INTRONLESS_PRE_MRNA|REACTOME_G1_S_TRANSITION|REACTOME_MRNA_3_END_PROCESSING|REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_ORIGIN_COMPLEX|REACTOME_SYNTHESIS_OF_DNA|REACTOME_AUTODEGRADATION_OF_THE_E3_UBIQUITIN_LIGASE_COP1|REACTOME_METABOLISM_OF_MRNA|REACTOME_METABOLISM_OF_RNA|REACTOME_MITOTIC_G1_G1_S_PHASES|REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE|REACTOME_MITOTIC_M_M_G1_PHASES|REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX|REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS|REACTOME_DESTABILIZATION_OF_MRNA_BY_AUF1_HNRNP_D0|REACTOME_DNA_REPLICATION|REACTOME_CLEAVAGE_OF_GROWING_TRANSCRIPT_IN_THE_TERMINATION_REGION_|REACTOME_APOPTOSIS|REACTOME_INFLUENZA_LIFE_CYCLE|REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION|REACTOME_HIV_INFECTION|REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS|REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1|REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PROTEINS|REACTOME_AUTODEGRADATION_OF_CDH1_BY_CDH1_APC_C|REACTOME_MITOTIC_PROMETAPHASE|REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_CYCLIN_B|REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1|REACTOME_CONVERSION_FROM_APC_C_CDC20_TO_APC_C_CDH1_IN_LATE_ANAPHASE|REACTOME_IMMUNE_SYSTEM|REACTOME_PHOSPHORYLATION_OF_THE_APC_C|REACTOME_ADAPTIVE_IMMUNE_SYSTEM|REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION|REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTION_COMPLEX|REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION|REACTOME_APC_CDC20_MEDIATED_DEGRADATION_OF_NEK2A|REACTOME_S_PHASE|REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_P27_P21|REACTOME_VIF_MEDIATED_DEGRADATION_OF_APOBEC3G|NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_UP|CASORELLI_APL_SECONDARY_VS_DE_NOVO_DN|BORCZUK_MALIGNANT_MESOTHELIOMA_UP|OSMAN_BLADDER_CANCER_DN|TIEN_INTESTINE_PROBIOTICS_2HR_UP|TIEN_INTESTINE_PROBIOTICS_6HR_UP|TIEN_INTESTINE_PROBIOTICS_24HR_DN|ENK_UV_RESPONSE_KERATINOCYTE_UP|CAIRO_PML_TARGETS_BOUND_BY_MYC_UP|OUELLET_OVARIAN_CANCER_INVASIVE_VS_LMP_UP|LUI_THYROID_CANCER_PAX8_PPARG_DN|LI_AMPLIFIED_IN_LUNG_CANCER|MATTIOLI_MGUS_VS_PCL|LUI_THYROID_CANCER_CLUSTER_3|LUI_TARGETS_OF_PAX8_PPARG_FUSION|SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUM|SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN|WAESCH_ANAPHASE_PROMOTING_COMPLEX|SAKAI_TUMOR_INFILTRATING_MONOCYTES_DN|WHITEHURST_PACLITAXEL_SENSITIVITY|BASSO_B_LYMPHOCYTE_NETWORK|MENSSEN_MYC_TARGETS|NING_CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE_DN|SANA_TNF_SIGNALING_DN|PENG_LEUCINE_DEPRIVATION_DN|POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_DN|TARTE_PLASMA_CELL_VS_PLASMABLAST_DN|FLECHNER_PBL_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP|FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN|SCHUHMACHER_MYC_TARGETS_UP|SANA_RESPONSE_TO_IFNG_DN|POMEROY_MEDULLOBLASTOMA_PROGNOSIS_DN|COLLER_MYC_TARGETS_UP|SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_UP|NING_CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE_UP|PENG_RAPAMYCIN_RESPONSE_DN|PENG_GLUTAMINE_DEPRIVATION_DN|MOREAUX_B_LYMPHOCYTE_MATURATION_BY_TACI_DN|BROWN_MYELOID_CELL_DEVELOPMENT_DN|FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_DN|HESS_TARGETS_OF_HOXA9_AND_MEIS1_UP|MOREAUX_MULTIPLE_MYELOMA_BY_TACI_DN|XU_RESPONSE_TO_TRETINOIN_AND_NSC682994_DN|RHODES_CANCER_META_SIGNATURE|DAZARD_RESPONSE_TO_UV_NHEK_UP|ZHANG_RESPONSE_TO_CANTHARIDIN_DN|MODY_HIPPOCAMPUS_PRENATAL|WHITESIDE_CISPLATIN_RESISTANCE_DN|DAZARD_RESPONSE_TO_UV_SCC_UP|DAZARD_UV_RESPONSE_CLUSTER_G1|WELCSH_BRCA1_TARGETS_DN|ZHONG_SECRETOME_OF_LUNG_CANCER_AND_MACROPHAGE|ZHONG_SECRETOME_OF_LUNG_CANCER_AND_ENDOTHELIUM|ZHONG_SECRETOME_OF_LUNG_CANCER_AND_FIBROBLAST|PELLICCIOTTA_HDAC_IN_ANTIGEN_PRESENTATION_UP|PELLICCIOTTA_HDAC_IN_ANTIGEN_PRESENTATION_DN|HILLION_HMGA1_TARGETS|HILLION_HMGA1B_TARGETS|WONG_PROTEASOME_GENE_MODULE|DAIRKEE_CANCER_PRONE_RESPONSE_BPA|DAIRKEE_CANCER_PRONE_RESPONSE_BPA_E2|CHUNG_BLISTER_CYTOTOXICITY_UP|GRADE_METASTASIS_DN|CHNG_MULTIPLE_MYELOMA_HYPERPLOID_UP|MALONEY_RESPONSE_TO_17AAG_DN|WANG_TUMOR_INVASIVENESS_UP|LEE_LIVER_CANCER_SURVIVAL_DN|FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_UP|NUTT_GBM_VS_AO_GLIOMA_DN|HSIAO_HOUSEKEEPING_GENES|IRITANI_MAD1_TARGETS_DN|JISON_SICKLE_CELL_DISEASE_DN|CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN|YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP|SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_UP|DANG_REGULATED_BY_MYC_UP|DANG_MYC_TARGETS_UP|YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_11|YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_14|YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_17|KARLSSON_TGFB1_TARGETS_UP|WIERENGA_PML_INTERACTOME|BILANGES_SERUM_SENSITIVE_GENES|BILANGES_SERUM_AND_RAPAMYCIN_SENSITIVE_GENES|BILANGES_RAPAMYCIN_SENSITIVE_GENES|BILANGES_RAPAMYCIN_SENSITIVE_VIA_TSC1_AND_TSC2|BILANGES_SERUM_RESPONSE_TRANSLATION|PECE_MAMMARY_STEM_CELL_UP|ABRAMSON_INTERACT_WITH_AIRE|HOLLEMAN_ASPARAGINASE_RESISTANCE_B_ALL_UP|HOLLEMAN_ASPARAGINASE_RESISTANCE_ALL_UP|ATAACCT_MIR154|MORF_ATOX1|MORF_BAG5|MORF_BECN1|MORF_BUB1|MORF_BUB3|MORF_CTBP1|MORF_CCNI|MORF_DNMT1|MORF_ESPL1|MORF_FEN1|MORF_GPX4|MORF_HAT1|MORF_HDAC1|MORF_HDAC2|MORF_MSH2|MORF_PRDX3|MORF_PCNA|MORF_PSMC1|MORF_PSMC2|MORF_PRKDC|MORF_RAD21|MORF_RAD23A|MORF_RAD23B|MORF_RAD54L|MORF_RFC4|MORF_RPA1|MORF_RPA2|MORF_RRM1|MORF_SMC1L1|MORF_SP3|MORF_SOD1|MORF_TERF1|MORF_TERF2IP|MORF_UNG|MORF_XPC|MORF_XRCC5|MORF_AATF|MORF_ACP1|MORF_ACTG1|MORF_ANP32B|MORF_AP2M1|MORF_AP3D1|MORF_BMI1|MORF_BUB1B|MORF_CDC10|MORF_CDC16|MORF_CDK2|MORF_CSNK1D|MORF_CSNK2B|MORF_CUL1|MORF_DAP|MORF_DAP3|MORF_DDB1|MORF_DEAF1|MORF_DEK|MORF_EI24|MORF_EIF3S2|MORF_EIF3S6|MORF_EIF4A2|MORF_ERH|MORF_FBL|MORF_G22P1|MORF_GMPS|MORF_GNB1|MORF_GSPT1|MORF_JUND|MORF_MAP2K2|MORF_MBD4|MORF_MTA1|MORF_NME2|MORF_NPM1|MORF_PAPSS1|MORF_PHB|MORF_PPP1CA|MORF_PPP1CC|MORF_PPP2CA|MORF_PPP2R4|MORF_PPP2R5E|MORF_PPP6C|MORF_PRKAG1|MORF_PRKAR1A|MORF_PTPN11|MORF_RAB11A|MORF_RAB1A|MORF_RAB5A|MORF_RAB6A|MORF_RAC1|MORF_RAF1|MORF_RAN|MORF_SART1|MORF_SKP1A|MORF_SNRP70|MORF_TPT1|MORF_UBE2A|MORF_UBE2I|MORF_UBE2N|MORF_USP5|GCM_HDAC1|GCM_PSME1|GCM_RAD21|GCM_ACTG1|GCM_ANP32B|GCM_APEX1|GCM_CBFB|GCM_CSNK2B|GCM_DDX5|GCM_MSN|GCM_NPM1|GCM_PFN1|GCM_PPP1CC|GCM_RAF1|GCM_TPR|GCM_TPT1|GNF2_BUB3|GNF2_HAT1|GNF2_HDAC1|GNF2_TDG|GNF2_MLH1|GNF2_MSH2|GNF2_MSH6|GNF2_RPA1|GNF2_SMC1L1|GNF2_XRCC5|GNF2_ANP32B|GNF2_APEX1|GNF2_CBFB|GNF2_DAP3|GNF2_DDX5|GNF2_DEK|GNF2_DENR|GNF2_EIF3S6|GNF2_ELAC2|GNF2_FBL|GNF2_G22P1|GNF2_GLTSCR2|GNF2_KPNB1|GNF2_MBD4|GNF2_MCM5|GNF2_NPM1|GNF2_NS|GNF2_PA2G4|GNF2_PPP6C|GNF2_RAN|GNF2_RBBP6|GNF2_ST13|GNF2_TPT1|GNF2_UBE2I|MODULE_4|MODULE_28|MODULE_29|MODULE_32|MODULE_50|MODULE_81|MODULE_82|MODULE_83|MODULE_86|MODULE_87|MODULE_91|MODULE_114|MODULE_115|MODULE_149|MODULE_150|MODULE_151|MODULE_159|MODULE_183|MODULE_233|MODULE_278|MODULE_388|MODULE_429|MODULE_447|EUKARYOTIC_TRANSLATION_INITIATION_FACTOR_3_COMPLEX|RIBONUCLEOPROTEIN_COMPLEX|SMALL_NUCLEAR_RIBONUCLEOPROTEIN_COMPLEX|UBIQUITIN_LIGASE_COMPLEX|PROTEASOME_COMPLEX|SPLICEOSOME|NUCLEAR_UBIQUITIN_LIGASE_COMPLEX|U12_DEPENDENT_SPLICEOSOME|BIOPOLYMER_CATABOLIC_PROCESS|PROTEIN_POLYUBIQUITINATION|SPLICEOSOME_ASSEMBLY|TRANSLATIONAL_INITIATION|CELLULAR_PROTEIN_CATABOLIC_PROCESS|REGULATION_OF_TRANSLATIONAL_INITIATION|RESPONSE_TO_HEAT|RESPONSE_TO_CARBOHYDRATE_STIMULUS|CELLULAR_CATABOLIC_PROCESS|RHYTHMIC_PROCESS|RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY|RNA_PROCESSING|PROTEIN_RNA_COMPLEX_ASSEMBLY|PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION|PROTEIN_UBIQUITINATION|PROTEIN_CATABOLIC_PROCESS|EMBRYO_IMPLANTATION|PROTEOLYSIS|RESPONSE_TO_TEMPERATURE_STIMULUS|REGULATION_OF_ACTION_POTENTIAL|RNA_3END_PROCESSING|MRNA_PROCESSING_GO_0006397|MACROMOLECULE_CATABOLIC_PROCESS|GLIOGENESIS|CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS|MRNA_SPLICE_SITE_SELECTION|RNA_SPLICINGVIA_TRANSESTERIFICATION_REACTIONS|OVULATION_CYCLE|MRNA_METABOLIC_PROCESS|RNA_SPLICING|CATABOLIC_PROCESS|UBIQUITIN_CYCLE|RESPONSE_TO_ORGANIC_SUBSTANCE|RESPONSE_TO_HYPOXIA|TRANSLATION_REGULATOR_ACTIVITY|ACID_AMINO_ACID_LIGASE_ACTIVITY|GTP_BINDING|LIGASE_ACTIVITY_FORMING_CARBON_NITROGEN_BONDS|LIGASE_ACTIVITY|RNA_SPLICING_FACTOR_ACTIVITYTRANSESTERIFICATION_MECHANISM|STRUCTURAL_CONSTITUENT_OF_RIBOSOME|OXIDOREDUCTASE_ACTIVITY_GO_0016706|RNA_BINDING|TRANSLATION_FACTOR_ACTIVITY_NUCLEIC_ACID_BINDING|GUANYL_NUCLEOTIDE_BINDING|SMALL_PROTEIN_CONJUGATING_ENZYME_ACTIVITY|SMALL_CONJUGATING_PROTEIN_LIGASE_ACTIVITY|TRANSLATION_INITIATION_FACTOR_ACTIVITY|UBIQUITIN_PROTEIN_LIGASE_ACTIVITY	GSE4356,MYC OE 2-8h vs 0h 1 day 21 day pancreatic beta cells|GSE5823,MYC WT vs MYC KD (RNAi)|GSE30726,MYC WT vs KD (RNAi) Blue1 Raji|GSE32239,premalignant (hi Myc) vs wt B lymphcytes (lo Myc)|GSE37792,Emu-Myc vs WT bone marrow B220+ cells	GSE11791,Myc vs vector|GSE15808,CMYC_high Artemis/P53_null vs mature B and progenitor B IV|GSE20916,colon carcinoma (high MYC) vs normal (low MYC)	5111	5714	5713	6418	6627	5901	6427	10146	56910	4869	9184	8664	7514	2091	1973	821	4673	11335	7203	708	7307	7332	6742	6426	6950	4171	8662	10213	6626	11137	328	10907	10236	5690	3251	4175	4830	6632	1933	3329	790	6141	5230	8886	6187	3939	10856	10921	1965	5902	4174	3376	7324	4609	1176	5984	1854	5685	6188	6637	11331	6741	7458	6428	10575	7027	8894	1019	6634	5707	10399	2806	8761	22948	5634	52	26121	10576	3735	7913	1982	11260	6723	10054	3837	5688	6434	9377	5036	5093	3178	890	5478	8669	4999	5683	10492	3066	57819	7411	5687	7555	1017	23435	9221	2935	3181	2107	6128	9868	10728	5682	5706	1503	3336	23196	5496	3184	26135	1478	10549	1977	4953	7398	6146	220988	4686	6175	6059	1964	7531	4176	10971	7416	6599	6633	3192	51020	5709	6240	10291	51690	2079	9045	5691	3475	22916	2739	4706	8454	55651	1207	10155	26156	3183	10987	2547	5250	65005	54107	5425	3015	7965	10528	10935	28973	2058	3838	3326	6164	6732	4085	1665	4173	6193	10574	3068	6194	6629	5704	991	7284	9136	8318	7298	3608	7419	3615	23450	51491	6432	26354	23016	6150	5887	6204	5245	9188	1537	26986
HALLMARK_MYC_TARGETS_V2	M5928								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	A subgroup of genes regulated by MYC - version 2 (v2).			BILD_MYC_ONCOGENIC_SIGNATURE|E2F3_UP.V1_DN|MYC_UP.V1_DN|MYC_UP.V1_UP|SRC_UP.V1_DN|SRC_UP.V1_UP	GSE4356,MYC OE 2-8h vs 0h 1 day 21 day pancreatic beta cells|GSE5823,MYC WT vs MYC KD (RNAi)|GSE30726,MYC WT vs KD (RNAi) Blue1 Raji|GSE32239,premalignant (hi Myc) vs wt B lymphcytes (lo Myc)|GSE37792,Emu-Myc vs WT bone marrow B220+ cells	GSE11791,Myc vs vector|GSE15808,CMYC_high Artemis/P53_null vs mature B and progenitor B IV|GSE20916,colon carcinoma (high MYC) vs normal (low MYC)	6573	51154	27346	9136	23481	64216	56915	79711	29078	79050	4609	6723	5036	26354	9221	23160	10244	51491	9238	8886	51388	54663	705	3329	10733	4839	56342	10528	10171	4869	7965	23223	23082	6949	4174	3099	11335	5347	5245	4173	1019	1844	10514	27340	10196	2193	9064	81887	80324	3336	3177	79077	6832	6652	92856	83743	7374	10199
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	M5930								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes defining epithelial-mesenchymal transition, as in wound healing, fibrosis and metastasis.			KEGG_ECM_RECEPTOR_INTERACTION|BIOCARTA_ACE2_PATHWAY|BIOCARTA_PLATELETAPP_PATHWAY|BIOCARTA_VITCB_PATHWAY|PID_INTEGRIN1_PATHWAY|PID_INTEGRIN3_PATHWAY|PID_INTEGRIN4_PATHWAY|PID_AVB3_INTEGRIN_PATHWAY|PID_SYNDECAN_1_PATHWAY|PID_A6B1_A6B4_INTEGRIN_PATHWAY|REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION|REACTOME_COLLAGEN_FORMATION|REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS|REACTOME_NCAM1_INTERACTIONS|REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH|NAKAMURA_CANCER_MICROENVIRONMENT_UP|WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_DN|TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_UP|TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_UP|TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP|TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_DN|WILCOX_RESPONSE_TO_PROGESTERONE_DN|VANHARANTA_UTERINE_FIBROID_UP|WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP|BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_DN|LINDGREN_BLADDER_CANCER_HIGH_RECURRENCE|FARMER_BREAST_CANCER_CLUSTER_4|OXFORD_RALA_TARGETS_DN|OXFORD_RALB_TARGETS_UP|OXFORD_RALA_AND_RALB_TARGETS_DN|LI_WILMS_TUMOR_VS_FETAL_KIDNEY_2_DN|SASAI_RESISTANCE_TO_NEOPLASTIC_TRANSFROMATION|LIEN_BREAST_CARCINOMA_METAPLASTIC|GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP|PETRETTO_CARDIAC_HYPERTROPHY|SUNG_METASTASIS_STROMA_UP|NIKOLSKY_BREAST_CANCER_21Q22_AMPLICON|ROZANOV_MMP14_TARGETS_SUBSET|ROZANOV_MMP14_TARGETS_UP|KANNAN_TP53_TARGETS_DN|CHANG_POU5F1_TARGETS_UP|SWEET_KRAS_TARGETS_UP|RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_UP|KANG_IMMORTALIZED_BY_TERT_UP|PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN|PETROVA_PROX1_TARGETS_DN|WESTON_VEGFA_TARGETS_6HR|CUI_TCF21_TARGETS_UP|WESTON_VEGFA_TARGETS_12HR|KUNINGER_IGF1_VS_PDGFB_TARGETS_DN|LINDVALL_IMMORTALIZED_BY_TERT_DN|WESTON_VEGFA_TARGETS|VERRECCHIA_RESPONSE_TO_TGFB1_C2|VERRECCHIA_RESPONSE_TO_TGFB1_C1|VERRECCHIA_EARLY_RESPONSE_TO_TGFB1|ZHU_CMV_8_HR_DN|ZHU_CMV_24_HR_DN|BURTON_ADIPOGENESIS_4|ZHU_CMV_ALL_DN|CHIBA_RESPONSE_TO_TSA_DN|CUI_TCF21_TARGETS_2_UP|SCHLINGEMANN_SKIN_CARCINOGENESIS_TPA_DN|JACKSON_DNMT1_TARGETS_DN|BURTON_ADIPOGENESIS_11|KAYO_CALORIE_RESTRICTION_MUSCLE_UP|URS_ADIPOCYTE_DIFFERENTIATION_DN|WESTON_VEGFA_TARGETS_3HR|CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS_DN|HARRIS_BRAIN_CANCER_PROGENITORS|LEIN_CHOROID_PLEXUS_MARKERS|JI_CARCINOGENESIS_BY_KRAS_AND_STK11_DN|LEE_METASTASIS_AND_ALTERNATIVE_SPLICING_UP|BRUECKNER_TARGETS_OF_MIRLET7A3_DN|THUM_MIR21_TARGETS_HEART_DISEASE_UP|CROMER_TUMORIGENESIS_UP|HELLEBREKERS_SILENCED_DURING_TUMOR_ANGIOGENESIS|GU_PDEF_TARGETS_UP|SCHRAETS_MLL_TARGETS_DN|CROONQUIST_STROMAL_STIMULATION_UP|CROONQUIST_NRAS_VS_STROMAL_STIMULATION_DN|WOO_LIVER_CANCER_RECURRENCE_UP|YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_16|NAKAMURA_ADIPOGENESIS_EARLY_DN|NAKAMURA_ADIPOGENESIS_LATE_DN|ZEMBUTSU_SENSITIVITY_TO_METHOTREXATE|KANG_AR_TARGETS_UP|VANDESLUIS_COMMD1_TARGETS_GROUP_4_DN|BILANGES_SERUM_SENSITIVE_VIA_TSC2|ANASTASSIOU_CANCER_MESENCHYMAL_TRANSITION_SIGNATURE|LIM_MAMMARY_LUMINAL_MATURE_DN|GNF2_CDH11|GNF2_MMP1|GNF2_PTX3|MODULE_122|PROTEINACEOUS_EXTRACELLULAR_MATRIX|EXTRACELLULAR_MATRIX_PART|EXTRACELLULAR_REGION|BASEMENT_MEMBRANE|BASAL_LAMINA|DYSTROPHIN_ASSOCIATED_GLYCOPROTEIN_COMPLEX|EXTRACELLULAR_REGION_PART|EXTRACELLULAR_SPACE|EXTRACELLULAR_MATRIX|COLLAGEN|EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT|CAHOY_ASTROGLIAL	GSE23952,TGFB1 vs control Panc-1 (pacreas epithelioid carcinoma)|GSE24249,GATA3 OE vs control MDA-MB-231 (breast carcinoma)|GSE40613,mesenchymal (MSC) vs epithelial (PEC) cells|GSE43495,Twist/Snail or Slug vs controls HMLE cells	GSE29156,distal stroma from malignant tumor vs malignant tumor|GSE32254,TNF vs untreated A549 (non small cell carcinoma)	1281	1290	1289	2200	1277	2335	1293	5054	1278	1282	1284	1462	3486	7045	6678	4060	3915	4015	3918	1490	6876	1294	4017	1292	3685	7058	1307	4837	7168	1000	4313	1301	7057	2191	633	871	11167	10631	7070	6696	3371	7980	22795	3693	4314	7431	4016	10516	1303	2006	1009	1311	6695	649	9235	3909	7076	5768	7078	7412	3491	10085	800	57692	2192	6443	1893	3908	10272	7169	3624	1601	2014	10409	3678	4256	7422	2919	7474	6382	5352	5118	26585	3688	50509	388	5654	2247	6641	1647	4232	131578	4982	966	59	30008	4147	26577	5270	2817	25890	2517	6586	284217	56937	1296	2201	3485	5217	6385	960	4616	3576	11010	290	64175	7424	4323	6444	5351	4148	10398	6535	813	5396	51330	2331	3398	2669	5329	4638	7040	6422	8985	3569	333	2199	4487	5806	8325	3725	10979	22943	6591	667	7171	1634	2697	5376	3487	1314	4035	3673	2316	8076	5744	7049	6424	3956	5999	1004	6303	4907	1809	5479	7052	6445	3690	8572	115908	1842	9244	374	3600	4176	2619	5645	23705	5021	7857	6372	4312	7128	822	10486	25878	2303	50863	2026	355	627	8038	5817	6387	5159	9353	4853	79709	2882	7456
HALLMARK_INFLAMMATORY_RESPONSE	M5932								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes defining inflammatory response.			chr4q21|chr11q11|chr11p15|chr1q44|KEGG_CHEMOKINE_SIGNALING_PATHWAY|KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION|KEGG_OLFACTORY_TRANSDUCTION|REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_AND_MAPK|REACTOME_SIGNALING_BY_GPCR|REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS|REACTOME_CLASS_A1_RHODOPSIN_LIKE_RECEPTORS|REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES|REACTOME_OLFACTORY_SIGNALING_PATHWAY|REACTOME_AMINE_LIGAND_BINDING_RECEPTORS|REACTOME_SEROTONIN_RECEPTORS|REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS|REACTOME_P2Y_RECEPTORS|REACTOME_NUCLEOTIDE_LIKE_PURINERGIC_RECEPTORS|REACTOME_GPCR_DOWNSTREAM_SIGNALING|REACTOME_G_ALPHA_I_SIGNALLING_EVENTS|REACTOME_GPCR_LIGAND_BINDING|KOINUMA_COLON_CANCER_MSI_UP|ZIRN_TRETINOIN_RESPONSE_DN|DIERICK_SEROTONIN_FUNCTION_GENES|SHIN_B_CELL_LYMPHOMA_CLUSTER_1|ROETH_TERT_TARGETS_DN|WORSCHECH_TUMOR_REJECTION_UP|AUJLA_IL22_AND_IL17A_SIGNALING|YOSHIMURA_MAPK8_TARGETS_UP|KUROZUMI_RESPONSE_TO_ONCOCYTIC_VIRUS|KUROZUMI_RESPONSE_TO_ONCOCYTIC_VIRUS_AND_CYCLIC_RGD|WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_UP|MODULE_27|MODULE_46|MODULE_63|MODULE_64|MODULE_75|MODULE_76|MODULE_92|MODULE_108|MODULE_121|MODULE_134|MODULE_146|MODULE_223|MODULE_263|MODULE_274|MODULE_288|MODULE_289|MODULE_367|MODULE_375|MODULE_433|MODULE_454|MODULE_488|MODULE_521|INTRINSIC_TO_PLASMA_MEMBRANE|INTRINSIC_TO_MEMBRANE|MEMBRANE_PART|MEMBRANE|INTEGRAL_TO_MEMBRANE|INTEGRAL_TO_PLASMA_MEMBRANE|PLASMA_MEMBRANE_PART|PLASMA_MEMBRANE|REGULATION_OF_BIOLOGICAL_QUALITY|G_PROTEIN_SIGNALING_COUPLED_TO_IP3_SECOND_MESSENGERPHOSPHOLIPASE_C_ACTIVATING|POSITIVE_REGULATION_OF_CELL_PROLIFERATION|PHOSPHOLIPASE_C_ACTIVATION|CELL_SURFACE_RECEPTOR_LINKED_SIGNAL_TRANSDUCTION_GO_0007166|DEFENSE_RESPONSE|BEHAVIOR|LOCOMOTORY_BEHAVIOR|CELL_CELL_SIGNALING|FEEDING_BEHAVIOR|NEUROPEPTIDE_SIGNALING_PATHWAY|INFLAMMATORY_RESPONSE|RESPONSE_TO_STRESS|CELLULAR_CATION_HOMEOSTASIS|RESPONSE_TO_CHEMICAL_STIMULUS|SENSORY_PERCEPTION|PHOSPHOINOSITIDE_MEDIATED_SIGNALING|SYNAPTIC_TRANSMISSION|G_PROTEIN_SIGNALING_COUPLED_TO_CAMP_NUCLEOTIDE_SECOND_MESSENGER|G_PROTEIN_SIGNALING_ADENYLATE_CYCLASE_ACTIVATING_PATHWAY|NEUROLOGICAL_SYSTEM_PROCESS|HOMEOSTATIC_PROCESS|CELLULAR_HOMEOSTASIS|NEGATIVE_REGULATION_OF_CELL_PROLIFERATION|SECOND_MESSENGER_MEDIATED_SIGNALING|G_PROTEIN_SIGNALING_COUPLED_TO_CYCLIC_NUCLEOTIDE_SECOND_MESSENGER|CELL_PROLIFERATION_GO_0008283|RESPONSE_TO_EXTERNAL_STIMULUS|CHEMICAL_HOMEOSTASIS|ION_HOMEOSTASIS|CATION_HOMEOSTASIS|RESPONSE_TO_WOUNDING|G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY|ADENYLATE_CYCLASE_ACTIVATION|CYCLIC_NUCLEOTIDE_MEDIATED_SIGNALING|TRANSMISSION_OF_NERVE_IMPULSE|CELLULAR_DEFENSE_RESPONSE|SYSTEM_PROCESS|CAMP_MEDIATED_SIGNALING|REGULATION_OF_CELL_PROLIFERATION|SEROTONIN_RECEPTOR_ACTIVITY|G_PROTEIN_COUPLED_RECEPTOR_BINDING|AMINE_RECEPTOR_ACTIVITY|NEUROPEPTIDE_BINDING|NEUROPEPTIDE_RECEPTOR_ACTIVITY|PEPTIDE_BINDING|CHEMOKINE_ACTIVITY|NEUROTRANSMITTER_BINDING|NEUROTRANSMITTER_RECEPTOR_ACTIVITY|CHEMOKINE_RECEPTOR_BINDING|RHODOPSIN_LIKE_RECEPTOR_ACTIVITY|PEPTIDE_RECEPTOR_ACTIVITY|G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY|RECEPTOR_BINDING|RECEPTOR_ACTIVITY|TRANSMEMBRANE_RECEPTOR_ACTIVITY|CYTOKINE_ACTIVITY|GROWTH_FACTOR_ACTIVITY	GSE19340,LPS vs untreated macrophages|GSE24897,P. gingivalis vs saline macrophages|GSE32141,LPS vs control THP-1 (acute myeloid leukemia)|GSE40885,LPS vs Saline 6h alveolar macrophages	GSE6785,LPS vs control MH-S (macrophages)|GSE32358,ATF3 KO vs WT macrophages	3627	6347	6352	2357	6364	3552	3576	6354	6367	6373	1236	1906	958	4283	3569	3553	7097	3554	969	3383	9034	366	2069	719	2769	1240	5734	3976	3600	10135	4986	3696	5724	133	5329	4790	3624	5008	8743	9966	3460	2015	3593	1435	6372	3604	4067	92	3949	623	3269	2152	684	5739	1604	10203	1440	29933	3566	114548	3601	136	2643	4973	5732	1441	4609	5970	7130	3575	3606	2550	3732	8744	10316	3560	7096	1902	3656	8767	4323	5027	4891	6402	5029	19	2867	60675	2773	6869	6541	1026	1536	7076	1839	8578	10148	4792	6717	6542	6361	7098	187	9180	3587	5663	1880	490	7133	7439	2719	6324	91	3249	10507	1316	962	10663	6506	2811	6892	6004	6504	3932	3091	196	9111	391	7162	10886	3454	23308	10125	8519	3759	4061	8809	3586	3738	3037	131566	27074	7432	970	5996	1317	11047	10242	5054	4084	558	4210	5817	6369	5142	3937	10630	3665	4233	488	1318	7855	3678	166929	8685	929	5610	6098	27032	4693	7832	4481	5791	255488	5099	8877	8807	64108	5894	9435	3690	23095	6401	64127	728	2014	23601	6870	8671	4224	55829	4049	23533	23166	3659	3386	5025	10006	6376	9153
HALLMARK_XENOBIOTIC_METABOLISM	M5934								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes encoding proteins involved in processing of drugs and other xenobiotics.			chr2q37|chr6p12|chr4q13|KEGG_PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS|KEGG_ASCORBATE_AND_ALDARATE_METABOLISM|KEGG_STEROID_HORMONE_BIOSYNTHESIS|KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM|KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM|KEGG_CYSTEINE_AND_METHIONINE_METABOLISM|KEGG_ARGININE_AND_PROLINE_METABOLISM|KEGG_TAURINE_AND_HYPOTAURINE_METABOLISM|KEGG_SELENOAMINO_ACID_METABOLISM|KEGG_GLUTATHIONE_METABOLISM|KEGG_STARCH_AND_SUCROSE_METABOLISM|KEGG_GLYOXYLATE_AND_DICARBOXYLATE_METABOLISM|KEGG_ONE_CARBON_POOL_BY_FOLATE|KEGG_RETINOL_METABOLISM|KEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM|KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450|KEGG_DRUG_METABOLISM_CYTOCHROME_P450|KEGG_DRUG_METABOLISM_OTHER_ENZYMES|REACTOME_SULFUR_AMINO_ACID_METABOLISM|REACTOME_BIOLOGICAL_OXIDATIONS|REACTOME_XENOBIOTICS|REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE|REACTOME_PHASE1_FUNCTIONALIZATION_OF_COMPOUNDS|REACTOME_ENDOGENOUS_STEROLS|REACTOME_METABOLISM_OF_POLYAMINES|REACTOME_AMINO_ACID_SYNTHESIS_AND_INTERCONVERSION_TRANSAMINATION|REACTOME_GLUCURONIDATION|REACTOME_GLUTATHIONE_CONJUGATION|REACTOME_PHASE_II_CONJUGATION|SAENZ_DETOX_PATHWAY_AND_CARCINOGENESIS_DN|SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4|LEE_LIVER_CANCER_CIPROFIBRATE_DN|LEE_LIVER_CANCER_MYC_TGFA_DN|LEE_LIVER_CANCER_ACOX1_DN|LEE_LIVER_CANCER_MYC_E2F1_DN|LEE_LIVER_CANCER_DENA_DN|LEE_LIVER_CANCER_MYC_DN|LEE_LIVER_CANCER_E2F1_DN|HSIAO_LIVER_SPECIFIC_GENES|SU_LIVER|YANG_MUC2_TARGETS_DUODENUM_3MO_DN|YANG_MUC2_TARGETS_DUODENUM_6MO_DN|YANG_MUC2_TARGETS_COLON_3MO_DN|LEE_LIVER_CANCER|ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN|ACEVEDO_LIVER_CANCER_DN|ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN|BOCHKIS_FOXA2_TARGETS|LEE_LIVER_CANCER_SURVIVAL_UP|MELLMAN_TUT1_TARGETS_UP|BOYAULT_LIVER_CANCER_SUBCLASS_G3_DN|BOYAULT_LIVER_CANCER_SUBCLASS_G123_DN|CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_DN|HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN|HOSHIDA_LIVER_CANCER_SURVIVAL_DN|YAMASHITA_LIVER_CANCER_WITH_EPCAM_DN|YAMASHITA_LIVER_CANCER_STEM_CELL_UP|YAMASHITA_LIVER_CANCER_STEM_CELL_DN|WOO_LIVER_CANCER_RECURRENCE_DN|HOSHIDA_LIVER_CANCER_SUBCLASS_S3|CAIRO_HEPATOBLASTOMA_DN|CAIRO_HEPATOBLASTOMA_CLASSES_DN|CAIRO_LIVER_DEVELOPMENT_DN|HOFFMAN_CLOCK_TARGETS_UP|OHGUCHI_LIVER_HNF4A_TARGETS_DN|SERVITJA_LIVER_HNF1A_TARGETS_DN|CAR_HPX|CAR_IGFBP1|GNF2_GSTM1|GNF2_HPX|GNF2_TST|GNF2_CEBPA|GNF2_CYP2B6|GNF2_HPN|GNF2_IGF1|GNF2_LCAT|MODULE_40|MODULE_78|MODULE_101|MODULE_106|MODULE_132|MODULE_135|MODULE_212|MODULE_235|MODULE_272|MODULE_310|MODULE_349|MODULE_440|MODULE_505|VESICULAR_FRACTION|CELL_FRACTION|MICROSOME|MEMBRANE_FRACTION|SOLUBLE_FRACTION|BIOGENIC_AMINE_METABOLIC_PROCESS|CARBOXYLIC_ACID_METABOLIC_PROCESS|GLUTAMINE_FAMILY_AMINO_ACID_METABOLIC_PROCESS|AMINO_ACID_METABOLIC_PROCESS|RESPONSE_TO_XENOBIOTIC_STIMULUS|AMINO_ACID_DERIVATIVE_METABOLIC_PROCESS|ORGANIC_ACID_METABOLIC_PROCESS|NITROGEN_COMPOUND_METABOLIC_PROCESS|MONOCARBOXYLIC_ACID_METABOLIC_PROCESS|AMINO_ACID_CATABOLIC_PROCESS|AMINE_CATABOLIC_PROCESS|AMINO_ACID_AND_DERIVATIVE_METABOLIC_PROCESS|XENOBIOTIC_METABOLIC_PROCESS|AMINE_BIOSYNTHETIC_PROCESS|AMINO_ACID_DERIVATIVE_BIOSYNTHETIC_PROCESS|AMINE_METABOLIC_PROCESS|AROMATIC_COMPOUND_METABOLIC_PROCESS|FATTY_ACID_METABOLIC_PROCESS|NITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS|NITROGEN_COMPOUND_CATABOLIC_PROCESS|OXIDOREDUCTASE_ACTIVITY_GO_0016705|OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_NH_GROUP_OF_DONORS|OXYGEN_BINDING|MONOOXYGENASE_ACTIVITY|TRANSFERASE_ACTIVITY_TRANSFERRING_ALKYL_OR_ARYLOTHER_THAN_METHYLGROUPS|GLUTATHIONE_TRANSFERASE_ACTIVITY|PKCA_DN.V1_UP	GSE6721,phenobarbital vs DMSO liver|GSE10082,TCDD vs corn oil both WT AHR liver|GSE11796,AHR WT vs MUT hepatoma cells|GSE29188,5 uM BaP vs DMSO both 12-24h HEPA-1c1c7 (hepatoma)|GSE36244,BaP vs DMSO HepG2 (hepatocellular carcinoma)	GSE17925,TCDD vs DMSO human AHR OE liver|GSE21272,TCDD vs DMSO CH12.LX (B cell lymphoma)	1543	2184	51181	1544	2940	1573	1593	126	7358	435	1728	211	2948	1562	5805	1528	8309	2052	3931	23169	2937	2328	3417	8644	6580	9446	383	1036	2326	223	5447	57447	51733	1891	9536	5166	191	1312	316	629	23564	3083	2160	1592	64087	866	27232	645	26061	4128	8942	1725	5054	6539	2643	51635	9060	217	3290	10237	3735	760	9663	847	29785	5909	2203	5950	2646	978	4522	131	115817	8876	55748	6533	26998	54677	2571	1646	26007	3479	6747	23710	7009	948	1066	6472	28959	2953	5340	3162	10653	218	2936	57406	7498	5467	60481	8529	54884	26999	65018	2729	2099	5372	6999	4502	488	1652	2168	53	225	2538	1644	8310	51128	2192	128	1401	1244	2114	4864	839	670	3554	957	7132	3487	5831	51380	7448	3398	2110	3273	7299	7378	9564	873	348	6560	27346	283537	5730	4355	22949	366	1969	5699	355	51	2618	3251	5226	8714	54498	7274	55502	2651	4121	3484	3700	5627	8460	116842	9054	10857	1586	10776	29950	384	3172	5967	6370	10400	50	9361	4836	10728	2159	6898	10299	3728	52	4153	7042	2028	3294	27329	5091	10611	1571	586	84913	6510	3394	4814	10717	116285	3697
HALLMARK_FATTY_ACID_METABOLISM	M5935								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes encoding proteins involved in metabolism of fatty acids.			chr4q23|KEGG_FATTY_ACID_METABOLISM|KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION|KEGG_LYSINE_DEGRADATION|KEGG_HISTIDINE_METABOLISM|KEGG_TYROSINE_METABOLISM|KEGG_PHENYLALANINE_METABOLISM|KEGG_TRYPTOPHAN_METABOLISM|KEGG_BETA_ALANINE_METABOLISM|KEGG_PROPANOATE_METABOLISM|KEGG_BUTANOATE_METABOLISM|KEGG_LIMONENE_AND_PINENE_DEGRADATION|KEGG_NITROGEN_METABOLISM|REACTOME_REVERSIBLE_HYDRATION_OF_CARBON_DIOXIDE|REACTOME_MITOCHONDRIAL_FATTY_ACID_BETA_OXIDATION|REACTOME_BRANCHED_CHAIN_AMINO_ACID_CATABOLISM|REACTOME_ETHANOL_OXIDATION|LUI_THYROID_CANCER_CLUSTER_5|IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_UP|VARELA_ZMPSTE24_TARGETS_DN|WENG_POR_TARGETS_GLOBAL_DN|WENG_POR_TARGETS_LIVER_DN|MOOTHA_FFA_OXYDATION|SANDERSON_PPARA_TARGETS|MODULE_184|MODULE_194|MODULE_221|MODULE_286|MODULE_294|MODULE_295|MODULE_305|MODULE_343|MODULE_354|MODULE_373|MODULE_464|MODULE_514|MODULE_519|LIPID_CATABOLIC_PROCESS|FATTY_ACID_BETA_OXIDATION|FATTY_ACID_OXIDATION|CELLULAR_LIPID_CATABOLIC_PROCESS|HYDRO_LYASE_ACTIVITY|ALDO_KETO_REDUCTASE_ACTIVITY|STEROID_DEHYDROGENASE_ACTIVITY|OXIDOREDUCTASE_ACTIVITY_GO_0016616|LYASE_ACTIVITY|CARBONATE_DEHYDRATASE_ACTIVITY|STEROID_DEHYDROGENASE_ACTIVITY_ACTING_ON_THE_CH_OH_GROUP_OF_DONORSNAD_OR_NADP_AS_ACCEPTOR|CARBON_OXYGEN_LYASE_ACTIVITY|OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS|OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_ALDEHYDE_OR_OXO_GROUP_OF_DONORS|OXIDOREDUCTASE_ACTIVITY_ACTING_ON_CH_OH_GROUP_OF_DONORS|OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_ALDEHYDE_OR_OXO_GROUP_OF_DONORSNAD_OR_NADP_AS_ACCEPTOR	GSE3889,SCD1 WT vs MUT both very low fat diet liver|GSE12147,CP-775146 vs vehicle liver|GSE12147,CP-868388 vs vehicle liver|GSE12147,CP-865520 vs vehicle liver|GSE32706,fenofibrate vs control liver|GSE37546,ACADM WT vs KO both stimulated with LPS liver	GSE30447,control vs FOXA1 OE HepG2 (hepatocellular carcinoma)|GSE51885,high fat diet vs 60% fructose diet liver	30	10449	33	34	10005	51	2180	224	131076	1376	1579	1666	1891	1632	60481	2168	2169	3033	26275	3155	51170	3417	4199	11343	23417	5092	54884	6281	8802	8876	1962	223	3032	1892	35	760	3028	216	37	3295	762	126	131	5805	4128	51179	51478	84693	39	549	3248	2271	3158	210	2819	50	873	9380	10965	50486	4191	3320	594	7390	7533	3939	1429	8608	11185	7358	2954	3420	4190	1384	2110	948	10455	6392	51703	84263	3157	6391	912	2639	2820	218	6584	5162	6999	2194	4683	5720	5465	29781	670	4953	765	1738	3052	2052	1743	2326	8639	7389	1374	387893	9246	4282	8801	1371	6611	874	4913	1149	3422	51166	92840	10808	328	50814	79602	2182	84532	2027	3421	3956	23173	226	6296	4056	728294	158	8803	6389	7503	58505	2752	284541	23710	364	1543	9588	10961	3015	26330	1718	2572	5793	259307	58476	5160	5910	1056	644	57515	658	51109	2026
HALLMARK_OXIDATIVE_PHOSPHORYLATION	M5936								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes encoding proteins involved in oxidative phosphorylation.			KEGG_CITRATE_CYCLE_TCA_CYCLE|KEGG_OXIDATIVE_PHOSPHORYLATION|KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_BIOSYNTHESIS|KEGG_ALZHEIMERS_DISEASE|KEGG_PARKINSONS_DISEASE|KEGG_HUNTINGTONS_DISEASE|KEGG_VIBRIO_CHOLERAE_INFECTION|KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION|BIOCARTA_ETC_PATHWAY|BIOCARTA_KREB_PATHWAY|REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYCLE|REACTOME_INSULIN_RECEPTOR_RECYCLING|REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT|REACTOME_MITOCHONDRIAL_PROTEIN_IMPORT|REACTOME_LATENT_INFECTION_OF_HOMO_SAPIENS_WITH_MYCOBACTERIUM_TUBERCULOSIS|REACTOME_REGULATION_OF_PYRUVATE_DEHYDROGENASE_PDH_COMPLEX|REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE|REACTOME_PYRUVATE_METABOLISM|REACTOME_RESPIRATORY_ELECTRON_TRANSPORT|REACTOME_IRON_UPTAKE_AND_TRANSPORT|REACTOME_TRANSFERRIN_ENDOCYTOSIS_AND_RECYCLING|REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMIOSMOTIC_COUPLING_AND_HEAT_PRODUCTION_BY_UNCOUPLING_PROTEINS_|REACTOME_FORMATION_OF_ATP_BY_CHEMIOSMOTIC_COUPLING|CREIGHTON_AKT1_SIGNALING_VIA_MTOR_DN|APPIERTO_RESPONSE_TO_FENRETINIDE_DN|ZUCCHI_METASTASIS_UP|MOOTHA_VOXPHOS|PARK_HSC_AND_MULTIPOTENT_PROGENITORS|TAKAO_RESPONSE_TO_UVB_RADIATION_UP|KAYO_CALORIE_RESTRICTION_MUSCLE_DN|RODWELL_AGING_KIDNEY_NO_BLOOD_DN|MARTINEZ_RESPONSE_TO_TRABECTEDIN_UP|KAYO_AGING_MUSCLE_DN|RODWELL_AGING_KIDNEY_DN|KAAB_HEART_ATRIUM_VS_VENTRICLE_DN|YEGNASUBRAMANIAN_PROSTATE_CANCER|STEIN_ESRRA_TARGETS_UP|STEIN_ESRRA_TARGETS_DN|WONG_MITOCHONDRIA_GENE_MODULE|MOOTHA_HUMAN_MITODB_6_2002|MOOTHA_PGC|MOOTHA_TCA|MOOTHA_MITOCHONDRIA|STEIN_ESRRA_TARGETS|YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13|MOOTHA_PYR|DAZARD_UV_RESPONSE_CLUSTER_G5|MODULE_22|MODULE_25|MODULE_42|MODULE_43|MODULE_62|MODULE_77|MODULE_93|MODULE_103|MODULE_116|MODULE_152|MODULE_273|MODULE_306|MODULE_307|MODULE_363|MODULE_414|ORGANELLE_INNER_MEMBRANE|MITOCHONDRIAL_PART|MITOCHONDRIAL_MEMBRANE|NADH_DEHYDROGENASE_COMPLEX|ENVELOPE|MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_I|ORGANELLE_ENVELOPE|MITOCHONDRIAL_INNER_MEMBRANE|MITOCHONDRIAL_RESPIRATORY_CHAIN|PROTON_TRANSPORTING_TWO_SECTOR_ATPASE_COMPLEX|MITOCHONDRION|MITOCHONDRIAL_ENVELOPE|RESPIRATORY_CHAIN_COMPLEX_I|MITOCHONDRIAL_MEMBRANE_PART|AEROBIC_RESPIRATION|GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY|COFACTOR_CATABOLIC_PROCESS|ELECTRON_TRANSPORT_GO_0006118|ENERGY_DERIVATION_BY_OXIDATION_OF_ORGANIC_COMPOUNDS|TRICARBOXYLIC_ACID_CYCLE_INTERMEDIATE_METABOLIC_PROCESS|CELLULAR_RESPIRATION|ANTIPORTER_ACTIVITY|ELECTRON_CARRIER_ACTIVITY|CYTOCHROME_C_OXIDASE_ACTIVITY|OXIDOREDUCTASE_ACTIVITY|COFACTOR_BINDING|OXIDOREDUCTASE_ACTIVITY_ACTING_ON_NADH_OR_NADPH|HYDROGEN_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY|INORGANIC_CATION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY|MONOVALENT_INORGANIC_CATION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY|COENZYME_BINDING	GSE5968,PPARGC1A OE vs control HepG2 (hepatocellular carcinoma)|GSE15072,HD vs CKD and HS PBMC|GSE27041,complex I WT vs MUT grown on galactose primary fibroblasts|GSE38007,MITF + BRAF(V600E) vs BRAF(V600E) melanoma cells	GSE41759,muscle vs brain	4722	7381	4720	6389	7384	4704	4724	4719	4695	4728	6390	23530	539	518	374291	498	4723	1329	7388	4694	509	506	1349	6392	54205	4700	4706	1351	50	516	1537	4712	514	9377	7385	1337	513	1345	522	4709	3420	4967	4714	6834	1340	4711	4697	4707	1327	1350	7386	6391	9296	1347	8802	4726	4701	2271	4729	5018	4717	10975	4698	1431	9550	515	3052	3032	10476	5160	4702	1738	4976	8402	521	5162	9551	4713	3418	10651	7419	4190	517	10989	4191	5250	51382	7417	34	9167	10440	529	4696	293	3421	37	2108	26520	3419	26521	537	26517	27089	22	7416	10632	11331	1666	8803	2806	1737	51606	4708	2230	3030	528	4129	4710	29796	2110	2879	8050	9927	9131	10449	2109	1353	1892	23203	533	292	1743	1355	1528	211	291	1374	788	4552	10063	1727	56993	38	64963	527	5166	26519	3939	1632	65003	2395	6183	1352	55288	30	36	3945	10884	481	56898	8604	92609	64981	81689	51318	3417	3313	29088	64960	9868	10312	23479	5435	4835	4718	56945	5447	8992	5264	51660	2821	10939	3028	840	10935	4259	27429	593	10128	54884	1891	89941	581	9617	2746	6832	80273	54704	4329	4942
HALLMARK_GLYCOLYSIS	M5937								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes encoding proteins involved in glycolysis and gluconeogenesis.			chr1p11|KEGG_GLYCOLYSIS_GLUCONEOGENESIS|KEGG_PENTOSE_PHOSPHATE_PATHWAY|KEGG_FRUCTOSE_AND_MANNOSE_METABOLISM|KEGG_GALACTOSE_METABOLISM|KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM|KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDROITIN_SULFATE|KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE|KEGG_PYRUVATE_METABOLISM|KEGG_SULFUR_METABOLISM|BIOCARTA_FEEDER_PATHWAY|BIOCARTA_GLYCOLYSIS_PATHWAY|PID_HIF1_TFPATHWAY|REACTOME_GLYCOGEN_BREAKDOWN_GLYCOGENOLYSIS|REACTOME_HS_GAG_DEGRADATION|REACTOME_CHONDROITIN_SULFATE_BIOSYNTHESIS|REACTOME_CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM|REACTOME_HS_GAG_BIOSYNTHESIS|REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM|REACTOME_GLYCOSAMINOGLYCAN_METABOLISM|REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIRED_FOR_GAG_SYNTHESIS|REACTOME_GLYCOLYSIS|REACTOME_GLUCONEOGENESIS|REACTOME_METABOLISM_OF_CARBOHYDRATES|REACTOME_CYTOSOLIC_SULFONATION_OF_SMALL_MOLECULES|REACTOME_GLUCOSE_METABOLISM|WINTER_HYPOXIA_UP|PRAMOONJAGO_SOX4_TARGETS_UP|ELVIDGE_HYPOXIA_UP|ELVIDGE_HYPOXIA_BY_DMOG_UP|ELVIDGE_HIF1A_TARGETS_DN|ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN|GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN|GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN|MOTAMED_RESPONSE_TO_ANDROGEN_UP|MAINA_VHL_TARGETS_DN|GROSS_ELK3_TARGETS_DN|GROSS_HYPOXIA_VIA_ELK3_DN|GROSS_HIF1A_TARGETS_DN|GROSS_HYPOXIA_VIA_HIF1A_DN|GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP|MANALO_HYPOXIA_UP|MENSE_HYPOXIA_UP|KIM_HYPOXIA|BRACHAT_RESPONSE_TO_METHOTREXATE_DN|HARRIS_HYPOXIA|LEONARD_HYPOXIA|BRACHAT_RESPONSE_TO_CAMPTOTHECIN_DN|SEMENZA_HIF1_TARGETS|WINTER_HYPOXIA_METAGENE|NGO_MALIGNANT_GLIOMA_1P_LOH|MOOTHA_GLUCONEOGENESIS|MOOTHA_GLYCOGEN_METABOLISM|MOOTHA_GLYCOLYSIS|QI_HYPOXIA|WANG_ADIPOGENIC_GENES_REPRESSED_BY_SIRT1|VANDESLUIS_COMMD1_TARGETS_GROUP_2_UP|VANDESLUIS_COMMD1_TARGETS_GROUP_3_UP|FARDIN_HYPOXIA_9|FARDIN_HYPOXIA_11|WACKER_HYPOXIA_TARGETS_OF_VHL|SMIRNOV_RESPONSE_TO_IR_2HR_DN|SMIRNOV_RESPONSE_TO_IR_6HR_DN|AMINO_SUGAR_METABOLIC_PROCESS|GLUCAN_METABOLIC_PROCESS|GLUCOSE_METABOLIC_PROCESS|ENERGY_RESERVE_METABOLIC_PROCESS|SULFUR_METABOLIC_PROCESS|GLUCOSE_CATABOLIC_PROCESS|SULFUR_COMPOUND_BIOSYNTHETIC_PROCESS|PROTEOGLYCAN_BIOSYNTHETIC_PROCESS|N_ACETYLGLUCOSAMINE_METABOLIC_PROCESS|CELLULAR_CARBOHYDRATE_METABOLIC_PROCESS|PROTEOGLYCAN_METABOLIC_PROCESS|ALCOHOL_METABOLIC_PROCESS|BIOPOLYMER_BIOSYNTHETIC_PROCESS|NUCLEOTIDE_SUGAR_METABOLIC_PROCESS|CARBOHYDRATE_METABOLIC_PROCESS|POLYSACCHARIDE_METABOLIC_PROCESS|CELLULAR_CARBOHYDRATE_CATABOLIC_PROCESS|CARBOHYDRATE_CATABOLIC_PROCESS|CARBOHYDRATE_BIOSYNTHETIC_PROCESS|GLUCOSAMINE_METABOLIC_PROCESS|CELLULAR_POLYSACCHARIDE_METABOLIC_PROCESS|SULFOTRANSFERASE_ACTIVITY|CARBOHYDRATE_KINASE_ACTIVITY|TRANSFERASE_ACTIVITY_TRANSFERRING_SULFUR_CONTAINING_GROUPS	GSE4142,plasma cell vs memory B cell|GSE27262,stage 1 lung adenocarcinoma vs adjacent normal tissue|GSE31042,NR4A1 KO and NR4A3 KO vs WT homeopoietic stem cells|GSE53231,KLF15 WT vs KO heart	GSE21217,FDG uptake high vs low|GSE33335,tumor vs normal gastric tissues	5230	226	2023	7167	5214	30001	229	7422	4601	5315	3099	3939	2131	1468	2990	5207	5223	5834	205	5033	5373	26355	6382	112399	5091	11285	8789	3486	79586	26229	55501	9653	4351	10007	10327	8497	27087	54480	2539	4191	4166	25796	5224	8534	2817	7264	56052	2673	5631	2805	4190	23443	2584	1956	51129	10370	5352	5768	4200	6676	8974	26330	2026	2806	2132	10165	3161	5165	7852	2239	11319	10020	8704	2530	55586	1462	2719	126792	3309	4199	136	7360	4282	140838	23036	8614	8460	55276	2997	8277	7039	9435	5256	3925	2582	4233	3938	8660	51728	2683	1944	56956	11015	6888	10570	7436	960	178	6662	54541	3425	839	26035	9276	1824	90161	983	5351	6383	29925	22976	50814	5917	9123	2745	79644	9672	3069	1289	9080	7033	6781	10112	2998	2542	64077	6391	4678	6790	10331	3669	3948	10776	1058	9456	638	1528	10456	22796	3597	8996	1365	375790	54982	7295	5066	726	5318	10058	1634	29926	10380	283	53836	9514	501	4907	3417	5836	4731	9348	5516	5704	7162	7045	2585	1491	3796	8912	55139	8819	10616	1999	6120	8702	55635	58528	8870	223	1738	10461	2729	2288	6647	9862	50808	64132	9048	5478	10164
HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY	M5938								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated by reactive oxigen species (ROS).			HOUSTIS_ROS|FERRANDO_LYL1_NEIGHBORS|ABBUD_LIF_SIGNALING_2_UP|SINGH_NFE2L2_TARGETS|MOOTHA_ROS|ZEMBUTSU_SENSITIVITY_TO_CYCLOPHOSPHAMIDE|MODULE_530|NEGATIVE_REGULATION_OF_HYDROLASE_ACTIVITY|REGULATION_OF_HOMEOSTATIC_PROCESS|RESPONSE_TO_OXIDATIVE_STRESS|OXIDOREDUCTASE_ACTIVITY_ACTING_ON_SULFUR_GROUP_OF_DONORS|OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PEROXIDE_AS_ACCEPTOR|ANTIOXIDANT_ACTIVITY	GSE16836,CD16- vs CD16+ PBMC|GSE17639,cord vs adult blood|GSE22463,0h vs 6h H2O2 PBMC|GSE39843,DNMQ vs control airway cell lines	GSE1776,SOD2 KD (siRNA) vs control WT-AML-12 (hepatocytes)|GSE14855,control vs starved C2C12 (myoblasts)	2936	7001	7296	6647	2729	847	2879	4353	5052	9588	2730	7295	6648	10549	55829	9124	10587	10542	2539	4482	4155	140809	1728	9943	51022	3163	2242	5214	4710	2878	57466	1032	4257	4363	2512	475	10494	112398	2068	22904	3726	5524	4046	4700	3087	2745	4720	5621	26034
HALLMARK_P53_PATHWAY	M5939								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes involved in p53 pathways and networks.			chr9p21|chr5q32|KEGG_P53_SIGNALING_PATHWAY|BIOCARTA_P53HYPOXIA_PATHWAY|PID_P73PATHWAY|PID_HDAC_CLASSIII_PATHWAY|PID_P53_DOWNSTREAM_PATHWAY|PID_DELTA_NP63_PATHWAY|PID_MYC_REPRESS_PATHWAY|PID_TAP63_PATHWAY|GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_UP|NEWMAN_ERCC6_TARGETS_DN|CASTELLANO_HRAS_AND_NRAS_TARGETS_UP|CASTELLANO_NRAS_TARGETS_UP|CAIRO_PML_TARGETS_BOUND_BY_MYC_DN|KERLEY_RESPONSE_TO_CISPLATIN_UP|TANG_SENESCENCE_TP53_TARGETS_UP|BUSA_SAM68_TARGETS_UP|SANCHEZ_MDM2_TARGETS|SCHAVOLT_TARGETS_OF_TP53_AND_TP63|HEIDENBLAD_AMPLIFIED_IN_SOFT_TISSUE_CANCER|HEIDENBLAD_AMPLIFIED_IN_BONE_CANCER|KOMMAGANI_TP63_GAMMA_TARGETS|AMUNDSON_DNA_DAMAGE_RESPONSE_TP53|SCHRAMM_INHBA_TARGETS_DN|SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_DN|MEINHOLD_OVARIAN_CANCER_LOW_GRADE_UP|MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_UP|MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP|MANN_RESPONSE_TO_AMIFOSTINE_UP|MURATA_VIRULENCE_OF_H_PILORI|CEBALLOS_TARGETS_OF_TP53_AND_MYC_DN|SCHWAB_TARGETS_OF_BMYB_POLYMORPHIC_VARIANTS_UP|CAFFAREL_RESPONSE_TO_THC_24HR_3_UP|SHEPARD_CRUSH_AND_BURN_MUTANT_UP|KANNAN_TP53_TARGETS_UP|PENG_GLUTAMINE_DEPRIVATION_UP|PEART_HDAC_PROLIFERATION_CLUSTER_UP|SHEPARD_BMYB_MORPHOLINO_UP|AFFAR_YY1_TARGETS_UP|BRACHAT_RESPONSE_TO_CISPLATIN|WHITESIDE_CISPLATIN_RESISTANCE_UP|GENTILE_UV_LOW_DOSE_UP|ONGUSAHA_TP53_TARGETS|ZHANG_RESPONSE_TO_CANTHARIDIN_UP|INGA_TP53_TARGETS|BRACHAT_RESPONSE_TO_METHOTREXATE_UP|BRACHAT_RESPONSE_TO_CAMPTOTHECIN_UP|GENTILE_UV_HIGH_DOSE_UP|VARELA_ZMPSTE24_TARGETS_UP|YIH_RESPONSE_TO_ARSENITE_C3|MARZEC_IL2_SIGNALING_DN|KUMAMOTO_RESPONSE_TO_NUTLIN_3A_UP|JONES_TCOF1_TARGETS|DONATO_CELL_CYCLE_TRETINOIN|ZHANG_TLX_TARGETS_36HR_UP|ZHANG_TLX_TARGETS_60HR_UP|ZHANG_TLX_TARGETS_UP|MIKKELSEN_PARTIALLY_REPROGRAMMED_TO_PLURIPOTENCY|DANG_REGULATED_BY_MYC_DN|DANG_MYC_TARGETS_DN|KIM_PTEN_TARGETS_UP|LIU_TOPBP1_TARGETS|WAKABAYASHI_ADIPOGENESIS_PPARG_BOUND_36HR|BOUDOUKHA_BOUND_BY_IGF2BP2|SMIRNOV_RESPONSE_TO_IR_2HR_UP|SMIRNOV_RESPONSE_TO_IR_6HR_UP|WARTERS_RESPONSE_TO_IR_SKIN|WARTERS_IR_RESPONSE_5GY|ROAZ_01|G2_M_TRANSITION_OF_MITOTIC_CELL_CYCLE|REGULATION_OF_GROWTH|NEGATIVE_REGULATION_OF_GROWTH|GROWTH|NEGATIVE_REGULATION_OF_PHOSPHORYLATION|REGULATION_OF_CYCLIN_DEPENDENT_PROTEIN_KINASE_ACTIVITY|NEGATIVE_REGULATION_OF_PHOSPHATE_METABOLIC_PROCESS|REGULATION_OF_CELL_GROWTH|KINASE_BINDING|KINASE_REGULATOR_ACTIVITY|PROTEIN_KINASE_INHIBITOR_ACTIVITY|KINASE_INHIBITOR_ACTIVITY|PROTEIN_KINASE_REGULATOR_ACTIVITY|PROTEIN_KINASE_BINDING|ENZYME_BINDING	GSE8939,UVC 2h and 12h vs untreated CS-B wt-rescued cells|GSE23994,epithelial vs stromal normal breast cells|GSE28416,P53 WT + (DOXO or H2O2) vs MUT untreated or H2O2 MEF|GSE30240,ionizing radiation vs untreated TK6 (lymphoblasts)	GSE22083,1 MED solar simulated radiation vs control skin	1026	7832	4193	900	355	10140	1647	23612	6890	1030	2810	64393	1643	9538	64065	54541	467	581	27244	2232	55367	6303	1029	64782	8493	2309	694	10628	10560	8870	7157	4851	6236	51181	4814	2353	6281	55294	1263	7508	203	51499	578	894	317	5154	10397	5900	5268	1606	26999	9314	51447	100	8744	11202	5564	2040	8651	10769	834	25898	5111	51065	5925	23645	5429	57799	2073	1012	1649	7040	2517	92815	8626	22824	2052	63874	55766	9618	8722	51278	30851	8848	6004	3265	5820	677	6382	49856	5912	56997	23654	10614	10544	8877	55035	50619	6667	3714	9738	55332	6141	1050	23303	4084	10906	29948	57763	1839	5889	3691	57761	3625	8673	4013	18	1509	5791	3094	247	7421	8518	11059	26471	6948	55602	9883	22891	1969	3725	7867	23657	29946	3654	10057	7378	975	3976	25873	26355	127544	8851	55240	26207	23169	51002	23378	3552	5372	7164	10437	2760	6206	64787	4071	10904	2872	3732	10399	6768	7062	8841	8812	79651	55270	7039	23479	3945	7135	2258	6256	351	2149	9635	10668	81566	91	650	2877	3872	51768	7704	5784	64061	6520	6275	27165	896	3275	4808	10458	54884	4033	3006	30836	10608	29927	3162	5883
HALLMARK_UV_RESPONSE_UP	M5941								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated in response to ultraviolet (UV) radiation.			DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_UP|DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_UP|DACOSTA_UV_RESPONSE_VIA_ERCC3_UP|BROWNE_HCMV_INFECTION_20HR_UP|BROWNE_HCMV_INFECTION_16HR_UP|BROWNE_HCMV_INFECTION_8HR_UP|BROWNE_HCMV_INFECTION_48HR_UP|BROWNE_HCMV_INFECTION_14HR_UP|BROWNE_HCMV_INFECTION_18HR_UP|BROWNE_HCMV_INFECTION_10HR_UP|BROWNE_HCMV_INFECTION_12HR_UP|BROWNE_HCMV_INFECTION_24HR_UP|DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_UP|BROWNE_HCMV_INFECTION_30MIN_UP|BROWNE_HCMV_INFECTION_1HR_UP|BROWNE_HCMV_INFECTION_4HR_UP	GSE2032,UV vs sham|GSE8939,UVC 12h vs 0h|GSE38189,UV vs dox|GSE59445,UV vs mock	GSE22083,1 MED solar simulated radiation vs control skin	10482	6535	578	988	3306	5437	211	7277	725	898	2052	80273	3383	2237	409	3726	1515	8694	467	836	10125	7009	2353	6890	1875	5873	896	291	6697	1030	6474	10439	3485	4067	1212	10018	9355	4792	4487	3014	3164	2744	997	4323	10494	11333	5243	682	6415	3659	6257	7037	10105	1028	3134	8804	55937	650	9392	9	51706	6236	54107	3569	10652	30	1181	27161	6648	5504	388	5979	27295	4072	3301	6817	1119	1543	9296	1036	226	23467	1968	1267	2907	637	11232	3572	8692	2354	4245	1482	5471	5045	6150	3363	2920	116138	9129	3337	1175	5702	7263	10280	2643	7832	1054	6897	7389	10038	10950	1742	1138	4885	528	360	5334	9818	7301	3162	6184	694	2326	440	9188	3757	1280	4128	7062	80777	6782	8836	51083	4916	5538	8817	2288	10963	1983	2026	2878	5566	5580	10948	2011	6539	8878	5789	23542	1017	3175	5984	760	6870	262	3192	58525	885
HALLMARK_UV_RESPONSE_DN	M5942								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes down-regulated in response to ultraviolet (UV) radiation.			DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_DN|DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_DN|BROWNE_HCMV_INFECTION_16HR_DN|BROWNE_HCMV_INFECTION_10HR_DN|BROWNE_HCMV_INFECTION_24HR_DN|BROWNE_HCMV_INFECTION_14HR_DN|BROWNE_HCMV_INFECTION_20HR_DN|BROWNE_HCMV_INFECTION_48HR_DN|BROWNE_HCMV_INFECTION_8HR_DN|BROWNE_HCMV_INFECTION_18HR_DN|RAMASWAMY_METASTASIS_UP|BROWNE_HCMV_INFECTION_6HR_DN|BROWNE_HCMV_INFECTION_12HR_DN|BROWNE_HCMV_INFECTION_30MIN_DN|BROWNE_HCMV_INFECTION_1HR_DN|BROWNE_HCMV_INFECTION_2HR_DN|BROWNE_HCMV_INFECTION_4HR_DN	GSE2032,sham vs UV|GSE8939,UVC 0h vs 12h|GSE38189,dox vs UV|GSE59445,mock vs UV	GSE22083,control vs 1 MED solar simulated radiation skin	7082	4781	7049	7035	4325	4363	5607	55109	5332	4233	3667	5797	10000	26037	9975	8455	302	120	1027	6310	10486	7799	23116	6383	4088	6541	2650	861	390	8613	2908	91746	5468	23266	1739	493	25836	5195	4609	5922	2535	657	1902	5578	4255	5581	6256	4052	3949	11030	773	5999	1290	11099	5577	2697	594	27109	5054	273	54468	10370	1278	3638	2534	22884	57178	5376	50937	8503	4853	8871	4092	4131	11044	5728	1859	140609	8405	2152	2064	2869	1843	7436	857	1301	8476	8621	51460	136	8553	1281	3778	23345	3480	10659	9112	2202	3915	23469	22828	7410	10401	92	8829	10240	3491	1601	9863	307	1277	29970	23576	5159	546	8997	7048	5737	27032	23229	4790	11343	10516	10611	1432	6717	8821	3488	3690	627	3397	6591	6334	490	2274	3815	323	5293	10395	4493	1628	3037	5002	3382
HALLMARK_ANGIOGENESIS	M5944								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated during formation of blood vessels (angiogenesis).			LU_TUMOR_VASCULATURE_UP|ROY_WOUND_BLOOD_VESSEL_UP|LU_TUMOR_ENDOTHELIAL_MARKERS_UP|LU_TUMOR_ANGIOGENESIS_UP|MODULE_96|MODULE_385|MODULE_410|CARBOHYDRATE_BINDING|MONOSACCHARIDE_BINDING|SUGAR_BINDING|HEPARIN_BINDING|POLYSACCHARIDE_BINDING|PATTERN_BINDING|GLYCOSAMINOGLYCAN_BINDING	GSE1567,day 7 vs day 0 alveolar epithelial type II cells|GSE15892,PDGFB WT vs MUT brain microvascular fragments|GSE19098,unspread vs spread HUVEC|GSE33717,control vs PDGF-bb S17 (bone marrow stroma)|GSE43288,tumor vs normal pancreas	GSE31152,CD146+/PDGFRB+ (MSC) vs CD146+/PDGFRB- (endothelium) endometrial biopsy	1462	10631	11167	4043	6781	4023	7422	5196	7056	2260	27242	894	1290	3685	5104	3764	351	182	1281	6696	8829	4973	5154	5747	6578	8993	7410	6275	4487	7448	7076	350	5553	3714	4060	6372
HALLMARK_HEME_METABOLISM	M5945								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes involved in metabolism of heme (a cofactor consisting of iron and porphyrin) and erythroblast differentiation.			chr4q28|chr8q|BIOCARTA_AHSP_PATHWAY|REACTOME_METABOLISM_OF_PORPHYRINS|WELCH_GATA1_TARGETS|SCHURINGA_STAT5A_TARGETS_UP|IVANOVA_HEMATOPOIESIS_MATURE_CELL|KYNG_DNA_DAMAGE_BY_4NQO_OR_GAMMA_RADIATION|VALK_AML_CLUSTER_7|VALK_AML_CLUSTER_8|CHYLA_CBFA2T3_TARGETS_DN|ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_DN|JUBAN_TARGETS_OF_SPI1_AND_FLI1_UP|GNF2_BNIP3L|GNF2_PRDX2|GNF2_RAD23A|GNF2_ANK1|GNF2_CDC27|GNF2_MAP2K3|GNF2_PCAF|GNF2_SPTA1|GNF2_SPTB|GNF2_TAL1|MODULE_227|MODULE_335|MODULE_539|COFACTOR_METABOLIC_PROCESS|COENZYME_METABOLIC_PROCESS|COENZYME_BIOSYNTHETIC_PROCESS|SECONDARY_METABOLIC_PROCESS|HEME_BIOSYNTHETIC_PROCESS|PIGMENT_BIOSYNTHETIC_PROCESS|PIGMENT_METABOLIC_PROCESS|HETEROCYCLE_METABOLIC_PROCESS|COFACTOR_BIOSYNTHETIC_PROCESS|HEME_METABOLIC_PROCESS	GSE1922,imatinib vs control K562 (leukemia)|GSE4655,erythroid progenitor maturation days 7-11 vs days 1-5|GSE17639,cord vs adult blood|GSE22552,Int-E and Late-E vs CFU-E and Pro-E erythroblasts	GSE25100,ID4+/+TCL1 vs ID4+/-TCL1 B lymphocytes	212	5498	2235	3145	2994	210	6007	2993	8991	645	2996	2995	2038	6521	6006	6005	6886	220972	6710	7389	3049	80344	114625	27102	1371	4354	51218	10098	23762	286	4778	51327	6708	5606	665	6583	1193	66008	2729	3792	57610	10107	222642	7390	7504	6622	4140	10422	759	760	682	2309	10661	996	8850	26502	2730	25793	3005	50865	3045	11163	26268	5886	84809	9911	644	2623	55544	7001	63891	9562	7145	1510	2039	3068	23039	23608	54498	7029	4601	3043	56180	51312	7779	10058	6535	7037	10171	7150	2057	23112	23305	26130	4259	55532	847	4059	3050	2532	5715	81689	10158	8364	3386	55034	118	10841	119	55589	669	1182	1870	3029	80853	10133	5909	1497	4779	22936	6513	9091	51274	2035	3920	56674	2145	1508	115201	9258	4635	25897	7832	4891	51094	440	54165	10840	79269	51646	6397	9958	8780	51092	55810	6917	7716	9663	5091	3044	1039	896	54977	54855	55030	571	2908	360	25893	4005	8301	8031	51573	6536	23530	23365	5526	718	51257	7351	8867	64122	9429	23002	56895	25901	8833	54	8273	4329	9541	10181	27429	3321	8945	25796	80148	6386	26020	140609	23568	23052	8974	10553	23657	23351	129642	535	831	7299
HALLMARK_COAGULATION	M5946								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes encoding components of blood coagulation system; also up-regulated in platelets.			chr13q34|chr11q21|KEGG_COMPLEMENT_AND_COAGULATION_CASCADES|KEGG_PRION_DISEASES|BIOCARTA_AMI_PATHWAY|BIOCARTA_CLASSIC_PATHWAY|BIOCARTA_COMP_PATHWAY|BIOCARTA_EXTRINSIC_PATHWAY|BIOCARTA_FIBRINOLYSIS_PATHWAY|BIOCARTA_INTRINSIC_PATHWAY|BIOCARTA_LECTIN_PATHWAY|REACTOME_GAMMA_CARBOXYLATION_TRANSPORT_AND_AMINO_TERMINAL_CLEAVAGE_OF_PROTEINS|REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX|REACTOME_REGULATION_OF_COMPLEMENT_CASCADE|REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2_|REACTOME_COMMON_PATHWAY|REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE|REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION|REACTOME_INTRINSIC_PATHWAY|REACTOME_HEMOSTASIS|REACTOME_COMPLEMENT_CASCADE|REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION|REACTOME_CREATION_OF_C4_AND_C2_ACTIVATORS|REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT|VETTER_TARGETS_OF_PRKCA_AND_ETS1_DN|OZANNE_AP1_TARGETS_UP|MAHADEVAN_GIST_MORPHOLOGICAL_SWITCH|BAKER_HEMATOPOESIS_STAT1_TARGETS|OXFORD_RALA_TARGETS_UP|OXFORD_RALB_TARGETS_DN|OXFORD_RALA_AND_RALB_TARGETS_UP|GROSS_HYPOXIA_VIA_HIF1A_ONLY|MAGRANGEAS_MULTIPLE_MYELOMA_IGG_VS_IGA_DN|SMID_BREAST_CANCER_RELAPSE_IN_LIVER_UP|WILSON_PROTEASES_AT_TUMOR_BONE_INTERFACE_UP|JU_AGING_TERC_TARGETS_UP|MODULE_58|MODULE_107|MODULE_109|MODULE_130|MODULE_131|MODULE_172|MODULE_209|MODULE_210|MODULE_211|MODULE_226|MODULE_280|MODULE_281|MODULE_324|MODULE_371|MODULE_562|HEMOSTASIS|REGULATION_OF_BODY_FLUID_LEVELS|BLOOD_COAGULATION|WOUND_HEALING|COAGULATION|ACUTE_INFLAMMATORY_RESPONSE|CATION_BINDING|SERINE_TYPE_PEPTIDASE_ACTIVITY|ZINC_ION_BINDING|CALCIUM_ION_BINDING|METALLOPEPTIDASE_ACTIVITY|CYSTEINE_TYPE_PEPTIDASE_ACTIVITY|ION_BINDING|ENDOPEPTIDASE_ACTIVITY|SERINE_HYDROLASE_ACTIVITY|PEPTIDASE_ACTIVITY|CYSTEINE_TYPE_ENDOPEPTIDASE_ACTIVITY|TRANSITION_METAL_ION_BINDING|SERINE_TYPE_ENDOPEPTIDASE_ACTIVITY|METALLOENDOPEPTIDASE_ACTIVITY	GSE3126,HNF4A WT vs KO embryonic liver|GSE19339,thrombus-derived vs normal leukocytes|GSE23031,ribavirin vs PBS HuH-7 (hepatocellular carcinoma)	GSE11524,sickle cell disease vs normal platelets|GSE27034,PAD vs control PBMC	2147	5624	716	4323	2159	5340	715	5054	710	717	2161	3426	4313	718	2158	1519	164656	4318	8858	4312	629	649	7450	2243	2160	7056	5045	4320	2157	5641	3249	1508	4153	2165	7076	1515	4317	2	4319	10747	2266	731	5328	8754	2934	824	5327	2335	1512	4973	6678	9104	732	3920	735	5627	1191	2151	928	3075	5550	4048	2815	11072	1513	9615	842	341	1397	11202	462	301	3697	11098	2200	4485	2152	8609	1510	3690	726	1465	3818	22921	7980	4314	4224	2811	335	5265	7018	553115	55970	22933	1311	5654	23764	4035	5196	10404	4324	5877	3273	733	344	5055	10411	1369	3673	5879	1803	9948	7057	2534	5155	10603	5175	4316	1848	1361	6284	1675	1638	7044	283	712	3158	23479	5341	345	5028	8237	7078	8309	3172	6271	2783	378
HALLMARK_IL2_STAT5_SIGNALING	M5947								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated by STAT5 in response to IL2 stimulation.			LU_IL4_SIGNALING|GAVIN_FOXP3_TARGETS_CLUSTER_T4|GAVIN_FOXP3_TARGETS_CLUSTER_P4|GAVIN_FOXP3_TARGETS_CLUSTER_P7|ZHENG_FOXP3_TARGETS_UP|MARZEC_IL2_SIGNALING_UP|WIERENGA_STAT5A_TARGETS_UP|WIERENGA_STAT5A_TARGETS_GROUP1|WIERENGA_STAT5A_TARGETS_GROUP2|BOSCO_ALLERGEN_INDUCED_TH2_ASSOCIATED_MODULE|IL15_UP.V1_UP|IL2_UP.V1_UP|IL21_UP.V1_UP	GSE1419,T reg (CD25+) vs T eff (CD25-)|GSE6085,IL2 4-12h vs 0-0.5h or untreated T lymphocytes|GSE6813,CD25+ vs CD25- T lymphocytes|GSE36888,WT IL2 vs STAT5 double knocked in IL2	GSE23398,Scrufy vs Sf.Il2-/-|GSE37781,STAT5A vs STAT5B	8835	1154	5292	3559	7293	8651	3604	7494	58528	3099	22822	3560	1493	4783	9308	22807	3586	8784	9249	1893	8728	6515	28996	55509	8553	5732	23258	80760	57157	4616	8829	8202	974	196	7133	10397	598	23710	3976	7074	659	1326	388	4609	6271	254013	822	6484	5179	3662	8530	79971	51284	64375	115361	6004	6696	3596	3177	64332	3566	4084	1437	2184	1522	3682	4582	9261	27242	4907	2323	894	7185	253558	3563	23191	596	10875	5621	221143	80324	3685	23413	28960	23600	285172	5745	4953	3480	5727	2027	975	23764	2012	1028	825	7850	23208	158219	307	10538	5033	8477	6510	3482	10970	1233	960	5025	2623	1316	10124	84525	10888	3655	962	92749	6403	152007	10924	5359	5045	5269	8600	2879	84230	898	836	83699	51429	5339	650	29851	214	4050	5167	9173	4641	3459	123	8809	79026	5583	943	9144	130589	5451	8320	4839	51651	399	990	4643	3627	57231	3664	3587	4135	8743	200734	6402	462	64866	6095	1690	1435	2151	7371	760	10410	7372	10075	1291	5243	6050	3394	2983	191	11230	9446	57045	56990	5325	333	11217	8611	81848	6335	126669	84306	896	26018	23075	64116	9910	7052	4860	177	2118	942
HALLMARK_BILE_ACID_METABOLISM	M5948								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes involve in metabolism of bile acids and salts.			chr11p|chr15q|KEGG_PRIMARY_BILE_ACID_BIOSYNTHESIS|KEGG_ABC_TRANSPORTERS|KEGG_PEROXISOME|REACTOME_BILE_ACID_AND_BILE_SALT_METABOLISM|REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_7ALPHA_HYDROXYCHOLESTEROL|REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_24_HYDROXYCHOLESTEROL|REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS|REACTOME_ABCA_TRANSPORTERS_IN_LIPID_HOMEOSTASIS|REACTOME_ALPHA_LINOLENIC_ACID_ALA_METABOLISM|REACTOME_ABC_FAMILY_PROTEINS_MEDIATED_TRANSPORT|REACTOME_PEROXISOMAL_LIPID_METABOLISM|MODULE_404|PEROXISOMAL_MEMBRANE|PEROXISOMAL_PART|MICROBODY_MEMBRANE|MICROBODY_PART|MICROBODY|PEROXISOME|PEROXISOME_ORGANIZATION_AND_BIOGENESIS|STEROID_METABOLIC_PROCESS|BILE_ACID_METABOLIC_PROCESS|HORMONE_METABOLIC_PROCESS|STEROID_BIOSYNTHETIC_PROCESS|RESPONSE_TO_DRUG|NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY|PROTEIN_C_TERMINUS_BINDING	GSE3126,HNF4A WT vs KO liver|GSE3889,SCD1 WT vs MUT both very low fat diet liver|GSE27391,THRSP+ vs THRSP- (by GFP) neural stem cells|GSE37546,vehicle vs LPS liver|GSE41295,LPS vs mock macrophages	GSE20599,FXR WT and SHP KO vs FXR KO and FXR/SHP double KO liver	6342	5825	11001	80270	3295	6718	225	5189	1582	50640	5264	10998	9420	1593	55670	189	5191	54677	51302	21	1581	26061	51268	5190	6647	8443	3283	20	54363	9409	215	2180	23417	64241	366	51015	9971	5824	4864	51170	23600	10858	5194	3417	8800	8630	2053	25824	5827	8424	9415	223	335	10133	373156	64137	64577	4306	23460	54884	3992	55825	5193	847	27232	10350	51703	83752	1718	10351	5213	1733	6256	2232	7276	10661	2030	8412	3932	92960	6579	216	27284	8856	2638	24	347734	9963	83594	19	196743	5002	1734	5947	9962	6310	2730	4734	6258	367	654	866	3991	114327	3418	3422	9023	23461	6820	8435	29842	8431
HALLMARK_PEROXISOME	M5949								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes encoding components of peroxisome.			chr11p|chr15q|KEGG_PRIMARY_BILE_ACID_BIOSYNTHESIS|KEGG_ABC_TRANSPORTERS|KEGG_PEROXISOME|REACTOME_BILE_ACID_AND_BILE_SALT_METABOLISM|REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_7ALPHA_HYDROXYCHOLESTEROL|REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_24_HYDROXYCHOLESTEROL|REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS|REACTOME_ABCA_TRANSPORTERS_IN_LIPID_HOMEOSTASIS|REACTOME_ALPHA_LINOLENIC_ACID_ALA_METABOLISM|REACTOME_ABC_FAMILY_PROTEINS_MEDIATED_TRANSPORT|REACTOME_PEROXISOMAL_LIPID_METABOLISM|MODULE_404|PEROXISOMAL_MEMBRANE|PEROXISOMAL_PART|MICROBODY_MEMBRANE|MICROBODY_PART|MICROBODY|PEROXISOME|PEROXISOME_ORGANIZATION_AND_BIOGENESIS|STEROID_METABOLIC_PROCESS|BILE_ACID_METABOLIC_PROCESS|HORMONE_METABOLIC_PROCESS|STEROID_BIOSYNTHETIC_PROCESS|RESPONSE_TO_DRUG|NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_TRANSMEMBRANE_TRANSPORTER_ACTIVITY|PROTEIN_C_TERMINUS_BINDING	GSE8292,PPARA WT WY14643 vs PPARA KO WY14643|GSE12147,CP-865520 vs vehicle liver|GSE13376,REST vs DCA SKGT4 (adenocarcinoma of Barrett's epithelium)|GSE20498,hepatocyte vs bile duct|GSE32706,fenofibrate vs control liver|GSE3889,SCD1 WT vs MUT both very low fat diet liver	GSE46960,adult donors vs other cholestasis	5825	10005	51	2180	1891	10455	1962	373156	3295	23417	8800	54884	11001	5194	5195	6342	80270	8443	225	10478	5828	30	51179	51170	1384	8799	83752	3417	51024	5190	5244	6647	5243	51015	7533	2053	215	3155	51703	223	1718	60481	390916	25824	1503	3416	9962	5830	8915	8856	706	7555	4436	9249	1733	291	5052	3422	3265	9961	6833	54982	847	2182	3418	10057	6648	347734	2224	213	3992	412	6599	9270	6477	60386	1022	6258	216	7367	23705	866	2055	51109	1487	3291	7276	2071	6310	6820	1382	1381	7153	7356	2067	1742	26986	2172	23457	774	10512	9525	1056	2100
HALLMARK_ALLOGRAFT_REJECTION	M5950								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated during transplant rejection.			KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION|KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION|KEGG_TYPE_I_DIABETES_MELLITUS|KEGG_LEISHMANIA_INFECTION|KEGG_ASTHMA|KEGG_AUTOIMMUNE_THYROID_DISEASE|KEGG_ALLOGRAFT_REJECTION|KEGG_GRAFT_VERSUS_HOST_DISEASE|KEGG_VIRAL_MYOCARDITIS|BIOCARTA_CSK_PATHWAY|BIOCARTA_ASBCELL_PATHWAY|BIOCARTA_CTL_PATHWAY|BIOCARTA_CYTOKINE_PATHWAY|BIOCARTA_INFLAM_PATHWAY|BIOCARTA_DC_PATHWAY|BIOCARTA_ERYTH_PATHWAY|BIOCARTA_TCAPOPTOSIS_PATHWAY|BIOCARTA_IL17_PATHWAY|BIOCARTA_IL5_PATHWAY|BIOCARTA_IL12_PATHWAY|BIOCARTA_TCRA_PATHWAY|BIOCARTA_NO2IL12_PATHWAY|BIOCARTA_STEM_PATHWAY|BIOCARTA_TOB1_PATHWAY|BIOCARTA_NKT_PATHWAY|BIOCARTA_TCYTOTOXIC_PATHWAY|BIOCARTA_THELPER_PATHWAY|BIOCARTA_TH1TH2_PATHWAY|BIOCARTA_CTLA4_PATHWAY|PID_TCR_PATHWAY|PID_IL27_PATHWAY|PID_IL12_2PATHWAY|PID_CD8_TCR_PATHWAY|PID_IL23_PATHWAY|PID_IL12_STAT4_PATHWAY|REACTOME_ENDOSOMAL_VACUOLAR_PATHWAY|REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL|REACTOME_TRAFFICKING_AND_PROCESSING_OF_ENDOSOMAL_TLR|REACTOME_TCR_SIGNALING|REACTOME_DOWNSTREAM_TCR_SIGNALING|REACTOME_PHOSPHORYLATION_OF_CD3_AND_TCR_ZETA_CHAINS|REACTOME_TRANSLOCATION_OF_ZAP_70_TO_IMMUNOLOGICAL_SYNAPSE|REACTOME_GENERATION_OF_SECOND_MESSENGER_MOLECULES|REACTOME_PD1_SIGNALING|REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC|DEBOSSCHER_NFKB_TARGETS_REPRESSED_BY_GLUCOCORTICOIDS|LUI_THYROID_CANCER_CLUSTER_4|GALE_APL_WITH_FLT3_MUTATED_DN|MOREIRA_RESPONSE_TO_TSA_DN|GAURNIER_PSMD4_TARGETS|WEST_ADRENOCORTICAL_CARCINOMA_VS_ADENOMA_DN|BEIER_GLIOMA_STEM_CELL_DN|RAY_ALZHEIMERS_DISEASE|BUDHU_LIVER_CANCER_METASTASIS_UP|BUDHU_LIVER_CANCER_METASTASIS_DN|KUROKAWA_LIVER_CANCER_EARLY_RECURRENCE_DN|SEIKE_LUNG_CANCER_POOR_SURVIVAL|MODULE_143|MODULE_293|POSITIVE_REGULATION_OF_TRANSLATION|RESPONSE_TO_VIRUS|POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION|POSITIVE_REGULATION_OF_PHOSPHATE_METABOLIC_PROCESS|POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS|NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS|REGULATION_OF_SECRETION|REGULATION_OF_DEFENSE_RESPONSE|MULTI_ORGANISM_PROCESS|REGULATION_OF_DNA_BINDING|JAK_STAT_CASCADE|NEGATIVE_REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS|CELL_ACTIVATION|HORMONE_SECRETION|REGULATION_OF_CYTOKINE_SECRETION|REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS|REGULATION_OF_HORMONE_SECRETION|POSITIVE_REGULATION_OF_PHOSPHORYLATION|T_CELL_PROLIFERATION|REGULATION_OF_TYROSINE_PHOSPHORYLATION_OF_STAT_PROTEIN|POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS|NEGATIVE_REGULATION_OF_CELLULAR_BIOSYNTHETIC_PROCESS|REGULATION_OF_PROTEIN_AMINO_ACID_PHOSPHORYLATION|LYMPHOCYTE_DIFFERENTIATION|BIOSYNTHETIC_PROCESS|HEMOPOIESIS|POSITIVE_REGULATION_OF_BINDING|IMMUNE_SYSTEM_DEVELOPMENT|NEGATIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS|POSITIVE_REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS|REGULATION_OF_PROTEIN_MODIFICATION_PROCESS|REGULATION_OF_INTERFERON_GAMMA_BIOSYNTHETIC_PROCESS|CYTOKINE_METABOLIC_PROCESS|REGULATION_OF_TRANSLATION|INTERLEUKIN_8_BIOSYNTHETIC_PROCESS|PRODUCTION_OF_MOLECULAR_MEDIATOR_OF_IMMUNE_RESPONSE|REGULATION_OF_PROTEIN_METABOLIC_PROCESS|POSITIVE_REGULATION_OF_IMMUNE_RESPONSE|NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS|REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION|T_CELL_DIFFERENTIATION|REGULATION_OF_T_CELL_ACTIVATION|CYTOKINE_PRODUCTION|REGULATION_OF_PHOSPHORYLATION|CELLULAR_BIOSYNTHETIC_PROCESS|POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS|ACTIVATION_OF_NF_KAPPAB_TRANSCRIPTION_FACTOR|MYELOID_CELL_DIFFERENTIATION|LEUKOCYTE_DIFFERENTIATION|IMMUNE_EFFECTOR_PROCESS|POSITIVE_REGULATION_OF_T_CELL_PROLIFERATION|POSITIVE_REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS|REGULATION_OF_TRANSCRIPTION_FACTOR_ACTIVITY|REGULATION_OF_MYELOID_CELL_DIFFERENTIATION|DEFENSE_RESPONSE_TO_VIRUS|MYELOID_LEUKOCYTE_DIFFERENTIATION|LEUKOCYTE_ACTIVATION|INTERLEUKIN_1_SECRETION|ADAPTIVE_IMMUNE_RESPONSE_GO_0002460|INTERLEUKIN_2_PRODUCTION|POSITIVE_REGULATION_OF_DEFENSE_RESPONSE|B_CELL_DIFFERENTIATION|ACTIVATION_OF_IMMUNE_RESPONSE|B_CELL_ACTIVATION|INTERLEUKIN_8_PRODUCTION|REGULATION_OF_CELL_DIFFERENTIATION|NEGATIVE_REGULATION_OF_DNA_BINDING|POSITIVE_REGULATION_OF_CYTOKINE_SECRETION|RESPONSE_TO_BACTERIUM|IMMUNE_RESPONSE|HEMOPOIETIC_OR_LYMPHOID_ORGAN_DEVELOPMENT|POSITIVE_REGULATION_OF_TRANSCRIPTION_FACTOR_ACTIVITY|REGULATION_OF_CYTOKINE_PRODUCTION|HOMEOSTASIS_OF_NUMBER_OF_CELLS|RESPONSE_TO_BIOTIC_STIMULUS|PROTEIN_SECRETION|NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION|MACROMOLECULE_BIOSYNTHETIC_PROCESS|RESPONSE_TO_OTHER_ORGANISM|POSITIVE_REGULATION_OF_T_CELL_ACTIVATION|POSITIVE_REGULATION_OF_PROTEIN_SECRETION|REGULATION_OF_RESPONSE_TO_STIMULUS|POSITIVE_REGULATION_OF_DNA_METABOLIC_PROCESS|GENERATION_OF_A_SIGNAL_INVOLVED_IN_CELL_CELL_SIGNALING|POSITIVE_REGULATION_OF_LYMPHOCYTE_ACTIVATION|ADAPTIVE_IMMUNE_RESPONSE|PEPTIDYL_TYROSINE_PHOSPHORYLATION|NEGATIVE_REGULATION_OF_SECRETION|DEFENSE_RESPONSE_TO_BACTERIUM|NEGATIVE_REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS|PEPTIDYL_AMINO_ACID_MODIFICATION|IMMUNE_SYSTEM_PROCESS|REGULATION_OF_T_CELL_PROLIFERATION|PEPTIDYL_TYROSINE_MODIFICATION|T_CELL_ACTIVATION|CYTOKINE_BIOSYNTHETIC_PROCESS|NEGATIVE_REGULATION_OF_BINDING|REGULATION_OF_JAK_STAT_CASCADE|CYTOKINE_AND_CHEMOKINE_MEDIATED_SIGNALING_PATHWAY|REGULATION_OF_LYMPHOCYTE_ACTIVATION|NEGATIVE_REGULATION_OF_TRANSLATION|NEGATIVE_REGULATION_OF_MYELOID_CELL_DIFFERENTIATION|NEGATIVE_REGULATION_OF_TRANSCRIPTION_FACTOR_ACTIVITY|POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS|INNATE_IMMUNE_RESPONSE|LYMPHOCYTE_ACTIVATION|POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS|DETECTION_OF_BIOTIC_STIMULUS|NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS|HUMORAL_IMMUNE_RESPONSE|TRANSLATION|POSITIVE_REGULATION_OF_DNA_BINDING|REGULATION_OF_PROTEIN_SECRETION|POSITIVE_REGULATION_OF_SECRETION|INTERFERON_GAMMA_BIOSYNTHETIC_PROCESS|CYTOKINE_SECRETION|REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS|POSITIVE_REGULATION_OF_PROTEIN_AMINO_ACID_PHOSPHORYLATION|INTERFERON_GAMMA_PRODUCTION|REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS|REGULATION_OF_IMMUNE_SYSTEM_PROCESS|REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS|TYROSINE_PHOSPHORYLATION_OF_STAT_PROTEIN|REGULATION_OF_IMMUNE_EFFECTOR_PROCESS|REGULATION_OF_IMMUNE_RESPONSE|REGULATION_OF_BINDING|NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS|POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION|POSITIVE_REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION|DOUBLE_STRANDED_RNA_BINDING|PATTERN_RECOGNITION_RECEPTOR_ACTIVITY	GSE1563,acute rejection vs control kidney biopsy|GSE3418,allograft vs isograft 14 or 25 days after|GSE14328,acute rejection vs stable graft|GSE25902,post-transplant rejection vs baseline|GSE30718,acute kidney injury vs other	GSE4315,during vs before rejection cardiac allograft	5788	3593	7040	3592	916	915	940	4067	3059	3606	56253	3458	917	942	3586	7334	8915	920	3932	4690	717	3105	3689	3117	912	941	3122	7070	7096	3135	3109	3574	3565	7124	919	3558	3108	6772	3662	5552	3624	7098	7535	972	958	7186	567	602	4050	3459	1234	959	3111	11146	3569	3133	914	6352	355	356	10333	5196	7042	973	3625	1991	6688	6885	3600	1520	961	5551	3594	3937	8651	1029	6775	924	3112	925	3383	6351	3002	1435	3589	23166	3559	114548	896	8661	27240	3455	9734	9607	50852	6367	322	2533	3553	7076	6223	3717	3848	7453	3460	729230	2069	4318	1956	3603	5199	7454	3683	3824	5917	7097	894	3561	2113	3702	9437	11184	6363	5699	6170	8669	6059	926	2147	2000	9450	2213	2634	5582	6203	4528	3001	16	10225	1445	3091	6347	23308	4869	3566	6356	4830	2316	8477	43	8664	10261	2149	3596	6890	1615	3665	92	2833	5579	4283	5777	4689	7321	3976	1230	4153	8560	7163	207	8767	3551	2650	9655	3394	6891	8672	10006	6354	3560	672	2268	8807	11222	10563	822	1984	6189	2589	7903	6357	6123	4065	6892	4843	6133	586	3578	9466	8444
HALLMARK_SPERMATOGENESIS	M5951								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated during production of male gametes (sperm), as in spermatogenesis.			SU_TESTIS|WEBER_METHYLATED_HCP_IN_FIBROBLAST_UP|WEBER_METHYLATED_HCP_IN_FIBROBLAST_DN|WEBER_METHYLATED_HCP_IN_SPERM_DN|WEBER_METHYLATED_HCP_IN_SPERM_UP|MATZUK_SPERMATID_DIFFERENTIATION|MATZUK_SPERMATOZOA|MEISSNER_BRAIN_HCP_WITH_H3_UNMETHYLATED|MIKKELSEN_IPS_WITH_HCP_H3K27ME3|MIKKELSEN_IPS_HCP_WITH_H3_UNMETHYLATED|WEBER_METHYLATED_LCP_IN_FIBROBLAST_UP|WEBER_METHYLATED_ICP_IN_FIBROBLAST|WEBER_METHYLATED_ICP_IN_SPERM_UP|WEBER_METHYLATED_ICP_IN_SPERM_DN|WEBER_METHYLATED_LCP_IN_SPERM_UP|MIKKELSEN_ES_HCP_WITH_H3K27ME3|MIKKELSEN_ES_HCP_WITH_H3_UNMETHYLATED|MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED|WAGSCHAL_EHMT2_TARGETS_UP|MADAN_DPPA4_TARGETS|GNF2_CCNA1|GNF2_MLF1|SPERMATID_DEVELOPMENT|SPERMATID_DIFFERENTIATION	GSE640,adult and days 14-29 vs days 1-4 and controls testis|GSE6872,normal vs teratozoospermic|GSE45885,control vs NOA_SCOS|GSE45887,control vs NOA_SCOS	E-TABM-130,testis vs other tissues|GSE8607,normal vs seminoma pT3	5161	23617	7141	11055	64180	2515	10880	26330	7278	3948	29118	5620	6954	9063	56903	51686	51533	4956	84519	51087	1459	84779	7288	132612	6847	54514	4291	27285	54558	5232	3306	56	81570	7180	79696	8852	8900	10693	135138	83445	51298	22824	10047	1630	3305	2947	165721	3598	814	23175	79882	8161	5261	11004	116832	6518	54760	6790	8028	4842	419	9133	4867	1047	23139	2475	1033	148066	3267	9892	8624	55743	7142	2146	3050	10124	6558	673	7419	5443	8100	8277	4751	10254	3010	64395	4543	5984	10926	5576	7272	11144	23397	5037	1132	11073	6447	4744	9053	699	5414	9489	4889	7247	983	126669	10038	7137	27344	3416	11318	5884	7091	1636	23411	3361	6888	4771	157807	254263	2918	55342	116	246	4225	29106	2672	83401	3595	1761	2571	1080	83700	9807	3211
HALLMARK_KRAS_SIGNALING_UP	M5953								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes up-regulated by KRAS activation.			PRC1_BMI_UP.V1_DN|PRC2_EDD_UP.V1_DN|PRC2_EZH2_UP.V1_DN|PRC2_SUZ12_UP.V1_DN|KRAS.AMP.LUNG_UP.V1_UP|KRAS.300_UP.V1_UP|KRAS.50_UP.V1_UP|KRAS.600_UP.V1_UP|KRAS.600.LUNG.BREAST_UP.V1_UP|KRAS.BREAST_UP.V1_UP|KRAS.KIDNEY_UP.V1_UP|KRAS.LUNG_UP.V1_UP|KRAS.LUNG.BREAST_UP.V1_UP|KRAS.PROSTATE_UP.V1_UP	E-TABM-304,p48-Cre KrasG12D vs wt|GSE32277,pancreatic tumor cells Tet ON (high KRAS) vs Tet OFF (low KRAS)|GSE32277,orthotopic tumors Tet ON (high KRAS) vs Tet OFF (low KRAS)|GSE33322,PDAC vs normal|GSE33322,panIN vs normal	GSE43288,GSM1059985-GSM1060004 PanABC vs Normal and PaCa	51129	3673	10253	1839	5950	3290	2118	2745	1848	6447	2119	3689	208	5473	50486	2556	3394	330	2254	131566	3624	7035	10103	101	6590	5593	4320	4319	25907	7128	639	2591	2113	4318	7476	3486	6696	2115	50856	894	7102	9358	2012	81602	3800	28951	10806	5121	3080	8854	8431	220	9949	6304	2982	1437	347	163590	1240	28959	25960	7805	951	81617	1149	51193	3553	2995	23643	2324	10418	650	26499	3481	9971	6616	1636	5396	719	7185	51311	3398	55273	5329	10912	57332	6324	58155	4674	9590	5327	29106	55107	8808	3627	83734	79693	9734	5178	7869	7139	3976	629	685	23645	5801	6364	383	56729	9314	23531	80380	3018	3237	10221	2150	11199	27075	54893	3075	7462	30001	5649	3783	55365	11184	5743	90865	9935	3936	4803	760	12	6004	1520	219333	1363	8404	5243	10083	1438	22903	3561	23268	3587	2069	51012	2048	26272	54677	10205	56172	84869	1794	51704	9910	7851	6801	6480	5284	4013	5696	2162	8829	6662	3728	64123	11179	23136	27344	2517	83483	6868	23080	27299	80201	9053	3575	5936	669	2022	9945	5328	2791	79810	4214	867	7852	51199	10320	55339	4613	2207	5175	54462	9892	7813	7133	10457	7166
HALLMARK_KRAS_SIGNALING_DN	M5956								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes down-regulated by KRAS activation.			BRCA1_DN.V1_DN|CTIP_DN.V1_DN|PTEN_DN.V2_DN|DCA_UP.V1_DN|PTEN_DN.V1_UP|NOTCH_DN.V1_UP|KRAS.AMP.LUNG_UP.V1_DN|KRAS.300_UP.V1_DN|KRAS.50_UP.V1_DN|KRAS.600_UP.V1_DN|KRAS.600.LUNG.BREAST_UP.V1_DN|KRAS.BREAST_UP.V1_DN|KRAS.KIDNEY_UP.V1_DN|KRAS.LUNG_UP.V1_DN|KRAS.LUNG.BREAST_UP.V1_DN|KRAS.PROSTATE_UP.V1_DN	E-TABM-304,p48-Cre KrasG12D vs wt|GSE32277,pancreatic tumor cells Tet ON (high KRAS) vs Tet OFF (low KRAS)|GSE32277,orthotopic tumors Tet ON (high KRAS) vs Tet OFF (low KRAS)|GSE33322,PDAC vs normal|GSE33322,panIN vs normal	GSE43288,GSM1059985-GSM1060004 PanABC vs Normal and PaCa	1014	6712	2261	4842	5158	54847	4908	6336	50832	1838	3352	23031	6531	9073	7051	29930	7068	29799	6262	2668	57118	258	3955	51156	242	797	55277	6707	525	1906	80761	2593	5625	6261	2842	55315	1907	55890	727	79696	10913	3779	54855	10734	3851	79085	10022	2811	8085	64137	4625	676	5737	3780	6414	10964	5626	3963	658	5164	1630	6620	1280	7367	5540	65989	51384	11254	26548	6559	51087	1158	1360	79917	398	51806	3848	4524	8647	9499	1952	5650	55258	1146	4929	959	3860	2813	50489	1237	7704	5071	1358	4210	8900	10991	11202	51302	3785	7781	9435	3699	1950	4439	56154	1208	57089	9746	1585	10686	3291	56997	6927	27006	29842	5020	3750	55506	83714	8786	22849	7038	5795	55190	2488	3425	7137	9328	7032	6754	51226	5133	9194	9992	54842	55220	1271	3567	4868	7356	29903	5077	7441	7252	778	57016	9127	3866	5078	7832	2827	2895	8115	5324	5317	8471	3593	2044	6663	8303	786	56848	3485	10753	83439	7042	23676	27076	5409	11346	4599	3458	2649	70	91543	152	580	3351	8823	57451	54901	6474	6446	26150	6498	58157	140460	51168	6528	3852	7771	7021	55610	941	495	10777	5055	3195	80303	5030
HALLMARK_PANCREAS_BETA_CELLS	M5957								HUMAN_GENE_SYMBOL	Arthur Liberzon	Broad Institute	Genes specifically up-regulated in pancreatic beta cells.			chr3q24|chr11p13|KEGG_PROTEIN_EXPORT|KEGG_MATURITY_ONSET_DIABETES_OF_THE_YOUNG|PID_HNF3B_PATHWAY|REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT|REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_BETA_CELLS|REACTOME_SYNTHESIS_SECRETION_AND_DEACYLATION_OF_GHRELIN|REACTOME_SYNTHESIS_SECRETION_AND_INACTIVATION_OF_GIP|REACTOME_INCRETIN_SYNTHESIS_SECRETION_AND_INACTIVATION|REACTOME_SYNTHESIS_SECRETION_AND_INACTIVATION_OF_GLP1|BENPORATH_ES_CORE_NINE|TESAR_ALK_TARGETS_HUMAN_ES_5D_UP|WEBER_METHYLATED_IN_COLON_CANCER|TESAR_ALK_TARGETS_EPISC_3D_UP|TESAR_ALK_TARGETS_EPISC_4D_UP|TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_UP|ZHOU_PANCREATIC_EXOCRINE_PROGENITOR|ZHOU_PANCREATIC_ENDOCRINE_PROGENITOR|ZHOU_PANCREATIC_BETA_CELL|MIKI_COEXPRESSED_WITH_CYP19A1|KANG_GLIS3_TARGETS|CDPCR3_01|PAX3_01	GSE30802,GSM764141-GSM764154 NGN3 OE vs control days 14-20 pancreas duct cells|GSE30803,pancreas beta cells vs skeletal muscle and heart|GSE40709,INSGFP+ vs INSGFP-|GSE52258,pancreas beta cells vs Pdx1-deficient cells	GSE12025,induced beta cells vs non-islet|GSE54374,beta cell vs acinar duct and Ngn3-null	5080	4760	3670	4821	5122	4825	6514	23478	1641	28972	3170	2645	9935	3630	3651	6833	3375	6726	50674	2308	10000	2641	1803	5078	57586	10590	6927	6812	1113	7421	5126	3642	6750	26610	58477	5063	57818	5313	4005	6727
